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HIV-infected persons are at particularly high risk of tuberculosis (TB) disease, 
especially in TB endemic countries where M. tuberculosis transmission is common.  
Although antiretroviral therapy (ART) reduces risk of TB, it does not return to that of 
HIV-uninfected persons. In addition, a previous history of TB disease significantly 
increases the risk of recurrent TB disease. Identification of HIV-infected individuals at 
greatest risk of recurrent TB for highly targeted therapy before disease manifestation 
would be a major advance in the fight against TB. This would also allow the provision 
of TB treatment in persons with subclinical TB. 
 
Diagnosis of TB in HIV-infected persons is markedly undermined by the 
paucibacillary nature of HIV-associated disease. A non-sputum based diagnostic test 
that is highly sensitive and specific, such as a blood-based RNA signature, would be 
an important new tool. Such a test may also facilitate monitoring of TB treatment, 
opening the possibility for customizing the duration of TB treatment to that necessary 
for cure.  
We previously discovered and validated a 16-gene transcriptomic signature with 
promising prognostic and diagnostic utility for TB in HIV-uninfected persons. The 
transcriptomic signature could predict progression to active TB disease up to a year 
before diagnosis and was shown to be a useful tool for TB treatment response 
monitoring in a treatment cohort of HIV-uninfected persons. The signature was 
reduced to an 11-gene signature to improve throughput with equivalent prognostic 
and diagnostic performance. In addition, we developed a smaller, 6-gene signature 
in preparation for translation to point-of-care testing. In this thesis, we aimed to 
determine (1) the diagnostic performance of these two transcriptomic signatures in 
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HIV-infected persons, (2) whether they could predict recurrent TB disease in HIV-
infected persons, and (3) their utility to monitor TB treatment response in HIV-
infected persons.  
 
To assess aim 1, we designed a cross-sectional study of HIV-infected (n=40) and 
uninfected persons (n=60), each comprising equal numbers of active TB cases and 
QuantiFERON-positive controls. To assess aims 2 and 3, we designed retrospective 
substudies among participants enrolled into two clinical studies previously completed 
by our collaborators at CAPRISA, namely the TRuTH and IMPRESS studies. In the 
TRuTH cohort participants who developed recurrent TB diagnosis, diagnosed by 
microbiological testing of induced sputum, were assigned as progressors  (n=43), 
while those who remained asymptomatic were assigned as non-progressors (n=86). 
In the IMPRESS cohort, participants with a new diagnosis of recurrent TB who 
initiated TB treatment were stratified into early (n=44) and late (n=19) converters 
based on time to sputum culture conversion from diagnosis. RNA was isolated from 
cryopreserved PBMC or PAXgene whole blood and gene expression measured by 
microfluidic qRT-PCR. Signature scores were generated using in-house customised 
scripts in R  and performance of the signatures was measured using receiver 
operating characteristic area under the curve (ROC AUC), calculated using the 
pROC and verification packages in R.  
 
The 11-gene and 6-gene signatures could diagnose active TB disease in HIV-
infected persons with good accuracy (AUC = 0.83 and 0.92, respectively), although 
performances were lower than those observed in HIV-uninfected persons (AUC = 
0.97 and 0.96). Signature performance was decreased in HIV-infected persons due 
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to higher signature scores, reflecting high expression of IFN-stimulated genes, 
especially in HIV-infected controls. In the TRuTH cohort, these signatures could 
identify those with recurrent TB within 3 months of diagnosis (AUC = 0.77, p = 
0.003), suggesting detection of subclinical disease. Scores of both signatures 
decreased during TB treatment in the IMPRESS cohort, in participants with early or 
late sputum conversion. Importantly, two months after initiating TB treatment, the 
ACS 11-gene signature could differentiate early from late converters. Detectable 
plasma viral load was associated with higher signature scores in both cohorts, 
leading to a decrease in signature specificities.  
 
 
We show that the 11-gene and 6-gene signatures performed well as blood-based 
diagnostic tests for active TB disease in HIV-infected persons. The signatures could 
detect recurrent TB disease during the subclinical phase of disease progression and 
demonstrated promise as treatment response markers in HIV-infected persons.  The 
signatures performed best in persons with effectively suppressed HIV load, 
highlighting the importance of ART adherence and integration of HIV and TB care for 
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Chapter 1: Introduction and literature review 
 
Tuberculosis (TB) is a grave global emergency. In 2015, approximately three times 
more people died from TB every week (~30,000) (World Health Organization 2017) 
than the deaths attributable to the Ebola outbreak in West Africa between 2014 and 
2016 (~11, 000). Hence, TB remains the main cause of mortality due to an infectious 
disease and the ninth leading cause of all deaths, worldwide (World Health 
Organization 2017). Yet the global response to TB is inadequate, under resourced 
and lacks the appropriate urgency to combat the pandemic. Two of the specific aims 
of the End TB Strategy are an 80% reduction in incidence (new cases) and a 90% 
decrease in deaths due to tuberculosis (TB) by 2030 relative to incidence and deaths 
in 2015. In 2016, an increase of 0.2 million incident cases from 2015 was reported by 
National TB programmes to the World Health Organization (WHO) (World Health 
Organization 2017). This suggests that current tools are inadequate to prevent new 
cases, therefore more tools and strategies are needed to decrease incidence and 
prevent mortality due to TB disease.  
 
Mycobacterium tuberculosis (Mtb), the causative agent of TB, is transmitted via 
aerosol in 2 to 5µm microdroplet particles that contain the bacterium from lungs of 
individuals with active disease (Etna et al., 2014). The most common form of disease 
that can develop after inhalation of particles and infection with Mtb is pulmonary TB. 
In addition to pulmonary TB, disease can occur in other parts of the body and is then 
referred to as extra-pulmonary TB or disseminated TB. Infection with the bacterium 
leads to three possible outcomes: 1) about 5% of individuals rapidly progress to TB 
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disease with microbiological confirmation in the first two years after infection; 2) 
~90% of individuals are able to mount an effective immune response limiting 
proliferation of the bacilli, usually remaining healthy during their lifetime (known as 
latent infection, referred to as “Mtb infection” in this thesis); 3) in a proportion of Mtb-
infected persons who did not rapidly progress, infection can be reactivated leading to 
disease (~1% to 2% per year) (Young, Gideon, and Wilkinson 2009; Wiker et al. 
2010). The risk of developing TB disease in contacts of active TB patients is higher 
in low and middle-income countries than in high-income countries (Fox et al., 2013). 
Close contacts of TB cases are at their greatest risk of developing TB disease in the 
first two years after diagnosis of the index case (Fox et al. 2013; Wiker et al. 2010). 
However, they remain at risk of developing active TB disease for a lifetime with risk 
decreasing farther away from exposure. Immune suppression, aging, co-infections 
and repeated TB exposures may increase this risk of developing active TB disease.  
 
1.1 From Mtb infection to active TB disease in the absence of immune 
suppression 
Clinically, TB is classified into binary categories, active and latent TB (Barry et al., 
2009; Esmail et al., 2014; Pai et al., 2016). However, it has recently become clear 
that in reality TB exists in a highly heterogeneous spectrum of states, including 
sterilized prior infection, quiescent or controlled infection and a range of 
asymptomatic phases of disease wherein patients do not present with clinical 
disease but have evidence of replicating bacteria, commonly referred to as incipient, 
subclinical or percolating TB (Pai et al. 2016). The different stages in this spectrum 
are associated with broad ranges of bacterial load and progression through these 
stages are dependent on the ability of the immune system to contain bacterial 
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replication (Young, Gideon, and Wilkinson 2009). Persons who progress from such 
asymptomatic phases to ultimately develop active disease are thought to transition 
through a phase of percolating, subclinical disease with active bacterial replication 
prior to development of symptoms that typically trigger care-seeking behaviour and 
TB diagnosis (Pai et al., 2016; Salgame et al., 2015). New tools that allow 
establishment of the stage into which a Mtb-infected person falls could help to 
identify persons at risk of progression to active TB disease and those with subclinical 
TB, for appropriate treatment. 
 
 1.1.1 Mtb infection: Epidemiology !
The exact proportion of Mtb-infected persons is difficult to identify because 
individuals with Mtb infection are generally asymptomatic and the bacterium cannot 
be directly detected. Consequently, the magnitude of infection is estimated via 
mathematical models based on country-specific annual risk of infection, estimated 
from tuberculin skin test (TST) surveys, and transmission potential of active TB 
cases (Matteelli et al. 2017). A recent re-estimation of the global burden of Mtb 
infection based on such mathematical modelling suggested that an estimated 1.7 
billion (~23% of the global population) individuals are infected with Mtb (Houben and 
Dodd 2016), representing a huge reservoir of probable TB disease. Estimates of 
prevalent infection vary between regions. At least 20% of persons from Southeast 
Asia, Western Pacific and African regions are estimated to be Mtb-infected 
contributing to over 80% of global estimates (Houben and Dodd 2016). On the other 
hand, Eastern-Mediterranean, Europe, and the Americas had an estimated 
prevalence of less than 17% of the general population. Thus, the reservoir of 
probable TB disease is highest in Southeast Asian, Western Pacific and African 
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regions. The risk of reactivation or progression to active TB disease is highest within 
two to five years after primary infection (Dye et al. 1999; Wiker et al. 2010), affecting 
5% to 15% of Mtb-infected individuals, with some reactivating decades later 
(Lillebaek et al. 2002). Persons who reactivate within five years are termed “early” 
disease progressors, whilst those who reactivate later are termed “late” disease 
progressors (Lillebaek et al. 2002). Targeted interventions in Mtb-infected persons 
are critically important for the prevention of active TB disease in order to achieve TB 
elimination (Barry et al. 2009).  
 
1.1.2 Diagnosis of Mtb infection !
There is currently no “gold standard” for diagnosing Mtb infection because detection 
of the pathogen in asymptomatic persons is not possible. As a consequence 
infection is diagnosed via the detection of memory T-cell responses using in vivo 
(TST) and in vitro (Interferon gamma release assays (IGRAs)) assays. TST 
measures a delayed-type hypersensitivity reaction to an intradermal administration of 
a mixture of purified proteins derived from Mtb (purified protein derivative). Induration 
induced as a result of the hypersensitivity reaction is measured 48 to 72 hours after 
administration. An induration of five to 15 mm or more is considered positive, 
dependent on the setting, with an induration greater than 10mm classified as positive 
in most high-burden settings. Specificity of TST is confounded by Bacillus Calmette-
Guerin vaccination, and exposure to environmental non-tuberculous mycobacteria, 
both of which can induce immune responses that cross-react with purified protein 
derivative, whilst sensitivity of the test in immunocompromised persons is usually low 
(O’Garra et al., 2013; Thillai et al., 2014). In vitro assays such as the QuantiFERON-
TB Gold In Tube (QFT) and the T-SPOT TB assays measure T cell responses to Mtb 
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antigens such as the early secretory antigenic target-6 and culture filtrate protein-10 
(Thillai et al. 2014). These antigens are absent in the Bacillus Calmette-Guerin 
vaccine and most non-tuberculosis mycobacteria, thereby making IGRAs more 
specific to Mtb sensitisation than the TST (Andersen et al., 2000; Diel et al., 2011). 
The in vitro IGRAs include the mitogen phytohemagglutinin A as a positive control 
antigen, that allows identification of persons who might be immunocompromised 
because they cannot mount an appropriate immune response to the antigen 
(Andersen et al. 2000). TST and IGRAs can only detect host sensitisation to Mtb 
antigens, indicating possible Mtb infection, and do not accurately determine risk of 
progression to TB disease, nor do they indicate the stage of Mtb infection (Matteelli 
et al. 2017). Furthermore, these tests do not have the ability to differentiate between 
active TB and other respiratory diseases in those with Mtb infection and are unable 
to indicate the presence of replicating or viable bacteria (Barry et al. 2009). Time of 
Mtb infection is difficult to establish in the general population (Wallgren 1948), 
making it difficult to determine how long someone has been infected. Hence, 
determining when a person is at the highest risk of developing active TB disease is 
very challenging. 
 
1.1.3 Treatment of Mtb infection and prevention of progression to active  
TB disease !
Eradication of TB would require prevention of disease or elimination of the pathogen 
in the 23% of the global population who are estimated to be Mtb-infected. An 
obvious intervention would be antibiotic treatment in all who have evidence of Mtb 
infection. The benefits of such preventive therapy to stop TB disease progression in 
Mtb-infected persons have been known for more than 60 years (Schluger 2017). 
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WHO currently recommends isoniazid (INH) preventive therapy (IPT) for individuals 
at risk of developing TB in low-burden countries (World Health Organization 2015; 
Getahun et al. 2015). Soon after its efficacy in treatment of disease was established, 
INH was found to also be effective in preventing TB disease when provided to 
asymptomatic individuals (Lobue and Menzies 2010). Administration of IPT for six to 
12 months can lead to a 90% risk reduction in developing active TB disease in Mtb-
infected persons (Dye et al., 2013). The first efficacy trial of IPT was conducted by 
George Comstock in Alaskan natives from the USA, known as the Bethel trial 
(Comstock, Ferebee, & Hammes, 1967; Zwerling, Hanrahan, & Dowdy, 2016). In this 
doubled-blinded, randomized, placebo-controlled study, participants received either 
INH or placebo for a period of 12 months (Comstock et al., 1967). A lower TB 
incidence (1.90%) was observed in the INH arm than in the placebo arm (4.67%) 
after four years of follow-up (Comstock et al., 1967). This effect was greater in 
persons with a TST measuring at least 5mm and a reduction of incidence up to 90% 
was observed in these individuals (Comstock et al., 1967). This landmark trial 
suggested that IPT might be more effective in persons with prior sensitisation to Mtb 
or persons with memory responses to an Mtb antigen. The effect of the prophylaxis 
treatment persisted up to almost two decades after the initial evaluation, with a 68% 
reduction in TB cases in the study setting attributable to INH (Comstock et al., 1979). 
 
Many studies have confirmed the efficacy of INH since the first efficacy trial of IPT. 
INH taken daily for a year could prevent both pulmonary and extra-pulmonary TB in 
approximately 25,000 household contacts from the United States of America 
(Ferebee and Mount 1962). A study of contacts of TB cases observed a five-year 
cumulative risk of TB of 1.4 (95% CI: 0.03 to 2.6) in those who had preventive 
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therapy, compared to 2.4 (95% CI: 1.2 to 4.7) in those who did not receive therapy 
(Sloot et al., 2014). In South African children, INH reduced the risk of active TB 
disease in Mtb-infected children from a 16-fold to a 2.5-fold risk relative to Mtb-
infected children who did not receive IPT (Bunyasi et al. 2017). A systematic review 
of 11 randomised double-blinded trials consisting of over 73,000 HIV-uninfected 
participants randomised to receive either INH or placebo found that among 796 
participants who developed active TB disease, only 239 were from the INH arm, 
resulting in a relative risk of 0.40 (95% CI: 0.31 to 0.52) (Smieja et al. 1999).  
 
Due to long treatment duration and hepatotoxicity of INH, several studies have 
evaluated shorter treatment regimens and evaluated the safety and adherence of 
new regimens (Lobue and Menzies 2010). At present, none of these is less 
efficacious or results in fewer adverse events than nine months of INH therapy 
(Lobue and Menzies 2010). Consequently, five different treatment regimens are 
recommended for preventive therapy (Getahun et al. 2015; World health 
Organization 2015): (i) six or nine months of isoniazid, (ii) three months of rifampicin, 
(iii) three to four months of rifampicin alone, (iv) Rifampicin plus isoniazid, or (iv) 
rifapentine plus isoniazid, weekly for three months. A meta-analysis of randomised 
controlled trials observed comparable efficacy of these different treatment regimens 
in different study populations from various settings (Stagg et al. 2014). In high-
burden countries, provision of preventive therapy is not recommended to HIV-
uninfected adults because it is very challenging to treat such a large proportion of the 
population when only a small subset of Mtb-infected persons will progress to active 
TB during their lifetime. Furthermore, continuous re-exposure to Mtb results in 
reinfection, placing people at risk of disease soon after they have completed 
! 8!
preventive therapy. High prevalence of infection and exposure preclude 
determination of recent Mtb infection with TSTs and IGRAs. When these issues have 
to be balanced against inadequate adherence to long preventive therapy regimens 
that is often reported and a risk of liver damage from hepatotoxic effect of IPT.  
Perhaps, identification of persons most likely to progress to active TB disease in 
high-burden countries would enhance IPT uptake. In addition, the duration of the 
treatment could be determined by a person’s relative risk of developing active TB 
disease. For example, persons at highest risk of developing active TB disease within 
a short time (six to 12 months) can be given longer preventive therapy, whereas 
persons at a lower risk of developing active TB can be given shorter treatment 
regimens and be followed. This could be used to customise IPT to individual needs, 
thereby increasing adherence, but the tools to determine such risk are currently 
lacking. 
 
1.1.4 Diagnosis of active TB disease !
Active TB disease patients typically present with a number of the following signs and 
symptoms: fever, fatigue, drenching night sweats, chest pain, weight loss, anaemia, 
appetite loss, wasting and, in patients with pulmonary TB, persistent coughing 
(lasting at least two weeks) or haemoptysis (Davies and Pai 2008; Pai et al. 2016). 
Definite TB is defined by laboratory confirmation of Mtb from a clinical specimen, 
usually sputum (Davies and Pai 2008). Current diagnostic methods mainly rely on 
detection of the pathogen in sputum (microbiological confirmation), evaluation of 
clinical symptoms and radiological assessments of individuals presenting with the 
symptoms of the disease in clinics. The most common method of diagnosis used 
globally is sputum smear microscopy. However, the sensitivity of smear microscopy 
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is poor, ranging from between 34% to 80% in comparison to cultures, with 20% to 
66% of active TB cases being smear negative (Davies and Pai 2008). The current 
“gold standard” for TB diagnosis is detection of Mtb by culture in liquid or solid 
media, which yields a sensitivity ranging from 80% to 93% and a specificity of 98%. 
In addition, cultures allow speciation and drug susceptibility testing because the 
cultured organism can be characterised further (Davies and Pai 2008). Poor sample 
collection and paucibacillarity of sputum samples, however, reduces the sensitivity of 
this test (Ndzi et al. 2016). A major disadvantage of current culture methods is that it 
can take up to three or four weeks before diagnosis can be confirmed, due to the 
slow growth of Mtb (Davies and Pai 2008). Nucleic acid amplification tests (NAAT) 
are molecular diagnostic tests that can generate results within hours, thus 
theoretically facilitating diagnosis and prescription of appropriate treatment during 
the same patient visit. As a result, many countries have invested very significantly 
into implementation of the NAAT, Xpert MTB-RIF (Cepheid), as the first-line TB 
diagnostic in clinics and hospitals. Although Xpert MTB-RIF has led to more rapid 
diagnosis of TB in many settings, this has not resulted in very significant changes in 
TB mortality (World Health Organization 2017). NAATs fail to differentiate between 
live and dead bacteria, and are therefore not useful to monitor whether patients have 
cleared Mtb during TB treatment (Davies and Pai 2008). In addition to these 
diagnostics, clinical diagnosis can be done using imaging techniques such as chest 
X-rays and, more recently, positron emission tomography-computed tomography 
(PET-CT) scanning (Pai et al. 2016). These radiographic imaging techniques can 
detect pulmonary features that are consistent with TB disease, but they are 
inherently non-specific and therefore serve as screening tools, whilst microbiological 
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tests result in confirmation of the presence of viable bacilli in sputum. Thus, better 
tools are needed for TB to improve TB diagnosis.  
 
1.1.5 Immune response to TB disease   
!
“Immune response to TB requires an interaction between the cellular and humoral 
compartments including both the innate and adaptive responses. Knowledge of early 
immune response to Mtb in humans is limited and current knowledge is based on 
experimental animal models, such as mice, rabbits, guinea pigs and non-human 
primates. Alveolar macrophages are the first immune cells of contact with the 
pathogen and engulf the bacteria by receptor-mediated phagocytosis, requiring 
different receptors (van Crevel et al. 2002). Phagosome-lysosome fusion is blocked 
by the mycobacterium ensuring its survival. Thereafter, several cell types are 
recruited to the site of infection (i.e lungs) leading to granuloma formation, which is 
the hallmark of infection. Granulomas consist of both innate cells such as 
macrophages, foamy macrophages, neutrophils, and cells involved in the adaptive 
immune response such as T and B cells (O’Garra et al. 2013). Despite their 
presence in the granuloma, the role of neutrophils has not been fully characterised in 
the immune response against TB. Neutrophils are the predominant cell types in the 
sputum and bronchoalveolar lavage fluid of TB patients (Eum et al. 2010). 
Furthermore, neutrophils have been observed to be the predominant cell type to 
express the genes implicated in numerous published transcriptomic signatures of TB 
disease (Berry et al. 2010; Scriba et al. 2017), discussed in section 1.7. Although 
little is known about the role of B cells and antibodies in the protective immune 
response against TB, they play an integral role in the maintenance and formation of 
granulomas. In addition, they can present antigen to T cells in the granuloma and 
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could modulate the immune inflammation through IL-10 production (Rao et al. 2015). 
T cells are the hallmark of the adaptive immune response against Mtb and have 
been the most studied immune cells in TB research. Mtb-specific responses are 
dominated by CD4 T cells producing TNF-α and IFNγ and recently CD8 T cells have 
also been shown to play significant roles in patients with TB disease (reviewed by 
Scriba et al. 2017). Furthermore, susceptibility to TB disease is associated with an 
increase in the monocyte to lymphocyte ratio in both children (Naranbhai et al. 2014) 
and adults (Naranbhai et al. 2015) including HIV-infected persons (Naranbhai et al. 
2013).  
 
1.2 Treatment of active TB disease !
Standard pulmonary TB diagnosis requires six months of treatment, in most 
countries consisting of two months of intensive TB treatment with isoniazid, 
rifampicin, pyrazinamide and ethambutol (2HRZE) followed by four months of 
isoniazid and rifampicin (4HR) for the continuation phase of treatment (Parida and 
Kaufmann 2010). Such treatment results in cure in most patients, however due to 
poor adherence or poor treatment response cure is not achieved in some patients. 
This leads to a high risk of treatment failure and relapse due to insufficient treatment. 
The emergence and increasing prevalence of multiple drug resistant (MDR-TB) and 
extensively drug resistant (XDR-TB) strains presents a further challenge to the 
successful treatment of TB and has exacerbated the global TB problem (Raviglione 
and Smith 2007). MDR-TB is defined as resistance within a strain of Mtb to at least 
one first line drug, usually isoniazid or rifampicin. XDR-TB is resistance to 
fluoroquinolones and any of the injectable second-line aminoglycosides in addition to 
resistance to the first line drugs (Raviglione and Smith 2007). In 2016, approximately 
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600,000 new cases with drug resistance to rifampicin were reported, 490,000 of 
whom had MDR-TB (World Health Organization 2017). MDR-TB and XDR-TB are 
treated using second line drugs such as aminosalicylic acid, thioamides, 
ethionamide, prothionamide, capreomycin and fluoroquinolones and often for very 
long times, up to two years (Fernandes et al., 2017). Poor adherence to such long-
term regimens can lead to increase in transmission and insufficient treatment, which 
is assumed to be the main cause of drug resistance (Friedrich et al. 2013), in 
addition to an increase risk of treatment failure and relapse. Furthermore, drug 
penetration in the lungs (Dheda et al. 2018), host genetic factors, heterogeneous 
treatment responses in patients and simplified treatment due to poor public health 
control strategies (reviewed in Koch et al. 2018), significantly contribute to 
acquisition of drug resistance. It is clear that better tools for monitoring the response 
of TB patients to TB treatment would be extremely helpful such that the duration of 
treatment and type of treatment can be tailored to each patient’s need. 
 
1.2.1 New regimens to shorten TB treatment and prevent relapse.  !
Several studies have investigated new treatment regimens to shorten treatment in 
order to possibly increase adherence (Gillespie et al. 2014; Burman et al. 2006; 
Rustomjee et al. 2008; Tuberculosis Research Center 2002; Jindani et al. 2014; 
Merle et al. 2014). Gillespie and colleagues replaced INH or ethambutol with 
moxifloxacin (a fluoroquinolone) for four months to determine its non-inferiority to the 
standard six-month regimen (Gillespie et al. 2014). However, the moxifloxacin 
regimen was inferior to the standard of care after 18 months of follow-up of nearly 
2,000 newly diagnosed active TB cases. By substituting Moxifloxacin for ethambutol, 
Burman et al showed that despite resulting in higher proportions of negative cultures 
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at early time points, moxifloxacin did not have an effect on month-two culture 
conversion rates (Burman et al. 2006). This suggests that moxifloxacin has sterilising 
activity but has deficient activity when added to other drugs to support treatment 
shortening based on two-month culture conversion results (Burman et al. 2006). 
Burman and colleagues did not follow up patients to determine relapse rates, which 
is a more definitive measure of sterilizing activity. In two other studies, substituting 
ethambutol with fluoroquinolones to shorten treatment decreased time to culture 
negativity but did not decrease relapse rates in South Africa (Rustomjee et al. 2008) 
and India (Tuberculosis Research Center 2002). Higher relapse rates were observed 
in a treatment regimen of once-weekly rifapentine in the continuation phase 
compared to a twice-weekly rifampicin regimen (Benator et al. 2002). Higher relapse 
rates were also observed when a four-month regimen, in which moxifloxacin and 
rifapentine were given once weekly after the intensive phase in comparison to the 
six-month standard of care (Jindani et al. 2014). Culture conversion (i.e. a negative 
sputum Mtb culture) within two months after TB treatment is associated with lower 
relapse rates and treatment failure (Mitchison 1993). In the studies mentioned 
above, despite high culture conversion rates at two months the relapse rates in the 
intervention arms were equivalent or higher than those in the standard of care arm. 
This suggests that better markers of relapse and treatment failure are needed to 
monitor treatment response and predict relapse after clinical and microbiological 
cure.  
 
1.3 Recurrent TB disease and treatment !
A second episode of active TB disease after an initial “cured” TB episode is referred 
to as a recurrence (Lambert et al. 2003). In a five-year follow-up of “cured” active TB 
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persons, 18% of study participants developed recurrent TB (Verver et al. 2005). Of 
these, 14% had completed treatment and were classified as “clinically cured” (Verver 
et al. 2005). In 2016, an estimated 300,000 recurrent TB episodes were diagnosed 
by National TB programmes around the globe, representing an enormous burden on 
TB control efforts (World Health Organization 2017).  
 
If the recurrent TB episode is due to a different Mtb strain relative to the primary 
disease episode, this is referred to as reinfection. In cases where the same strain is 
isolated from the two TB episodes, this is referred to as relapse. Risk of TB 
recurrence due to reinfection is determined by the risk of reinfection after a first 
episode and the risk of the reinfection progressing to a second episode of active 
disease (Lambert et al. 2003). Relapse generally occurs because of bacterial 
persistence after apparent “clinical cure”, mainly due to insufficient treatment efficacy 
either because of inadequate duration or an inefficient regimen (Lambert et al. 2003). 
Recurrence due to either relapse or reinfection is clinically indistinguishable. 
However, with recent developments in molecular techniques, such as whole genome 
sequencing and IS6110-based restriction fragment-length polymorphism, 
identification of relapse and reinfection TB is possible by identifying TB strains from 
the first and the second TB episode diagnosis. In a study in the Karonga district of 
Malawi, 73.3% of recurrent TB cases were due to relapse (Guerra-Assuncąõ et al. 
2015). Recurrent TB generally occurred within a year of TB treatment completion, at 
a rate of 5.4 recurrences/100 person-years (py) (Guerra-Assuncąõ et al. 2015). A 
study in South Africa observed a similar trend whereby most relapses occurred in the 
first year, whilst reinfection featured mainly in the subsequent years (Marx et al. 
2014). In contrast to the Malawian study, at least half of all TB recurrences in the 
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South African cohort were due to reinfections. These studies, in addition to other 
studies with low sample sizes (Boer et al., 2003; Van Rie et al., 1999), suggest that 
previous TB disease is a strong risk factor for subsequent recurrent TB disease and 
that prior TB disease does not induce immune memory responses after cure that 
provide protection against subsequent episodes of TB.  
 
Due to the high incidence and probability of MDR-TB in recurrent TB cases, there is 
currently no standard of care for treating recurrent TB. The WHO recommends 
placing recurrent TB cases on empirical treatments whilst awaiting drug susceptibility 
testing results where available (World Health Organization 2010). In places where 
MDR-TB levels are low, an 8-month treatment regimen of either two months of 
HRZES or one month of HRZE and then five months of HRE should be 
administered, and, if MDR results become available, treatment should be adjusted 
accordingly.  
 
1.4 HIV and TB co-infection 
1.4.1 Epidemiology of TB disease and HIV co-infection!
The advent of the HIV/AIDS pandemic has markedly changed the global TB 
pandemic and still poses one of the greatest challenges to health systems around 
the world. An interaction between Mtb and HIV was detected circa 40 years ago, 
fuelling the TB disease burden and mortality due to TB in humans (Harries et al. 
2010). HIV co-infection is a major factor in the annual increase in global TB 
incidence rates between 1990 and 2004, leading to a five-fold increase in TB 
notification rates (Lawn et al., 2009). An estimated 46% of incident TB cases, in 
2016, were HIV co-infected with the highest proportions from the African region 
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(World Health Organization 2017). In addition to the 1.3 million TB deaths in HIV-
uninfected persons, 374,000 deaths occurred in HIV-infected persons, making TB 
the leading cause of mortality in HIV-infected persons (World Health Organization 
2017). Active TB disease has been associated with reduced survival in Ugandan 
HIV-infected persons despite being highly adherent to TB treatment (Whalen et al. 
2000). In a five-year follow up of 609 HIV-infected patients before the wide 
availability of antiretroviral therapy (ART), 103 (17%) deaths were recorded (Badri et 
al., 2002). Of these, 50 occurred in patients diagnosed with TB (Badri, Wilson, and 
Wood 2002). Progression to AIDS and AIDS defining illnesses were higher in 
persons with TB than in those without TB in the same cohort.  
 
ART has caused a decrease in HIV-associated morbidity and mortality due to the 
partial restoration of CD4 T cells and suppression of the virus, but health is not fully 
restored (Klatt et al., 2013). Of the HIV co-infected notified TB cases in 2016, 85% 
were on ART (World Health Organization 2017). ART given alone, can decrease the 
risk of TB disease in HIV-infected persons up to 65% (Suthar et al. 2012). Despite 
this, HIV-infected persons on ART still have a higher TB incidence rate in 
comparison to HIV-uninfected cohorts from the same communities (Golub et al., 
2009; Gupta et al., 2012; Lawn et al., 2009). In a well-defined South African township 
community, TB prevalence decreased from 44% to 6.7% over a three-year period in 
HIV-infected persons on ART (Middelkoop et al. 2010). TB incidence rates were 
higher in the first year after ART start, decreasing by almost half in the second year, 
from 12.43 cases per 100 py to 6.71 cases per 100 py (Gupta et al. 2012). These 
rates further decreased to 4.92 cases per 100 py after five years. A similar trend was 
observed in another study of TB incidence in persons beginning ART, wherein TB 
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incidence decreased from 13.9 per 100 py in the first three months to 1.6 per 100 py 
in the third year (Van Rie et al., 2011). A multi-centre study observed a decrease in 
incidence risk from 13.0 per 100 py in the first three months after ART start to 1.5 per 
100 py after a year in eight sub-Saharan African countries (Nicholas et al. 2011). In 
these studies, the higher TB incidence in the first year can be due to the incidence of 
immune reconstitution inflammatory syndrome (IRIS). Incidence of immune 
reconstituting inflammatory syndrome was highest in the first three months after ART 
start.  
 
The degree of immunosuppression, quantified by CD4 T cell counts, is a key 
determinant of TB risk in HIV-infected persons. ART increases CD4 T cell counts, 
thereby decreasing the risk of TB in HIV-infected persons. A 10% reduction in 
relative risk of TB disease attributable to ART was observed as CD4 T cell counts 
increase from less than 100 cells/mm3 to more than 500 cells/mm3 (Wood and Lawn 
2011). In patients starting ART, 42% of persons with prevalent TB had CD4 counts 
of less than 50 cells/mm3 (Van Rie, Westreich, and Sanne 2011). Early incident TB 
(TB within six months of ART start) was associated with advanced 
immunosuppression (Van Rie, Westreich, and Sanne 2011). In addition, patients 
with CD4 T cell counts less than 50 cells/mm3 were twice as likely to develop TB 
disease than those with CD4 T cell counts of at least 100 cells/mm3 (Van Rie, 
Westreich, and Sanne 2011). Patients initiated on ART during the early phases of 
HIV are only two times more likely to get TB in comparison to HIV-uninfected 
persons (Wood and Lawn 2011). Thus, reconstitution of functional CD4 T cell 
immune responses is used as a marker of effective ART in addition to a decline in 
HIV viral loads. Reconstitution of CD4 T cells occur initially for memory cells and 
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naïve cells, however, persistent impairments of specific CD4 T cell populations can 
be observed despite long-term ART (Walker et al., 2013). A 1.7-fold increased risk of 
TB was observed early after ART initiation in persons with CD4 T cell counts less 
than 100 cells/µl (Lawn et al., 2009). The authors attribute the high levels of TB 
during the early phases of ART treatment to the unmasking of subclinical TB in these 
patients.  
 
1.5 Preventing TB in HIV-infected people !
The WHO policy on collaborative TB/HIV activities has an aim to “reduce the burden 
of TB in people living with HIV, by ensuring the delivery of the three “I”s (intensified 
case finding, infection control, and IPT), for HIV/TB” (World Health Organization 
2012b). In addition to these, ART has been proposed to be included in TB prevention 
strategies in HIV-infected persons (Lawn et al., 2009). In order to achieve this, it is 
recommended that adults and adolescents living with HIV should be regularly 
screened for TB (World Health Organization 2012b). All HIV-infected persons not 
diagnosed with active TB should receive at least six months of IPT irrespective of 
degree of immune suppression (World Health Organization 2012b). The 
implementation of the three “I”s complements the effects of early ART and must be 
scaled up to prevent mortality and morbidity from TB in HIV-infected persons 
(Harries et al. 2010). However, only ART has been implemented on a large scale in 
most countries (Gupta et al. 2012). 
 
Intensified case finding aims to identify persons with subclinical TB and in need of 
treatment, leading to treatment start in those with TB disease and IPT in those 
without TB disease (Lawn et al., 2009). This is intended to reduce, 1) individual 
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morbidity and mortality through early diagnosis and treatment, 2) TB transmission via 
shortening of infectious period and, 3) exclude TB to allow preventive treatment 
(Corbett and MacPherson 2013). In a South African study passive case finding 
identified only 33% of HIV-infected persons with smear positive TB (Wood et al. 
2007), strengthening the need to implement active and intensified case finding 
approaches in communities.  
 
ART reduces the risk of active TB disease in HIV-infected persons, albeit in a time 
dependent manner (Lawn et al., 2011). The incidence of TB disease can be more 
than halved if ART is started within five years of HIV seroconversion (Harries et al. 
2010). Mathematical modelling of HIV-associated TB in sub-Saharan African 
countries estimates a reduction in incidence rates by 66%, 95% and 98% if ART is 
started within five years, two years or one year of HIV seroconversion, respectively, 
by 2050 (Williams et al. 2010). Scale up of ART can thus result in an estimated 
reduction in TB incidence of up to 25% over a five-year period and up to 50% over a 
20-year period, according to a modelling approach (Chindelevitch et al. 2015). In 
agreement with this, a risk reduction of up to 70% (range: 54% to 92%) was 
observed in observational ART cohort studies in low burden and high burden 
countries (Lawn et al., 2010; Lawn, et al., 2009). 
 
Preventive TB therapy has been shown to reduce the risk of active TB disease by 
36% to 64% in a review of more than 5,000 HIV-infected persons from 13 trials 
(Volmink and Woldehanna 2004). A systematic review of 12 randomized controlled 
trials of HIV-infected individuals showed that a six to twelve month course of daily 
INH therapy can reduce TB incidence up to 32% (Akolo et al. 2010). Mass 
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administration of IPT protects individuals against TB disease but has no effect on TB 
incidence in the community in a high incidence setting (Churchyard et al. 2014; 
Vynnycky et al. 2015). In a Zambian study a two-fold decrease in TB incidence was 
observed in HIV-infected persons who received six months of IPT, relative to those 
who received placebo (Mwinga et al. 1998). However, this protective effect of IPT 
was lost during a seven-year follow-up of participants from the same study (Quigley 
et al. 2001), with a higher TB incidence rate of 4.0 per 100 py observed in the IPT 
group relative to an incident rate of 2.1 per 100 py in the placebo group. Durability of 
protection by six months of IPT is short-lived as a limited benefit has been observed 
as early as 12 months after commencement of therapy (Johnson et al. 2001). No 
significant effect of six months of IPT daily was observed on both TB incidence and 
prevalence after TB therapy in a massive trial of gold miners (Churchyard et al. 
2014). These studies suggest that there is limited duration of benefit after six months 
IPT in HIV-infected persons.  
 
This has led to other randomised trials examining the durability of protection against 
TB offered by IPT and the effect of increasing IPT duration in HIV-infected persons. 
Extending IPT to 36 months reduced TB incidence by 43% in a study in Botswana, 
but protection was sustained only in TST-positive individuals who completed therapy 
(Samandari et al. 2015, 2011). In India, six-month treatment of daily IPT and 
ethambuthol was equivalent to a 36-month regimen of daily IPT only in preventing 
active TB (Swaminathan et al. 2012). Extending therapy to six years did not provide 
any additional benefits in preventing active TB when compared to six months of daily 
therapy in a South African cohort (Martinson et al. 2011). A meta-analysis of the 
three studies mentioned above detected a 38% reduction in risk of developing active 
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TB with 36 months IPT compared to six months of IPT (Boon et al., 2016). This 
suggests that long-term IPT is required to provide adequate protection against TB 
disease in HIV-infected persons. The lack of durable protection after completion of 
six months of INH was attributed to repeated exposure to Mtb, or high force of re-
infection, seen in TB endemic settings (Havlir et al., 2008). However, a recent clinical 
trial demonstrated that a shortened treatment regimen consisting of once weekly 
high-dose rifapentine and isoniazid for three months was as effective as and non-
inferior to nine months of daily INH (Sterling et al. 2016). Treatment completion rates 
were higher in the shorter rifapentine arm compared to the isoniazid only arm, 
suggesting better adherence in the three-month study arm. Protection against active 
TB was observed to last up to three years after a three-month prophylaxis of 
rifampicin containing drugs (Johnson et al. 2001). In addition to preventing active TB 
disease, IPT can prevent TB-associated mortality in HIV-infected persons up to 37% 
(Badje et al. 2017; Durovni et al. 2013). These studies suggest that shortening 
preventive therapy can prevent TB in HIV-infected persons and increases 
adherence, thereby reducing the risk of active TB in HIV-infected persons.  
 
Daily IPT given in combination with ART for six months offers durable protection 
against TB, which lasted up to seven years after IPT initiation in a Brazilian study 
(Golub et al., 2007; Golub et al., 2015). Another study in both urban and rural 
settings in South Africa demonstrated TB risk reduction of 89% TB due to the 
combined effect of IPT and ART (Golub et al., 2009). In a South African township 
(informal residence), 12 months of IPT reduced TB incidence independent of ART by 
37% (Rangaka et al. 2014). These studies suggest that combining IPT and ART will 
be more effective in preventing TB in HIV-infected persons. Thus, combining TB and 
! 22!
HIV care in a clinical setting is likely to effectively reduce the burden of active TB in 
HIV-infected persons.  
 
The above-mentioned studies suggest that IPT should be given for extended periods 
in HIV-infected persons to prevent progression to active TB disease, as is 
recommended (World Health Organization 2011). In addition to poor adherence to 
treatment, as mentioned above, long-term IPT increases the risk of hepatotoxicity. 
Adherence may be increased if only those persons at risk are identified, provided 
counselling, and provided long-term directly observed therapy to decrease risk of 
progression to disease. In addition, such individuals should be further investigated 
for subclinical TB disease and if found to be sputum positive for Mtb, provided with 
TB treatment. Thus, markers to identify HIV-infected persons at greatest risk of 
progression to TB disease would enhance early case detection and customising 
length of preventive therapy or full treatment for TB disease.  
 
1.6 Progression to active TB, treatment and recurrence in HIV infection !
HIV infection increases the risk of progression and reactivation of Mtb infection to 
active TB disease (Kasprowicz et al. 2011; Gupta et al. 2012). Risk of TB disease 
doubles in the first year after HIV-seroconversion relative to HIV-uninfected persons 
(Sonnenberg et al., 2005) and remains elevated after the first year of seroconversion 
at levels 20 to 30 times higher than in HIV-uninfected persons (Getahun et al., 2010; 
World Health Organization, 2012). Clinical features of TB presentation are also 
highly dependent on the stage of HIV infection and immunodeficiency (Maher et al., 
2005). Pulmonary TB in persons with early HIV infection with mild/moderate 
immunodeficiency usually presents with the same signs and symptoms as HIV-
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uninfected persons whereas advanced/late HIV infection is associated with an 
increase in disseminated disease and less cavitary disease (Maher, Harries, and 
Getahun 2005; Tornheim and Dooley 2017). This makes TB much easier to 
diagnose in early HIV infection, as patients usually present with productive coughs 
and are more often smear positive TB (Maher, Harries, and Getahun 2005; Tornheim 
and Dooley 2017).  
 
1.6.1 Diagnosis and treatment of active TB disease in HIV-infected persons !
Diagnostic tests for active TB disease are not different for both HIV-infected and 
uninfected persons (Tornheim and Dooley 2017), and sputum culture or smear 
microscopy are the most commonly used methods of diagnosing pulmonary TB. 
Bacterial culture is considered as the “gold-standard” for diagnosis. However, 
diagnosis of TB in HIV-infected persons is complicated by the paucibacillary nature 
of disease, leading to smear- and culture-negativity in a large proportion of diseased 
individuals, particularly in non-cavitary pulmonary TB with advanced 
immunosuppression (Tornheim and Dooley 2017). In addition, chest X-rays are less 
reliable in HIV-infected persons as the disease presents with atypical patterns; up to 
14% of individuals with positive cultures present with normal chest x-rays (Getahun 
et al., 2007). Using the current WHO screening recommendations for culture positive 
active TB cases with HIV co-infection from three Southeast Asian countries, 179 
individuals had no coughs, whilst 75 individuals with coughs had normal chest X-rays 
and negative sputum smears from two sputum specimens (Cain et al. 2010). In the 
same study, mycobacterial culture was the most effective method of diagnosing TB, 
especially in participants with negative sputum smears. In a South African study 
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cultures were also more sensitive than sputum smears (81% and 41%, respectively) 
in diagnosing active TB in an ART roll out program (Lawn et al., 2006).  
 
The standard six-month treatment regimen for active TB in HIV-uninfected persons is 
recommended for drug susceptible pulmonary TB cases on ART (World Health 
Organization 2017). Early initiation of ART after starting TB treatment decreases the 
risk of mortality due to TB (Marcy et al. 2014; S. Abdool Karim et al. 2011). The 
WHO recommends that all newly diagnosed TB cases that are HIV co-infected 
should be started on both ART and TB treatment regardless of CD4 T cell counts 
(World Health Organization 2017). However, due to the risk of immune reconstitution 
inflammatory syndrome (IRIS), ART should be delayed to start within eight weeks of 
start of TB treatment, whereas individuals with CD4 T cell counts less than 50 
cells/mm3 should be started on ART within two weeks (World Health Organization 
2017). A systematic review of seven studies of HIV co-infected persons showed that 
treatment with a rifamycin-containing regimen for at least six months with ART is 
associated with lower treatment failure and relapse rates relative to treatment without 
ART (Khan et al. 2010). Hence, TB treatment given concurrently with ART 
decreases mortality due to TB in HIV co-infected persons.  
 
1.6.2 Recurrent TB disease in HIV-infected persons !
HIV infection is a risk factor for the development of recurrent TB disease (Korenromp 
et al., 2003). Several studies have shown that HIV-infected persons are more likely 
to develop recurrent TB disease than HIV-uninfected persons (Charalambous et al., 
2008; Fitzgerald et al., 2000; Mallory et al., 2000; Sonnenberg et al., 2001). In a 
study of TB notification rates in Cape Town, recurrent TB cases constituted 30% of 
! 25!
all HIV cases accounting for almost 4,000 TB cases (Wood et al. 2011). Recurrent 
TB rates were higher in HIV-infected persons on ART in comparison to those not on 
ART, suggesting better diagnosis of TB in individuals on ART, failed initial treatment, 
multiple re-infections, or reactivations (Wood et al. 2011). In a community cohort of 
HIV-infected persons on ARTs, recurrent TB diagnosis accounted for 75% of the TB 
disease burden (Gupta et al. 2012). In a systematic review of 47 studies of recurrent 
TB disease, an average recurrence rate of 4.5 per 100 py in HIV-infected persons 
was observed (Korenromp et al. 2003). In comparison, the recurrence rate was 1.9 
per 100 py in HIV-uninfected persons. Despite the higher number of recurrences in 
HIV-infected persons, median time to recurrent TB disease was not different 
between HIV-infected and uninfected persons, at 9.7 months (95% CI, 4.9 to 14 
months) and 7.1 months (95% CI, 4 to 10 months), respectively (Korenromp et al. 
2003). Rate of TB recurrence was two-fold higher in HIV-infected persons in 
comparison to HIV-uninfected persons in a study of recurrent TB disease over a 10-
year follow up period (Crampin et al. 2010). Therefore, recurrent TB contributes 
significantly to the TB burden in HIV co-infection, and identification of HIV-infected 
persons at risk of recurrent TB disease is important if we are to decrease the burden 
of TB in HIV-infected populations.  
 
1.6.3 HIV immmunopathogenesis and it’s relevance for TB!
Immune activation and systemic inflammation are hallmarks of HIV 
immmunopathogenesis and high levels of both are associated with risk of 
progression to AIDS. Hyper-activation and exhaustion of the immune system and 
depletion of CD4 T cells due to untreated HIV infection results in chronic immune 
dysfunction (Catalfamo et al., 2008; Klatt et al., 2013). Depletion of CD4 T cells and 
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HIV viremia lead to increased proliferation of CD4 T cells, which is accelerated by 
the inflammatory milieu induced by the virus (Catalfamo et al. 2008). This immune 
activation can be measured by CD38 and HLA-DR activation on CD8 and CD4 T 
cells, and is significantly higher in HIV-infected persons relative to uninfected 
controls (Joshi et al. 2016; Deeks et al. 2004).  
 
Damage to the mucosal barriers and lymphoid structures in the gut are major drivers 
of immune activation and dysfunction in HIV infection (Brenchley et al., 2006; Deeks 
et al., 2013; Klatt et al., 2013). In addition, gut leakage is a contributing factor to 
inflammation in HIV infection as it leads to an increase in inflammatory cells such 
plasmacytoid dendritic cells (pDCs), neutrophils and monocytes in peripheral blood 
(Klatt et al. 2013; Somsouk et al. 2015). This inflammation drives T cell migration to 
the damaged tissue, leading to a higher concentration of activated target cells, 
thereby making HIV replication more efficient (Klatt et al. 2013). HIV infection 
depletes CD4 T cells, an important cell subset in TB control, increasing susceptibility 
of HIV-infected people to progress from Mtb infection to TB disease (Caruso et al., 
1999; Diedrich & Flynn, 2011; Lawn et al., 2009; Lin et al., 2012). Furthermore, 
infection with HIV significantly decreases memory CD4 T cell responses to not only 
the virus but also to other opportunistic infections as early as a few days after 
infection (Veazey and Lackner 2005). Additionally, HIV infection impairs the ability of 
CD4 T cells to respond to Mtb-specific antigens by altering the balance of their 
functional profile through the selective depletion of IFNγ-producing cells (Riou et al. 
2016). Hence, HIV infection increases susceptibilty to TB disease and other 
opportunistic infections and is associated with high levels of immune activation and 
systemic inflammation. 
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Antiretroviral drugs that target HIV to arrest viral replication should be given as 
combination treatment, referred to as ART. ART regimens typically prescribed in 
recent years consists of two nucleoside/nucleotide reverse transcriptase inhibitors 
and a third drug from a different class, such as protease inhibitors (Cihlar and 
Fordyce 2016). ART suppresses the replication of HIV thereby decreasing circulating 
viral loads, resulting in an asymptomatic aviremic state in most HIV-infected persons. 
The associated immune reconstitution has been shown to decrease morbidity and 
mortality. However, immune activation and persistent inflammation remain elevated 
in HIV-infected persons who receive effective ART, in comparison to HIV-uninfected 
persons, even if viral loads become undetectable (Klatt et al. 2013). Consequently, 
the risk of opportunistic infections, including TB, remain elevated in persons on ART 
relative to HIV-uninfected persons. A biomarker or blood-based diagnostic test that 
could identify individuals at high risk of TB would allow targeted investigation and 
treatment of individuals either with TB treatment in those with disease, or with 
preventive therapy in those who are not yet sick.  
 
1.7 The search for a biomarker of TB disease and/or protection against TB: 
Transcriptomic signatures as biomarkers for TB disease  
Despite what has been learnt of the relationship between Mtb and the host, 
components of protective immunity remain largely unknown. A biomarker is “a 
characteristic that is objectively measured and evaluated as an indicator of 
physiological or pathological processes or pharmacological responses to a 
therapeutic intervention” (Parida & Kaufmann, 2010). Biomarkers of TB would ideally 
allow the diagnosis, prediction of risk and monitoring of treatment response of active 
TB disease using easily accessible bodily fluids such as blood. This would facilitate 
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early diagnosis of active TB, provision of targeted preventive therapy and allow 
customisation of the length of TB treatment. The advent of new genome-wide 
technology, particularly the “omics” technologies, offers new tools in the discovery of 
biomarkers in diagnosis of active TB using unbiased, hypothesis-generating 
approaches (Cliff et al., 2015). This has led to an explosion of data in the field of 
biomarker studies. A profile of combined biomarkers is known as a signature (Parida 
& Kaufmann, 2010).  
 
Early published studies showed that differential expression levels of selected 
mRNAs in blood leukocytes, measured by microarray, can accurately classify 
persons with Mtb infection and persons with active TB, demonstrating that 
combinations of transcriptomic biomarkers hold promise as diagnostic signatures 
(Jacobsen et al. 2007; Mistry et al. 2007). Mistry and colleagues identified nine gene 
transcripts that were differentially expressed between active TB, recurrent TB, cured 
and Mtb-infected persons (Mistry et al. 2007). Jacobsen et al, suggested that 
expression levels of only three genes could be used to discriminate between TB 
disease and healthy Mtb-infected controls with an accuracy of 85% (Jacobsen et al. 
2007). A more recent publication, the first study to describe in detail, a gene 
signature due to the presence of active TB disease, identified a 393-gene signature 
that distinguished active TB from healthy Mtb infection and other diseases with 
promising accuracy (Berry et al. 2010). The signature also correlated with the extent 
of radiographic disease, suggesting that this blood signature reflected pulmonary 
disease severity (Berry et al. 2010). A common theme in these studies was that 
many if the most differentially expressed genes mapped to the type I/II interferon 
(IFN) pathways and were interferon-stimulated genes (ISGs). Interestingly, the most 
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prominent differences in expression of these ISGs were observed in myeloid cells 
such as neutrophils and monocytes, although they were also differentially expressed 
to a lesser degree in lymphoid cells such as CD4 and CD8 T cells (Berry et al. 2010). 
In a Gambian cohort, Maertzdorf et al discovered a signature that could differentiate 
active TB from healthy Mtb infection (Maertzdorf et al., 2011). An increase in 
complement and inflammation-associated genes in active TB disease has been 
observed in addition to differences in type I IFN genes (Maertzdorf et al., 2011). 
However, the signature could not differentiate healthy non-Mtb-infected (TST 
negative) persons from Mtb-infected persons (Maertzdorf et al., 2011). Pathway 
analysis of the 1,000 most differentially expressed genes in this signature again 
revealed an enrichment of type I IFN genes, which have also been shown to be 
involved in systemic lupus erythematosus. Furthermore, genes involved in the JAK-
STAT and complement pathways were highly expressed in active TB patients. More 
recently, studies have been published using different transcriptomic analysis 
platforms that could differentiate active TB from healthy Mtb infection in whole blood 
and peripheral blood mononuclear cells (PBMCs) (Lee et al. 2016; Lu et al. 2011; 
Walter et al. 2016). These studies suggest that whole blood transcripts involved in 
type I/II IFN pathways are involved in TB disease pathology and that transcripts can 
be used to distinguish between TB diseased and Mtb-infected or healthy individuals. 
 
Since several diseases, such as sarcoidosis, melioidosis and pneumonia, share a 
similar pathology with TB, it is particularly challenging to definitively make a TB 
diagnosis in the absence of microbiological confirmation of Mtb. Diagnosis of TB 
using non-specific methods such as symptom screening and chest X-rays may 
therefore lead to a misdiagnosis and provision of incorrect care. To determine if 
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blood-based transcriptomic signatures can improve the diagnosis of TB, several 
studies have identified gene signatures that distinguish TB from other diseases, 
which mimic and/or present in the same manner as TB. Maertzdorf and colleagues 
observed a significant overlap in type I/II IFN signalling genes identified to be 
differentially expressed between active TB disease or sarcoidosis and healthy 
controls (Maertzdorf et al., 2012). Another transcript signature of active TB disease 
was also found to be expressed in sarcoidosis patients and increased type I/II IFN 
gene modules was observed in both diseases relative to healthy controls (Bloom et 
al. 2013). In contrast, these signatures were different from signatures expressed in 
pneumonia and lung cancer patients, in whom upregulation of myeloid inflammatory 
modules was observed (Bloom et al. 2013). Koth et al observed the same 
phenomenon, wherein differentially expressed transcripts overlapped between 
sarcoidosis and active TB (Koth et al. 2011). Another bacterial disease, melioidosis 
with pathology similar to TB, has been shown to also have a signature that largely 
overlaps with active TB signatures (Koh et al. 2013). An attempt to develop a 
signature that could distinguish melioidosis from active TB was not successful (Koh 
et al. 2013). These studies suggest that blood transcriptomic signature profiles 
reflect underlying systemic activation of proinflammatory pathways, such as type I/II 
IFN signalling genes, and might not have the appropriate specificity to stratify active 
TB disease from other relevant diseases.  
 
While considerable overlap is seen between the gene signatures of active TB 
disease identified in different studies mentioned above, each signature consists of 
unique sets of differentially expressed genes. This could be due to different clinical 
study designs, diagnosis methods, underlying epidemiology and the diverse 
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platforms, methodologies and statistical approaches used in assessing differentially 
expressed genes, which are very variable (Maertzdorf et al., 2015). A recent study 
attempted to combine analysis of all the genes identified in multiple TB biomarker 
studies (Berry et al., 2010; Cliff et al., 2013; Jacobsen et al., 2007; Maertzdorf et al., 
2012; Maertzdorf et al., 2011; Maertzdorf et al., 2011; Mistry et al., 2007; Ottenhoff et 
al., 2012) to assess common pathways involved in the pathogenesis of TB (Joosten 
et al., 2013). The study identified 409 genes associated with active TB, which were 
strongly associated with myeloid-derived inflammatory pathways, with the TREM1 
signalling pathway representing one of the most significant pathways. Genes 
involved in the type I/II IFN signalling pathway were identified, but expression 
differences were not as large as those associated with myeloid and TREM1 
signalling pathways (Joosten, Fletcher, and Ottenhoff 2013). A more recent study re-
analysed 16 published datasets in an attempt to update the study done by Joosten 
and colleagues (Blankley et al. 2016). A 380-gene signature, consistently up or down 
regulated in at least nine datasets, was identified. Five genes (AIM2, BATF2, 
FCGR1B, Haptoglobin and TLR5) were consistently differentially expressed in all 16 
datasets. As observed by Joosten et al, this signature consisted mainly of IFN 
signalling and TREM-1 signalling genes in addition to genes involved in complement 
activation, pattern recognition and IL-6 signalling pathways.  
 
There is a lack of concordance of signatures of active TB between studies, and 
significant overlap of transcript signatures with other diseases. Singhania and 
colleagues recently deposited a pre-peer reviewed article in the BioRxiv repository 
aimed at identifying a signature specific to active TB (Singhania et al. 2017). In this 
study, they re-identified the 393-transcript signature developed previously from 
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microarray data (Berry et al., 2010) by performing RNA sequencing (RNA-seq) on 
the same cohort. The newly developed 373-gene signature showed significant 
overlap with the 393-transcript microarray signature. They then applied their new 
373-gene signature, the 27 and 44-gene signatures from Kaforou et al, (discussed 
below) and the 16-gene signature from Zak et al, (discussed below) to independent 
published datasets of influenza, bacterial pneumonia, sarcoidosis, lung cancer and 
other viral and bacterial infections. A 303-gene signature was derived from the 373-
gene signature, which was specific to active TB, i.e. not detected in the other 
diseases. A smaller gene signature (n=20) was then refined, which could 
differentiate active TB from healthy Mtb infection with fewer false positives. The 
authors attributed this to the improved specificity since this signature did not detect 
viral and bacterial infections in the published datasets. This study suggests that 
despite overlap of TB signatures, a type I/II IFN signature highly specific for TB could 
be discovered if individuals with other diseases that mimic TB are included in the 
discovery and validation of TB signatures.  
 
The biomarkers and signatures described above were developed using expensive 
tools such as microarray, which make implementation of tests based on such 
signatures difficult in clinical settings of TB endemic regions. These biomarkers need 
to be translated into “clinically useful algorithms, using relatively simple tests” that 
can be used at point of care (Walzl et al. 2014). Due to the number of genes in many 
of the TB signatures it would be difficult to translate these signatures into point of 
care tests. Several studies have assessed smaller signatures using microarrays, 
some of which have attempted to translate these to allow simpler measurement, 
such as polymerase chain reaction (PCR) assays. A four-gene signature discovered 
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in HIV-uninfected persons by microarray and translated into reverse transcriptase 
PCR (RT-PCR) could distinguish active TB disease from healthy Mtb infection with 
an area under the receiver operating characteristic curve (ROC AUC) of 0.98 (95% 
CI: 0.97-1.00) (Maertzdorf et al., et al., 2015). The signature, consisting of GBP1, 
IFITM3, P2RY14, and ID3 genes, was validated in Ugandan and Gambian cohorts, 
and applied to published microarray datasets and differentiated active TB from 
healthy Mtb infection and other diseases (sarcoidosis, pneumonia, and lung cancer) 
with excellent sensitivity and specificity (Maertzdorf et al., 2015).  
 
Thirteen differentially expressed genes from the three published datasets of Berry et 
al, were applied to a Thai cohort to differentiate active TB from healthy Mtb infection 
(Satproedprai et al. 2015). A “TB sick score” was calculated from seven of 11 
quantifiable genes using predictive logistic regression. The TB sick scores could 
differentiate active TB disease from Mtb-infected healthy controls, however the 
sample size for this study was small and no external validation cohort was available. 
These smaller gene signatures can be more easily integrated into clinical settings 
using battery-operated devices such as gene chip devices, which may become 
available for point of care applications in the near future (Maertzdorf et al., 2015). 
One such device is the GeneXpert® Omni, a small and portable battery-operated 
diagnostic device from Cepheid (Cepheid 2017), which can extract, amplify and 
detect Mtb DNA. Expression of the BATF2 gene alone could distinguish active TB 
disease from healthy controls and was identified by comparing changes in transcript 
signatures of active TB patients at diagnosis and two to four years after the end of 
TB treatment,  (Roe et al. 2016). BATF2 expression could also diagnose active TB 
disease from healthy Mtb infection when applied to external datasets. BAFT2, 
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however, applied to a cohort of individuals with fever, could not differentiate between 
active TB and fever due to other infectious diseases (Roe et al. 2016).  
 
1.8 Biomarkers of TB in HIV co-infection!
TB mortality is higher in HIV-infected patients with smear negative TB compared to 
HIV-uninfected patients. This is likely due to many causes, but primarily the effect of 
HIV on immunosuppression, further underestimating disease intensity (Getahun et 
al. 2007). Low bacillary load in the sputum, as mentioned above, complicate the 
diagnosis of active TB disease in HIV infection. New tools are needed to diagnose 
and predict active TB disease in this population. Only very few studies have 
measured gene signatures for active TB disease in HIV-infected persons. 
Furthermore, to our knowledge only four published studies have developed transcript 
signatures aimed at differentiating active TB from other diseases in HIV-infected 
persons (Anderson et al., 2014; Dawany et al., 2014; Kaforou et al., 2013; Sweeney 
et al., 2016). Of these, three developed signatures in cohorts including HIV-infected 
persons (Kaforou et al. 2013; Anderson et al. 2014; Dawany et al. 2014), whilst one 
developed a signature from publicly available datasets which include both HIV-
infected and uninfected persons (Sweeney et al. 2016). Kaforou and colleagues 
developed a 27-transcript and 44-transcript signature to distinguish active TB from 
Mtb infection and other diseases, respectively (Kaforou et al. 2013). The signatures 
were developed using samples from both HIV-infected and uninfected participants. 
Signatures developed by Berry et al, were applied to the Kaforou cohort and a lower 
performance of the Berry signatures was observed, particularly in the HIV-infected 
participants. Anderson and colleagues discovered a 51-transcript and a 42-transcript 
signature that could differentiate active TB from other diseases and Mtb infection, 
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respectively in children (Anderson et al. 2014). Currently, only one published study, 
by Dawany et al, has derived a transcriptomic signature from HIV-infected persons 
only. The study identified 251 differentially expressed genese that could distinguish 
active TB from controls in HIV-infected persons (Dawany et al. 2014). The signature 
was applied to published datasets of HIV-uninfected persons and could differentiate 
participants with active TB from participants with Mtb infection with an accuracy of 
88.9% to 94.7%. The performance of the 393-gene signature from Berry and 
colleagues was also tested on this cohort, however it failed to accurately discriminate 
HIV-infected controls from HIV-infected TB cases (Dawany et al. 2014). Sweeney et 
al developed a three-gene signature from 14 publicly available datasets including 
HIV-infected persons, which was able to differentiate active TB from Mtb infection 
and other diseases (Sweeney et al. 2016). The signature was developed from the 
Berry (HIV-uninfected), Bloom (HIV-uninfected) and Kaforou (HIV-infected and 
uninfected) datasets (Berry et al., 2010; Bloom et al., 2013; Kaforou et al., 2013), 
and could differentiate active TB from Mtb infection and other diseases in both the 
discovery and validation sets. A lower performance of the Sweeney signature was 
observed in HIV-infected persons in differentiating active TB from Mtb infection ROC 
AUC, 0.89 (95 % CI: 0.87-0.91) in comparison to HIV-uninfected persons ROC AUC, 
0.97 (95 % CI: 0.95-0.98) from the same setting.   
 
Several recently published gene expression signatures have applied signatures 
developed from HIV-uninfected persons to the Kaforou and Dawany datasets. The 
four-gene signature of Maertzdorf and colleagues was applied to both datasets 
(Maertzdorf et al., 2015) and could differentiate active TB from Mtb infection in both 
cohorts and active TB from other diseases in the Kaforou dataset. The one-gene 
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signature from Roe and colleagues was also applied to the Kaforou HIV-infection 
dataset. A ROC AUC of 0.84 was observed in this cohort, possibly due to the higher 
expression of BATF2 in the HIV-infected Mtb-infected persons in comparison to their 
HIV-uninfected (AUC, 0.95) counterparts (Roe et al. 2016). Walter and coworkers 
applied their signatures to the Kaforou dataset and showed that the signatures could 
distinguish active TB from Mtb infection and other diseases in HIV-infected persons 
with a performance of 98.0% (95% CI: 97.8% to 98.3%) vs 82.8% (95% CI: 82.4% to 
83.2%). A lower specificity of 76.3% vs 87.9% was observed in the HIV-infected 
cohort in comparison to their discovery cohort of HIV-uninfected persons (Walter et 
al. 2016). In the above-mentioned studies, due to high gene expression in HIV-
infected Mtb-infected persons relative to HIV-uninfected controls, an increase in false 
positives was observed lowering the specificity of the signatures in HIV-infected 
persons. Hence, the signatures had a decreased specificity which led to consistently 
poorer performance in HIV-infected persons compared with HIV-uninfected cohorts. 
Consequently, these studies suggest that HIV-infection decreases the accuracy of 
transcriptomic signatures developed in HIV-uninfected persons. These signatures 
are promising for the  development of point-of-care screening tools to identify 
individuals who would be tested further to confirm active TB disease. The 
Foundation for Innovative New Diagnostics (FIND) and the WHO developed a 
document describing the product specifications of a screening test and non-sputum 
based diagnostic tool (World Health Organization 2014). The performance of such 
tests (signatures) and operational characteristics (sensitivity and specificity) should 
meet minimal requirements set out in the target product profile (TPP) document to be 
considered as a triage tool. As a triage test, a diagnostic or triage signature would 
ideally be used during a patient’s first encounter in a health care setting. Hence, it 
! 37!
has to perform with equivalent or greater sensitivity than the confirmatory test, 
otherwise patients would be missed by the test (Denkinger et al. 2015). The TPP for 
a screening tool states that it should have a diagnostic sensitivity of at least 95% and 
a specificity of 80% for culture-positive TB. Most publications of the signatures 
described above report ROC AUCs but not sensivities and specificities of the 
signatures, precluding assessment of performance against the TPP. It is important to 
note that in some of the studies mentioned in the sections above, the investigators 
aimed to identify gene expression profiles that could diagnose TB disease as well as 
describe the biological roles of the identified expression profiles in TB. Another 
limitation in some studies is the lack of validation cohorts making it near-impossible 
to determine the true performance of the suggested signatures and their true 
potential as triage tests. Thus, in designing studies for identification and 
development of triage tools, studies should include blinded validation in independent 
cohorts and report the performance as sensitivities and specificities as well as 
positive predictive values and negative predictive values of the signatures in such 
cohorts.   
 
1.9 Biomarkers of risk of TB (prognostic biomarkers)!
The post-2015 end-TB strategy aims to reduce the global TB incidence by 90% and 
mortality by 95% by the year 2035 (Uplekar et al. 2015). Another aim is a 50% and 
75% reduction in incidence and mortality, respectively by 2025 (Uplekar et al. 2015). 
Elimination of TB by 2050 will require a reduction in the annual TB incidence rate at 
an average of 20% between 2015 and 2050, which translates to less than 9,000 
cases amongst the estimated global population of nine billion people by 2050 (Dye et 
al. 2013). Attainment of the 2025 end TB strategy is feasible, but only if interventions 
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are carefully tailored to the epidemiology and existing TB control tools are used to 
their maximal capacity in individual countries (Houben et al. 2016). However, with 
current technologies, procedures and services TB elimination by 2050 is impossible 
(Dye et al. 2013). New technologies that improve diagnosis, treatment and pre-
exposure vaccination have the ability to decrease TB incidence by 71% in 2050 
(Abu-Raddad et al. 2009). However, such new technologies are still out of reach, 
emphasising the urgent need for research and development. Screening is still a 
public health priority in eliminating TB by the diagnosis and treatment of Mtb infection 
(Auguste et al., 2016). Without novel and more effective technologies, early case 
detection and effective treatment could be the best strategy to reduce TB incidence 
to achieve the stop-TB strategy by 2050 (Dye et al. 2013).  
It is thought that a tool that can identify individuals at risk of developing active TB 
before they present with symptoms, allowing targeted provision of preventive therapy 
would be major advance (Dowdy et al., 2008). Mathematical modelling suggests that 
mass treatment of Mtb-infected persons with preventive therapy may help to reduce 
TB incidence by up to 64% (Abu-Raddad et al., 2009). However, it is not feasible to 
provide mass preventive therapy to the estimated one-quarter of the global 
population who are Mtb-infected, when only 5% to 10% of infected individuals are 
likely to progress to disease (Esmail et al., 2014). Although this may prevent many 
cases of incident TB, adherence to long-course antibiotics is a serious challenge and 
those who are not at risk of progression would be exposed to the harmful 
hepatotoxic effects of drugs such as INH.   
 
Identification of those individuals at risk of developing TB disease has traditionally 
been very challenging (Lin et al. 2016) because individuals that comprise the 
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enormous Mtb infected reservoir are typically asymptomatic, detection of the 
infecting bacterium is not possible and the infection can last for decades (Rangaka et 
al. 2015). It is believed that adherence to preventive therapy can be increased if the 
subset of persons at real risk of progressing to active TB disease are identified 
(Dodd and Schlesinger 2017). Current Mtb infection diagnosis methods are very 
poor at predicting progression to active TB disease in Mtb-infected persons and 
close contacts of active TB persons. A weak association between positive IGRAs 
and development of active TB disease, incidence rate ratio, 2.10 (95% CI: 1.42 to 
3.08) was observed in a meta-analysis of published data sets (Rangaka et al. 2012).  
 
Biomarkers of risk of active TB disease will allow identification of persons at highest 
risk of developing TB at an early stage, before they are sick and ideally before 
transmission of Mtb has occurred. This would add to the arsenal of tools for Mtb 
elimination, because biomarkers of risk would allow targeted preventive antimicrobial 
therapy to prevent TB disease (Ottenhoff et al., 2012; Penn-Nicholson et al., 2016; 
Salgame et al., 2015). Many studies have discovered and validated blood 
transcriptomic signatures that differentiate individuals with active TB disease from 
healthy individuals with or without Mtb infection with promising accuracy (Berry et al. 
2010; Sweeney et al. 2016; J. Maertzdorf et al. 2011). This body of work has opened 
the possibility that such diagnostic blood transcriptomic signatures could be 
developed as triage tests that could identify persons with TB for more intensive 
investigation. These advances also provide feasibility and impetus to determine if 
prognostic blood transcriptomic signatures can be identified that can predict 
progression to incident TB. Monocyte/lymphocyte ratios were associated with in vitro 
mycobacterial growth and transcriptional signatures of monocytes (Naranbhai et al. 
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2015), suggesting an association between disease progression and 
monocyte/lymphocyte ratios. Additionally, activated CD4 T cells have been 
associated with an increased risk of progression to active TB disease in HIV-
uninfected South African adolescents (Fletcher et al. 2016). To date two studies 
have attempted to identify transcriptomic signatures that could predict active TB 
before the onset of disease (Sloot et al. 2015; Zak et al. 2016). Sloot and colleagues 
identified 50 genes that were differentially expressed in HIV-infected persons who 
developed active TB and controls who remained healthy, at least 180 days before 
diagnosis (Sloot et al. 2015). This study was cross-sectional, with a poorly 
characterised small cohort of 14 cases and 15 controls and the signature was not 
validated in an independent cohort. In a landmark study my colleagues at SATVI 
collaborated with investigators at the Center for Infectious Disease Research to 
identify a 16-gene, 57 transcript, signature by RNA-Seq that could predict active TB 
disease in a longitudinal cohort of South African adolescents more than a year 
before onset of disease (Zak et al. 2016). This signature is discussed in more detail 
in the section below.  
 
1.9.1 The ACS 16-gene signature (Zak et al., 2016)!
The adolescent cohort study was conducted in South African adolescents who were 
followed-up for two years to determine the prevalence and incidence of Mtb infection, 
TB disease and risk factors for developing TB (Mahomed et al. 2013). Healthy 
adolescents (n=6,363) were recruited at 11 high schools from the Worcester area 
outside Cape Town. Participants were allocated to two groups with different follow-
up methods. Those in the active follow-up group were assessed every 3 months and 
had blood samples drawn every six months for QFT, PAXgene, plasma and PBMC 
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collection. Those in the passive follow-up group were assessed and had blood 
collected at baseline and two years after enrolment. The surveillance team accessed 
clinical records to identify TB cases diagnosed in the public health sector for both 
groups. Whole blood was collected in PAXgene tubes from each study participant at 
the follow-up time points in addition to clinical data. Microbiologically confirmed 
active TB disease (two consecutive sputum smear tests or one sputum culture 
positive test) was diagnosed during follow-up in 87 adolescents in total, and 46 
qualified as progressors for our biomarker study (Zak et al. 2016). The progressors 
were matched to 107 healthy Mtb-infected controls by ethnicity, school, gender, age 
and prior episodes of TB disease at enrolment, and were referred to as non-
progressors. The progressors and non-progressors were split into a training set for 
signature discovery and a test set for blind validation at a ratio of 3:1. All participants 
included in this analysis were Mtb-infected (QFT and/or TST positive) at 
baseline/enrolment.  
 
RNA-sequencing was used to measure transcript expression in this cohort by 
comparing the progressors and non-progressors. Unlike microarrays, RNA-
sequencing does not rely on pre-defined probe-based sequences, thereby allowing 
less biased identification of novel transcripts which were previously unknown 
(Blankley et al. 2014). Support vector machines (SVMs), a generalised linear 
classifier, was used to generate the signature in this population (Zak et al. 2016). 
This algorithm “maps data points onto a multidimensional space in such a way that it 
is possible to calculate a hyperplane (a multidimensional plane), which separates the 
classes of samples” (Maertzdorf et al., 2015). Multiple pair-wise ensemble models 
(representing two transcripts each) that could predict TB disease risk based on 
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splice junction counts measured by RNA-seq were developed. A transcript signature 
consisting of 16 differentially expressed interferon response genes representing 47 
splice junctions plus 10 reference splice junctions could predict progression to TB 
disease in the progressors (Figure 1). The signature, henceforth referred to as the 
ACS 16-gene signature, was adapted to microfluidic quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) to reproduce the findings using a 
different measurement platform, allow more high-throughput and cheaper 
measurement, and to prepare for translation to near-patient testing. Splice junctions 
from the RNA-seq data were matched to TaqMan primer-probe sets for this and the 








Figure 1: Network visualisation of the transcript pairs in the ACS 16-gene 
signature (adapted from Zak et al., 2016). The nodes represent splice junctions 






























































The PCR-based signature model was fitted to the Ct value data in the training set. 
The qRT-PCR signature consisted of 47 genes of interest (GOI) primer-probes, 
representing 247 gene-pairs and 10 reference primer-probes for standardization (to 
calculate delta Ct values, Table 1). The signature is comprised of the following 
genes: FCGR1B, FCGR1A, STAT1, GBP1, GBP2, GBP4, GBP5, SERPING1, ETV7, 
BATF2, SCARF1, APOL1, TAP1, TRAFD1, ANKRD22 and SEPT4. Signature scores 
are calculated by summing the product of normalised abundances (delta Ct values) 
of two gene products (a gene-pair) with their coefficients and a coefficient of the 
gene-pair. Custom scripts, written in R, were applied on the results generated from 
the microfluidic qRT-PCR to calculate a single signature score per sample, 
expressed as a percentage. The signature scores are directly correlated with gene 
expression, thus an increasing signature score translates into a high gene 
expression. A higher score thus implies higher gene expression. The various 
transcripts could contribute differently to different sample types and signature scores 
would remain high in all these samples. The proportion of transcript-pairs voting a 
case relative to the total number of voting pairs is what determines the signature 
scores. 
 
In the training set, the signature score in progressors increased closer to TB 
diagnosis. The signature could predict active TB disease up to a year before TB 
diagnosis with a sensitivity of 71.2% (ROC AUC, 0.79, 95% CI: 0.76 to 0.82) and 
62.9% (ROC AUC, 0.77, 95% CI: 0.75 to 0.79) at 1-180 days and 181-360 days 
before TB diagnosis, respectively. RT-PCR data from the test set cohort were used 
to perform blind predictions, which demonstrated that the signature could predict 
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active TB in the test cohort up to a year before diagnosis with a sensitivity of 66% 
and specificity of 81%.  
 
For external validation, the signature was applied to blinded samples from an 
independent cohort of household contacts of active TB disease from the Grand 
Challenges 6-74 (GC6-74) cohort. Samples from 73 progressors and 301 non-
progressors from South Africa and Gambia were evaluated. The signature could 
predict active TB in this cohort up to a year before diagnosis with a sensitivity and 
specificity of 54% and 83%, respectively, with a ROC AUC of 0.72 (95% CI please). 
In addition, the signature was reparameterised to publicly available microarray 
datasets (Anderson et al., 2014; Berry et al., 2010; Bloom et al., 2012, 2013; Kaforou 
et al., 2013) to determine the diagnostic performance of the ACS 16-gene signature 
for discriminating active TB from uninfected or Mtb-infected controls or controls with 
other respiratory diseases. The signature performed well and showed excellent 
promise as a diagnostic and prognostic biomarker for TB. A more practical version of 
this signature (ACS 11-gene, described below) consisting of 48 transcripts was 
tested in this thesis.  
 
1.9.2 The ACS 11-gene signature: a more practical PCR-based signature 
derived from the ACS 16-gene signature  
Measurement of the 57 primer-probes (47 primer-probes and 10 reference primer-
probes) that comprise the ACS 16-gene signature by microfluidic qRT-PCR is ideally 
done using the 96.96 gene expression platform with the BioMark HD instrument 
(Fluidigm). To improve throughput and practicality of measurement, we set out to 
remove nine primer-probes to allow 48 primer-probes to be measured in duplicate on 
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the 96 by 96 platform. This would allow simultaneous testing of 96 samples in a 
96.96 gene expression chip. Primer-probes were removed based on three main 
criteria: 1) reproducibility in qRT-PCR assays, 2) redundant signal to overall 
signature and 3) number of pairs formed with other transcripts (Table 1) (Darboe et 
al., 2018, Appendix 1). Nine IFN response primer-probes were removed, 
representing ANKRD22, APOL1, FCGR1A, GBP4 and SEPT4 and the 10 reference 
genes were retained. The remaining 38 primer-probes represented 11 type I IFN 
genes and formed 231 gene-pairs. This new signature was referred to as the ACS 
11-gene signature. The ACS 11-gene signature scores are calculated in the same 
way as the ACS 16-gene signature scores, as described above.  New transcript pairs 
were not chosen during signature development, transcript pairs from the 16-gene 
signature were maintained. A pair was only removed if at least one of the transcripts 
in the pair was excluded from the signature.  
 
 
To determine how reduction of the ACS 11-gene signature affected the signature we 
compared signature scores and prognostic performance to that of the ACS 16-gene 
signature in the ACS training and test cohort samples (progressors vs non-
progressors). Signature scores were identical between the ACS 11 and 16-gene 
signatures in the ACS cohort (Figure 2A). In addition, the prognostic performance of 







Table 1: Primer-probes included in the ACS 16-gene and 11-gene signatures 
TaqMan primer probe in 
the ACS 16-gene signature Number of gene pairs  
Excluded from the ACS 11-
gene signature 
ACTR3.Hs01029159_g1 Reference   
ADRBK1.Hs01056345_g1 Reference  
CDC42.Hs03044122_g1 Reference  
CSDE1.Hs00918650_m1 Reference  
CYTIP.Hs00188734_m1 Reference  
TMBIM6.Hs01012081_m1 Reference  
TMBIM6.Hs00162661_m1 Reference  
TMBIM6.Hs01012082_g1 Reference  
TPM3.Hs01900726_g1 Reference  
USF2.Hs01100994_g1 Reference  
ANKRD22-j2 1 X 
APOL1.Hs00358603_g1 1 X 
FCGR1A.Hs02340030_m1 1 X 
GBP4.Hs00925073_m1 1 X  
STAT1.Hs01014001_m1 1 X 
TAP1.Hs00388675_m1 1  
GBP5.Hs00369472_m1 2  
STAT1.Hs01014006_m1 2 X 
STAT1.Hs01014008_m1 2 X 
ETV7.Hs00903228_m1 3  
FCGR1C.Hs00417598_m1 3  
GBP2.Hs00894840_mH 3  
SCARF1.Hs01092482_g1 3  
STAT1.Hs01013990_m1 3 X 
STAT1.Hs01014000_m1 3  
GBP5-j4 4  
SEPT4.Hs00910208_g1 4 X 
STAT1.Hs01013989_m1 4  
STAT1.Hs01013991_m1 4  
STAT1.Hs01013992_g1 4  
STAT1.Hs01013994_m1 5  
STAT1.Hs01013996_m1 6  
STAT1.Hs01013997_m1 6  
SCARF1.Hs00186503_m1 7  
STAT1.Hs01013995_g1 7  
BATF2.Hs00912736_m1 8  
SCARF1.Hs01092483_m1 8  
SERPING1.Hs00163781_m1 9  
SERPING1.Hs00934328_g1 9  
STAT1.Hs01013993_m1 9  
STAT1.Hs01014002_m1 9  
TAP1.Hs00897093_g1 9  
ETV7-j2 10  
ETV7.Hs00903230_g1 10  
SCARF1.Hs01092485_g1 12  
TRAFD1.Hs00938765_m1 14  
STAT1.Hs01013998_m1 15  
GBP2-j1 16  
GBP2.Hs00894842_g1 16  
SERPING1.Hs00934329_m1 19  
SERPING1.Hs00934330_m1 22  
SERPING1.Hs00935959_m1 23  
GBP1.Hs00977005_m1 25  
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GBP1-j1 32  
GBP2.Hs00894837_m1 33  
GBP1.Hs00266717_m1 40  





Figure 2: Comparison of signature scores and prognostic performance of the ACS 16 and 11-
gene signatures in the ACS cohort. A) Correlation of signature scores between the ACS 16 (57 
primer-probe) and 11-gene (48 primer-probe) signatures. The Spearman correlation coefficient is 
shown. B) Receiver Operating Characteristic curves depicting performance of the signatures in 














































































































































































































































































































Spearman r = 0.99






































 AUC (95% CI) p-value
B
57 primers    0.83 (0.77-0.83)      1.1 x 10-14
48 primers    0.84 (0.77-0.83)       6.0 x 10-15
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1.10 Biomarkers of treatment success in the presence and or absence of HIV 
infection!
Adherence to a long-term TB treatment is a major problem in the control of TB, as 
poor adherence has been observed to be one of the main factors leading to drug 
resistance. Biomarkers of treatment success and or failure would allow better 
treatment monitoring, customisation of treatment duration to individuals and 
detection of poor treatment response much earlier. These advances may reduce 
non-adherence and accelerate the recognition of poor outcomes before patients 
complete treatment (Walzl et al. 2014). In addition, they would allow ineffective 
treatment regimens to be adjusted in individuals not responding to treatment. An 
added potential advantage of treatment response markers is that they may inform 
shortening of treatment regimens in persons who are “cured” well before the 
traditional 6-month regimen is completed. Currently, sputum conversion from a 
positive to a negative culture at two months is used as an early marker of treatment 
response. This takes very long because a negative culture result requires up to 42 
days, and it a poor predictor of relapse. A meta-analysis of sputum conversion at two 
months observed a pooled sensitivity and specificity of 40% and 80% respectively for 
predicting relapse (Horne et al. 2010).  
 
Biomarkers of TB treatment response would allow more rapid and potentially more 
accurate prediction of cure. Expression of active TB disease transcriptional 
signatures have been shown to decrease during TB treatment, suggesting that blood 
transcriptional signatures may be used to monitor TB treatment (Berry et al., 2010; 
Bloom et al., 2012; Ottenhoff et al., 2012). The 393-transcriptomic signature 
identified by Berry et al. diminished in active TB patients by two months after start of 
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TB treatment (Berry et al., 2010). In addition, the signature was shown to be strongly 
associated with extent of disease on chest radiography. A 664-transcript signature 
derived to distinguish active TB disease from Mtb infection by Bloom et al. 
decreased during TB treatment as early as two weeks after initiation of therapy 
(Bloom et al. 2012). Similarly, a PBMC-derived transcriptomic signature decreased 
during TB treatment, with a similar profile observed at 28 weeks between “cured” 
participants and healthy Mtb-infected controls (Ottenhoff et al., 2012). Another study 
aimed at deriving a transcriptomic signature of TB treatment reported a perturbation 
of 1,261 genes in the first week of TB treatment (Cliff et al. 2013). Of these, 780 
genes remained differentially expressed after two and four weeks of therapy in 
comparison to at diagnosis. Genes involved in the IFN pathway were downregulated 
during TB treatment with the most significant changes occurring in the first week of 
therapy (Cliff et al. 2013). On the other hand, genes involved in the T cell, B cell and 
cytotoxic cells were upregulated at the end of 26 weeks of therapy, with the B cell 
modules being the most significant fold change from baseline. In the same study, a 
signature of 62 genes forming a neural network could determine the stage of TB 
therapy i.e. diagnosis from on-going treatment and end of treatment. Similarly, in a 
non-human primates (NHP) study of Mtb-infected cynomolgus macaques an 
association between transcriptomic signatures and bacterial load was observed that 
suggested blood IFN signatures may reflect pulmonary Mtb replication (Gideon et al., 
2016). 
 
We also showed that ACS-16 gene signature scores decreased during TB treatment 
in HIV-uninfected persons (Thompson et al. 2017). The signature could differentiate 
study participants based on their rate of bacteriological conversion measured by 
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sputum cultures. These data affirm that the ACS 16-gene signature could be a useful 
biomarker for predicting relapse and TB treatment failure.  
 
1.10 Biomarkers of risk of recurrent TB disease in the presence and or 
absence of HIV infection!
A history of previous TB is a risk factor for recurrent TB disease. Similarly, HIV 
infection increases risk of recurrent TB disease. Despite the risk of recurrent TB, only 
a few transcriptomic signatures have thus far been developed to identify individuals 
at risk of recurrent TB disease. Mistry et al derived a signature which could 
differentiate individuals who have completed antimycobacterial therapy from persons 
with recurrent TB in a cross-sectional study (Mistry et al. 2007). Another study 
identified 18 differentially expressed genes between relapse and “cured” HIV-
uninfected participants in a longitudinal cohort (Cliff et al., 2015). Genes involved in 
cell-mediated cytotoxicity were highly expressed in samples from relapse patients in 
comparison to the “cured” group.  
!
1.11 Type I IFN: Activation and role in active TB disease and HIV infection 
pathogenesis 
Most of the gene signatures of TB disease described above, including the ACS 16 
and 11-gene signatures comprise type I/II IFN transcripts. IFNs are cytokines that 
are classified into three classes (types I, II and III), with varying anti-viral and growth 
inhibitory functions, receptor usage, and structural features (Donnelly and Kotenko 
2010). The type I IFN family encodes 16 homologous IFNα subtypes in humans, an 
IFNβ gene and several genes encoding for IFNε, IFNτ, IFNκ, IFNω and IFNδ (Chen 
et al., 2017; McNab et al., 2015). Of these, IFNα and IFNβ are the most widely 
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expressed and best-defined type I IFN sub-types, which have the ability to induce 
gene transcription programmes resulting in interference with multiple stages of viral 
replication cycles. Type II IFN, on the other hand, consist of only IFNγ, whilst type III 
IFNs consists of the IFNλ family. In this thesis, type I IFN generally refers to IFNα 
and IFNβ and type I/II IFN refers to both IFNα and IFNβ in combination with IFNγ.  
 
Type I IFNs together with proinflammatory cytokines are the first effector molecules 
induced in the innate immune response against certain pathogens (Abel et al., 
2002). They are expressed by multiple cell types in response to stimulation of innate 
immune cell receptors, such as toll like receptors (TLRs), or as a response to viral 
infections (McNab et al., 2015). Mtb can also induce type I IFN expression in 
macrophages and dendritic cells (DCs) via the TANK-binding kinase 1 (TBK1), a 
serine/threonine kinase (Donovan et al., 2017). TBK1 is activated by pathogen 
recognition receptors such as TLR4 and the Nod-like receptor, NOD2. Interferon-
regulatory factors (IRFs) are required for the activation of interferon stimulated genes 
(ISGs); TBK1 facilitates the phosphorylation of IRFs in Mtb-infected cells inducing 
the production of IFNα and IFNβ (Donovan et al. 2017). Type I IFN signalling due to 
Mtb infection can hinder the host’s immune response in controlling replicating 
bacteria. Type I IFN inhibits macrophage killing of Mtb in mice by impeding the 
production of host protective cytokines such as TNFα, IL-1β and IL-12, whilst 
promoting the production of IL-10 (McNab et al., 2014). In addition, type I IFNs have 
the ability to prevent macrophage killing by hindering IFNγ-mediated-growth 
inhibition of Mtb-infected macrophages (McNab et al., 2014). IFNβ prevented the 
induction of IFNγ in human monocytes and macrophages infected with 
Mycobacterium leprae, which was reversed by the blocking of IL-10 (Teles et al. 
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2013). Thus, type I IFN can exacerbate mycobacterial replication by inhibiting the 
protective action of the type II IFN, IFNγ, by modulating IL-10 induction. In contrast, 
Moreira-Toxeira and colleagues observed a protective role of type I IFN by Mtb-
infected murine macrophages through the induction of nitric oxide synthase 2 and 
inhibition of arginase 1 gene expression thereby controlling bacterial replication 
(Moreira-Teixeira et al. 2016). Through this mechanism, induction of type I IFN 
seems to be able to provide protection to the murine host, particularly in the absence 
of IFNγ (Moreira-Teixeira et al. 2016). In humans, type I IFN signalling in the form of 
strongly upregulated expression of ISGs, has been observed in active TB cases 
relative to healthy controls, as discussed above. Blood leukocyte levels of ISG 
transcript expression have been associated with disease severity, progression to 
disease and treatment response, suggesting that type I/II IFN induction in humans is 
associated with bacterial replication and plays a role in exacerbating disease. It 
should be noted though that elevated type I IFN protein levels in peripheral blood 
have not been reported in persons with TB disease. 
 
A well-known function of type I IFNs is their protective role against viral infections. In 
HIV-infection the main cellular producers of IFNα are plasmacytoid dendritic cells 
(pDCs), which constitute <1% of blood leukocytes, and can produce up to a 1,000-
fold more IFNs than the other immune cell types (Herbeuval and Shearer 2007). 
IFNβ can be produced by all DCs (Chen, Liu, and Cao 2017). In response to HIV 
infection, some TLRs can induce IFN signalling via the TIR-domain-containing 
adaptor protein inducing IFNβ (TRIF) or the myeloid differentiation primary-response 
protein 88 (MyD88) dependent pathways (Gonzalez-Navajas et al. 2012). TLRs 3 
and 4 on pDCs can induce IFN expression via the TRIF pathway in a wide variety of 
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cells, whilst TLRs 7, 8 and 9 induce IFNs in DCs through the MyD88-dependent 
pathway (Gonzalez-Navajas et al. 2012) (Figure 3). Induction of type I IFNs has 
been observed in acute HIV infection (Bosinger and Utay 2015) and type I IFN levels 
are positively associated with HIV progression (Lehmann et al. 2008). In Simian 
Immunodeficiency Virus (SIV) infection, type I IFN was observed to have a protective 
effect against disease progression (Sandler et al. 2014). In this study, blocking of the 
IFN alpha-receptor (IFNAR) signalling during acute infection resulted in the reduction 
of antiviral gene expression in two rhesus macaques. Despite a decrease in T cell 
activation, SIV reservoir was increased and CD4 T-cell depletion was accelerated 
and an increased rate of progression to AIDS was observed. In acute HIV infection, 
up to 159 days after presumed infection, in vitro type I IFN production in response to 
herpes simplex virus stimulation was impaired in HIV-infected persons relative to 
healthy controls (Kamga et al. 2005). Furthermore, viremia in ART-naïve participants 
with acute HIV infection was inversely associated with IFN production, suggesting 
that type I IFN is highly associated with viral control. This, however, was not 
observed in those who received ART. These studies suggest that type I IFN 
production protects not only against disease progression but can also protect against 
other opportunistic infections.  
 
IFNα and IFNβ bind and signal through the heterodimeric IFN alpha-receptor 
subunits (IFNAR1 and 2), which are expressed on all cell types (Chen et al., 2017; 
McNab et al., 2015). Transcription of interferon stimulated genes (ISGs) primarily 
occurs upon the activation of the Janus Kinase 1 (JAK1) and tyrosine kinase 2 
(TYK2), which are receptor-associated protein kinases (McNab et al., 2015). JAK1 
and TYK2 are activated by the ligation of the IFNAR. Activation of the JAK1 and 
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TYK2 can result in type I IFN-mediated signalling through several mechanisms. In 
the canonical pathway, phosphorylation of STAT1 and STAT2 heterodimers leads to 
the formation of the ISG factor 3 (ISGF3) complex. This occurs via the binding of 
dimerized STAT1 and STAT2 heterodimers to IFN-regulatory factor (IRF) 9 (Figure 
3). The newly formed ISGF3 translocates to the nucleus where it binds to the DNA 
sequence motif, IFN-stimulated response elements (ISRE, Figure 3) (Chen, Liu, and 
Cao 2017). This binding activates the transcription and expression of ISGs (Chen, 
Liu, and Cao 2017; Ivashkiv and Donlin 2015). In addition, type I IFNs can signal 
through STAT1 homodimers which are associated with other cytokine-mediated 
signalling pathways, as well as through the mitogen-activated protein kinase 







Figure 3: Type I IFN induction and signalling pathways (adapted from McNab et al., 2015). HIV 
and Mtb are recognised by a range of cell receptors on dendritic cells and macrophages (Mtb) and 
plasmacytoid dendritic cells (HIV). Upon induction, type I IFN bind to IFN-alpha receptors 1 and 2 
activating type I IFN signalling pathways, leading to the transcription of interferon stimulated genes 
(ISGs).







































































In HIV-infected humans, ISG transcript levels were higher in participants with low 
CD4 T cell counts (<490 cells/µL) in comparison to HIV-infected persons with high 
CD4 T cell counts and HIV-uninfected healthy controls (Fernandez et al. 2011). The 
ISG levels in healthy controls were comparable to the levels in HIV-infected 
participants with high CD4 T cell counts. This study suggests that ISG expression 
normalisation may be associated with CD4 T cell reconstitution. This was probably 
virus driven, as CD4 T cell counts are biomarkers for viral replication-associated 
immunosuppression however, plasma viral load levels were not investigated in this 
study. Since HIV-infected persons with low CD4 T cell counts and high plasma viral 
loads are at a higher risk of developing active TB disease transcriptomic signatures 
of active TB disease mainly comprise ISGs, it is critical that the behaviour of IFN-
based transcriptomic signatures of TB is studies in HIV-infected persons.  
Therefore, in this thesis we explored the performance of ISG-based signatures, the 
ACS 11-gene signature, the rPSVM.1 signature and the ACS 6-gene signature at 
different stages in the TB timeline in HIV-infected persons.   
 
1.12 Objectives of this thesis !
The main aim of this thesis is to determine if the ACS 11-gene signature can predict 
recurrent TB disease and monitor treatment response in HIV-infected persons on 
ART. The signature was analysed in two prospective observational cohorts. In one of 
the cohorts, only PBMC samples were available for our analysis, thus we first 
determined if the ACS 11-gene and the ACS 6-gene (described in Chapter 7) 




I. To compare the diagnostic performance of the ACS 11-gene signature for 
TB disease from Mtb infection in HIV-infected and uninfected persons. 
 
II. To determine if the ACS 11-gene signature can predict recurrent TB 
disease in HIV-infected persons on ART. 
 
III. To determine if the ACS 11-gene signature can monitor retreatment 
response in HIV-infected persons on ART. 
 
IV. To determine the diagnostic performance of a newly identified smaller 
ACS 6-gene signature, and if it can predict recurrent TB disease and 
monitor treatment response in HIV-infected persons on ART.  
 
Hypotheses 
I. Diagnostic performance of the ACS 11-gene signature for active TB disease 
is equivalent in HIV-infected and uninfected persons. 
 
II. The ACS 11-gene signature has predictive utility for recurrent TB disease in 
HIV-infected persons on ART. 
 
III. The ACS 11-gene signature will monitor treatment response in HIV-infected 
retreatment patients by differentiating early treatment responders from late 
treatment responders after two months of TB treatment. 
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IV. The newly identified small ACS 6-gene signature has predictive utility for 
recurrent TB disease and will differentiate early treatment responders from 
late treatment responders in HIV-infected persons on ART. The performance 
of the ACS 6-gene signature will be equivalent to the performance of the ACS 

































Chapter 2: Materials and methods 
The aim of this chapter is to describe the methods used across the different aims in 
this thesis. Details of each human participant cohort and methods specific for each 
individual chapter are included in the results chapters. 
 
2.1 Institutional ethics review 
This PhD study was reviewed and approved by the Human Research Ethics 
Committee of the University of Cape Town Faculty of Health Sciences and assigned 
the ethics number HREC 761/2015. Details of the ethical considerations and review 
committees for human participation in each individual cohort (Table 2) are mentioned 
in the chapters where they are first described. 
 
Table 2: HIV status and sample types of participant cohorts analysed in this thesis. TRuTH = 
TB recurrence upon treatment with HAART, IMPRESS = Improving Retreatment Success, PBMC = 
Peripheral blood mononuclear cells 
Cohort HIV status of study 
participants 




Infected and uninfected Whole blood and PBMC Chapter 3 
TRuTH  Infected PBMC Chapter 4 
Esmail Infected Whole blood Chapter 4 
IMPRESS Infected Whole blood Chapter 5 
 
2.2: RNA extraction, processing and storage 
2.2.1 Extraction from PAXgene tubes 
!
Frozen PAXgene™ (Qiagen, Germany) tubes were left overnight at room 
temperature, in order to achieve complete lysis of samples. The tubes were 
centrifuged for ten minutes at 4,000 relative centrifugal force (rcf, g) to pellet the 
blood cells after which the supernatant was decanted. Pellets were resuspended in 
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4mL of RNAse free water and spun for 10 minutes at 4,000 rcf and supernatants 
decanted. RNA was either extracted manually with the PAXgene™ blood RNA kit 
(Qiagen, Germany) or the SimplyAmp extraction kit (Promega, USA) on an 
automated platform using the Freedom EVO 150 (Tecan, Switzerland).  
 
RNA was extracted using the PAXgene™ blood RNA kit as per the manufacturer’s 
instructions. Briefly, pellets were resuspended in the resuspension buffer (BR1) and 
pellets dissolved by vigorous vortexing. Binding buffer (BR2) and Proteinase K were 
added to samples upon transfer into 1.5mL Eppendorf tubes. Samples were 
incubated for 10 minutes at 55°C before transfer into QIAshredder columns and 
spun for three minutes at maximum speed (18,000 rcf) in a microfuge. To precipitate 
RNA, 96-100% ethanol (Sigma Aldrich, USA) was added to the flow-through after it 
was transferred into new Eppendorf tubes. Samples were transferred into PAXgene 
columns and spun for a minute at 8,000 rcf. BR3 wash buffer was added to the 
columns before spinning for a minute at 8,000 rcf. DNase I solution was added 
directly to the spin columns and incubated at room temperature for 15 minutes. The 
column was spun again using BR3 buffer and the flow-through was discarded. BR4 
wash buffer was added to the columns before the columns were spun for a minute at 
8,000 rcf. A second wash with BR4 was done and samples were spun for a further 
four minutes at maximum speed. To remove residual wash buffer from the columns, 
the empty columns were spun for a minute at maximum speed. The mRNA was 
eluted twice by adding 40µL of elution buffer BR5 and spinning for a minute at 8,000 
rcf. The eluate was incubated at 65°C for five minutes. Upon completion of 
incubation the samples were immediately placed on ice and aliquoted into four vials 
before storage at -80°C.  
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2.2.2 RNA extraction from PBMC  
Cryopreserved PBMC were placed on dry ice and thawed at 37°C with shaking in a 
water bath before placing on wet ice. In a biosafety hood, cells were added into 10 
mL of Roswell Park Memorial Institute media (RPMI; Sigma Aldrich, USA) media 
already warmed at 37°C. PBMC vials were rinsed with 1mL of warmed RPMI and the 
tubes centrifuged at 400 rcf for 10 minutes. Supernatants were decanted and pellets 
placed on ice.  
 
Thawed PBMC samples were extracted using the Qiagen RNeasy Plus Mini 
extraction kits (Qiagen, Germany) as per the manufacturer’s instructions. Briefly, one 
percent 2-mercaptoethanol (Sigma-Aldrich, USA) in lysis buffer RLT was added to 
the samples and vortexed vigorously for proper disruption of cell walls. Lysates were 
added to QIAshredder columns (Qiagen, Germany) and centrifuged for two minutes 
at full speed (18,000 rcf). The homogenised lysate was added to a genomic DNA 
(gDNA) eliminator spin column placed in a 2mL collection tube and centrifuged for 30 
seconds at 8,000 rcf. Seventy percent ethanol (Sigma Aldrich, USA) was added to 
the flow-through and samples were transferred into RNeasy MinElute spin columns 
before spinning at 8,000 rcf for 15 seconds. Wash buffer RW1 was added to the 
columns and centrifuged at 8,000 rcf for 15 seconds. Two more wash steps were 
carried out by adding another wash buffer, RPE, to the columns twice and 
centrifuging for 15 seconds at 8,000 rcf. Columns were placed into new collection 
tubes and spun for five minutes at full speed to remove any residual wash buffer. To 
elute the RNA, 40µL of RNase-Free water was added directly to the centre of the 
spin column membrane, twice,  before centrifuging for a minute at full speed. Eluted 
RNA was aliquoted into four tubes for storage at -80°C.  
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2.2.3 RNA quantification  
Extracted RNA was quantified using the Nanodrop ND2000 spectrophotometer 
(Thermo Fisher scientific, USA). Briefly, RNA background was measured using the 
elution buffer (BR5 or RNase-Free water). RNA concentration and purity were 
measured at a 260/230 wavelength and 230/280 wavelength, respectively.  All RNA 
samples were processed regardless of concentration.  
 
2.3 Measurement of gene expression  
Biomark HD multiplex microfluidic real time quantitative polymerase chain reaction 
(qRT-PCR) technology on the Fluidigm (Fluidigm, US) platform was used to measure 
gene expression.  
 
2.3.1 cDNA synthesis and pre-amplification PCR  
Complementary deoxyribonucleic acid (cDNA) was synthesized from RNA in 96-well 
plates. Incorporated into the 96-well plates were two controls: a control with no 
sample added (non-template control,NTC) and a control with no reverse 
transcriptase added (no reverse transcriptase, NoRT). The NoRT control was to test 
that there was no genomic DNA contamination in the samples and that the gene 
expression results were not confounded by genomic DNA amplification. cDNA 
synthesis of the samples was done in singlets in 96-well plates (Applied Biosystems, 
USA). A master mix of 500µg/ml of oligonucleotide (Oligo (dT)) 12-18 primer 
(Thermo Fisher Scientific, USA), 10mM of deoxynucleotide triphosphates (Sigma 
Aldrich, USA), sterile endotoxin free water (Sigma Aldrich, US) was added to 3µL of 
RNA (±100ng), to initiate cDNA synthesis. Contents of the mix were briefly 
centrifuged and incubated at 65°C for five minutes in a T100 thermocycler (Biorad, 
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Belgium) and put on hold at 4°C. Another master mix containing 5x First-strand 
buffer (Invitrogen, USA), 0.1M of 1,4-Dithiothreitol (DTT) (Invitrogen, USA), 40 
units/µL of RNAseOUT (Invitrogen, USA) and sterile endotoxin free water (Sigma 
Adrich, USA) was added to the samples after a brief centrifugation and incubated at 
42°C for two minutes.  Two hundred units of SuperScript II reverse transcriptase 
(Invitrogen, USA) was added to the samples and the samples further incubated at 
42°C for 50 minutes, and then the reaction was inactivated at 70°C for 20 minutes. 
Samples were diluted to a final concentration of ±1ng/µL by adding 80µL of sterile 
endotoxin free water.  
 
Each cDNA sample is split into 96 microchambers of a 96.96 Fluidigm gene 
Expression (GE) Array chip (Fluidigm, USA) to mix with each of the 96 primer-probe 
assays, consequently allowing 96 separate qRT-PCR reactions from each cDNA 
sample. The Fluidigm 96.96 GE chip technology requires sufficient cDNA template in 
each of the 96 microchambers to ensure optimal amplification of each primer-probe 
set (Dominguez et al. 2013). Thus, to ensure consistent distribution of cDNA 
template into each of the 96 microchambers, a preamplification of synthesized cDNA 
using a pool of the relevant primer-probe sets of interest is necessary before loading 
samples on the Fluidigm GE chip. Hence, transcripts of interest were amplified by 
conventional PCR using a mix of 2x PCR master mix (Thermo Fisher Scientific, 
USA) and 0.2x of the primer probe master mix of the TaqMan primer probe assays of 
interest (Thermo Fisher Scientific, USA). Final volume of 10µL of the mix was added 
in new 96-well plates and plates were sealed with strips of dome caps. The 
thermocycler was set to the following parameters for the PCR: 95°C for 10 minutes, 
95°C for 15 seconds and 60°C for four minutes. Even distribution of mRNA in every 
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chamber requires at least 4,906 amplicons from 12 preamplification cycles 
(Dominguez et al. 2013). Therefore, steps two and three were run sixteen times (16 
cycles) before the reaction was put on hold at 4°C.  Samples were diluted 1:25 with 
endotoxin free water by adding 240µL per well. The samples generated from this 
step will henceforth be referred to as pre-amplified cDNA. 
 
A confirmatory RT-PCR was performed using one of the reference primers to ensure 
that the samples were pre-amplified and that the reagents and the negative controls 
were not contaminated. The confirmatory RT-PCR consisted of two samples of 
interest, duplicate NTC and NoRT, and was run on the Rotor-Gene 6000 series RT-
PCR instrument (Corbett life science). The RT-PCR was run using the following 
setting: 50°C for two minutes, 95°C for 10 minutes and for 40 cycles of 95°C for 15 
seconds and 60°C for one minute. Preamplification of cDNA was repeated if 
amplification was detected in the NTC and/or NoRT samples, indicating a false 
positive result or contamination. If either the NTC or NoRT yielded amplified product 
a second time suggesting that the contamination occurred during cDNA synthesis, 
the assay ws repeated from the cDNA synthesis step. If the samples selected for the 
confirmatory RT-PCR were not amplified in addition to both controls, the confirmation 
RT-PCR was repeated to ensure that samples were amplified.  
 
2.3.2 Fluidigm assay 
The Fluidigm Biomark HD instrument was used to perform microfluidic measurement 
of gene expression in the amplified cDNA samples. Transcripts of interest were 
measured using 96.96 Dynamic GE Array chips (Figure 4A), allowing 9,216 
simultaneous qRT-PCR reactions by quantifying abundance of 96 mRNA transcripts 
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in 96 samples. Samples and controls were run in duplicate, thus incorporating 45 
amplified cDNA samples, an internal positive control (IPC), a NoRT and NTC. The 
IPC was pooled from different previously pre-amplified samples (using our primer-
probes of interest) with varying levels of gene expression and was used to affirm that 
gene expression between the different experiments in each cohort (Chapters 4 and 
5) was comparable. To prepare a chip for sample transfer, it was first injected with a 
control fluid into each accumulator and primed using the integrated fluidic circuit 
controllers. Assay loading reagent (Fluidigm, USA) was added on to the primer-
probe assays at a 1:2 dilution, centrifuged and stored at 4°C until ready to load the 
chip. The samples were prepared by adding 2x TaqMan universal PCR master mix 
(Applied Biosystems, USA) and 20x GE sample loading reagent to 5.4µL of 
preAmped cDNA. Upon completion of priming, assays were loaded into the assay 
inlets in singlet and samples loaded into the sample inlets in duplicate (Figure 4A). 
The chips were returned to the integrated fluidic circuit controller for loading and 
mixing of samples and assays, after which the chips were loaded into the Fluidigm 
Biomark HD machine. Runs were performed using the Biomark data collection 
software (Fluidigm, USA), and pre-analysed using the Fluidigm real-time PCR 
analysis software v3.1.3 (Fluidigm, USA). The quality threshold, baseline correction 
and Ct threshold method were set to 0.65, linear derivative and auto global 
normalisation, respectively. Comma separated value (.csv) files of the data were 










Figure 4: 96.96 dynamic array gene expression Fluidigm chip. (A) Layout and design of the 96.96 
array chip for gene expression measurement. (B) Representative heatmap of gene expression 
measured from a 96.96 array chip, non-template control (NTC), no reverse transcriptase (NoRT) and 






















2.4 Quality control (QC) of Fluidigm data  
!
Several QC steps were applied to the qRT-PCR data from each individual chip to 
verify that the data generated were reliable before gene expression analyses. A 
customised script in R programming software was used to analyse the data. The first 
QC step was to verify that the parameters and instrument settings listed in section 
2.3.2 in the Fluidigm RT-PCR analysis software were applied during the PCR run to 
generate the data. The script also tested to ensure that all samples were in 
duplicate. The controls were then tested to ensure that none of the primer-probes 
yielded detectable amplification (i.e. a cycle threshold, Ct, value) in the two negative 
controls (NTC and NoRT, Figure 4B). If amplification was detected for these controls, 
the experiment was repeated. Thereafter, the script determined whether any 
samples yielded failed amplification of at least 80% in the reference primer-probes 
(Table 3) and if so, these samples were excluded from further analyses. More than 
80% of transcripts of genes of interest (GOI) also had to demonstrate detectable 
amplification for a sample to be included in the analyses. Finally, each transcript 
(primer-probe) had to be detected in at least 20% of all samples to qualify for 
inclusion in the analyses. Delta Ct (dCt) values for each transcript of interest (non-
reference transcripts) were calculated by subtracting the Ct of the mean of the ten 
reference transcripts (Table 3) from the Ct of the primer-probe of interest (Table 1). 
Data (Ct and dCt values) from the internal positive controls (IPC) were analysed to 
ensure that gene expression was consistent between the different chips and runs. 
The Ct values of all transcripts were analysed by creating a correlation matrix 
between the replicates using Spearman’s correlation. Heat maps of the correlation 
matrices of the replicates are presented in Chapters 4 and 5. Distributions of the dCt 
of the transcripts representing the GOIs are shown as density plots. 
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Table 3: Ten reference primer-probes included in the gene expression analyses of the ACS 11-
gene signature and calculation of dCt values. 














2.5 Analysis methods 
Blind predictions of the signatures were applied on the gene expression data using R 
scripts that were prepared and tested by our collaborators at the Centre for 
Infectious Diseases Research (CIDR, Seattle) (manuscript in preparation). The sum 
of the relative abundance of two gene products (transcripts) forming a pair and 
coefficients representing the weights between the pairs is the first step in calculating 
signature scores, as previously described (Zak et al. 2016). A sample is assigned as 
a case or progressor by each transcript-pair if the product of the calculation is 
greater than zero and a non-progressor or control if the result is less than zero. An 
overall score was tallied using the number of progressor scores from each gene pair, 









           Score = “progressor” if: a*N1 + b*N2 + c > 0 
 Score = “control” if: a*N1 + b*N2 + c ≤ 0, 
 
Equation 1: Calculation of signature scores for the ACS 11-gene signature. N1 and N2 represent 
normalised abundances (dCt) of two transcripts in the pair and coefficients "a", "b" and "c" as 
identified and trained in the ACS progressor and control cohort (Zak et al. 2016) 
 
Area under the receiver operating characteristic curves (ROC AUC) were generated 
using the calculated signature scores in GraphPad Prism version 7.0a (GraphPad 
Prism). AUC values and 95% confidence intervals (CI) were calculated using the 
pROC (Robin et al. 2011) and verification (Pocernich 2015) packages in R, 
respectively. Head to head comparisons of AUCs were done using the “roc.test” 
function in the pROC package. For analysis of participant characteristics, Fisher’s 
exact test and Mann-Whitney U test were respectively used to analyse categorical 
and continuous data. P-values <0.05 were considered statistically significant; p-
values in this thesis have not been corrected for multiple comparisons. 
 
2.6 Contributions 
Ms F. Darboe wrote the study proposal, designed and conducted the experiments 









Chapter 3: The ACS11-gene signature can differentiate active TB from Mtb 
infection using PBMC from HIV-infected and uninfected persons  
 
The main aim of this chapter is to determine if the ACS 11-gene signature can 




HIV infection increases the risk of progression to active TB in Mtb-infected persons 
(Parida and Kaufmann 2010). A five-fold increase in TB notification rates has been 
observed due to HIV infection (Lawn et al. 2009). In 2016, 46% of incident TB cases 
were HIV-infected (World Health Organization 2017). HIV-infected persons present 
with paucibacillary disease (low numbers of acid-fast bacilli in sputum) thereby 
making diagnosis of TB using current diagnostic tools difficult. Sputum culture is a 
more sensitive technique in diagnosing TB in HIV-infected persons than sputum 
smear microscopy, however, it takes days to week to confirm the diagnosis 
(Tornheim and Dooley 2017; Cain et al. 2010; Stephen D Lawn et al. 2006). 
Furthermore, a large proportion of HIV-infected persons do not have productive 
coughs (Cain et al. 2010) and are thus unable to provide sputum specimens. Hence, 
new tools to improve and shorten time to diagnosis of active TB in HIV-infected 
persons are essential in the fight against TB. 
 
Transcriptomic signatures of TB are promising tools for the diagnosis of active TB 
disease. Many diagnostic TB signatures have been shown to yield good diagnostic 
performance in HIV-uninfected persons, either to differentiate between active TB 
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cases and healthy infected or uninfected controls, or symptomatic controls with other 
respiratory diseases (Berry et al. 2010; Blankley et al. 2016; Bloom et al. 2012, 2013; 
Kaforou et al. 2013; Maertzdorf et al. 2011; Maertzdorf et al. 2011; Walter et al. 
2016; Zak et al. 2016). Only a few studies have developed transcriptomic TB 
diagnostic signatures in HIV-infected populations (Kaforou et al. 2013; Anderson et 
al. 2014; Dawany et al. 2014). Colleagues at SATVI and CIDR developed a 
transcriptomic 16-gene correlate of risk of TB signature capable of  predicting TB 
disease in HIV-uninfected persons more than a year prior to TB diagnosis (Zak et al. 
2016).  This 16-gene risk signature also performed well in diagnosing active TB 
disease, when re-parameterised and applied to public, published microarray 
datasets from the Berry et al 2010, Bloom et al 2012, Kaforou et al 2013 and 
Maertzdorf et al 2011 (Zak et al. 2016). The performance of this risk signature in 
diagnosing active TB disease in HIV-infected persons has not been compared to its 
performance in HIV-uninfected persons from the same population. Hence, we sought 
to determine the performance of the 11-gene TB risk signature derived from the 16-
gene signature (described in Chapter 1) in diagnosing active TB in HIV-infected 
persons.  
 
An important aim we sought to address in this project was to determine if our 
transcriptomic signatures could predict recurrent TB in HIV-infected persons. 
However, the only available clinical cohort to address this aim was the TRuTH study, 
in which PBMC samples and no whole blood RNA samples were collected and 
biobanked. Since the 16-gene signature from which the 11-gene signature was 
derived was developed on whole blood samples, and PBMC are distinct from whole 
blood in that they lack neutrophils and other granulocytes. We therefore reasoned 
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that a careful comparison of signature gene expression between whole blood and 
PBMC was necessary. This is especially relevant because the Type I IFN response 
genes found to be associated with active TB are most prominently expressed by 
neutrophils compared to other cell types (Berry et al. 2010; Singhania et al. 2017; 
Scriba et al. 2017).  
 
Previous studies have shown that transcriptomic signatures developed from PBMC 
samples can diagnose active TB disease in HIV-uninfected persons (Lee et al. 2016; 
Lu et al. 2011). Lee and colleagues developed gene signatures to differentiate active 
TB from healthy Mtb-infected and Mtb-uninfected persons. The study identified 297 
genes that were differentially expressed between active TB cases and Mtb-
uninfected persons, and 127 genes that were differentially expressed between Mtb-
infected and -uninfected persons. There were 169 genes differentially expressed 
genes active TB and Mtb infection,  and 14 of which genes were found to be 
differentially expressed between Mtb-infected and -uninfected persons. These genes 
were enriched in immune activation and regulation, cell differentiation, and mRNA 
transcription and translation modules. Three of the differentially expressed genes in 
the three comparisons differentiated Mtb-infected from uninfected persons and active 
TB cases in an external validation cohort from the same setting (Taiwan). Lu and co-
workers on the other hand, measured gene expression in active TB cases, Mtb-
infected, and uninfected persons using PBMC stimulated with PPD for four hours or 
unstimulated PBMC as controls. A three-way pair-wise analysis revealed 506 
differentially expressed genes amongst the three groups based on fold changes 
between PPD stimulated and unstimulated samples. Fifty-five genes mainly involved 
in T cell homeostasis were differentially expressed when active TB and Mtb-infected 
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individuals were compared to Mtb-uninfected persons. Furthermore, 229 genes 
related to chemotaxis and responses to external stimulus were differentially 
expressed for active TB (active TB relative to Mtb-infected and uninfected persons). 
Of the 506 genes from the three pair-wise analyses, 30 differentially expressed 
genes and 22 genes specific for active TB and Mtb infection were translated into 
qPCR. These genes were applied to a validation cohort of active TB cases, Mtb-
infected and uninfected persons using qPCR. Of these, a three-gene signature 
(CXCL10, ATP10A, TLR6) was found to be the most discriminatory in identifying 
active TB disease from Mtb infection using decision trees. The three-gene signature 
had a sensitivity and specificity of 80% and 89% respectively with an accuracy of 
85%. These studies suggest that gene signatures developed from PBMC samples 
can diagnose active TB with a high accuracy.  
 
However, the diagnostic performance of whole blood based transcriptomic 
signatures in differentiating between active TB disease and Mtb infection using 
PBMC samples is unknown. We therefore set out to assess the mRNA signal 
strength of the ACS 11-gene signature in PBMC. 
 
3.2 Aim and hypothesis 
Aim:  
 
To determine if the whole-blood based ACS 11-gene TB risk signature can diagnose 
active TB disease from Mtb infection in HIV-infected and uninfected persons using 





The ACS 11-gene signature measured on mRNA from PBMC can discriminate 
between Mtb infection from active TB disease with equivalent performance to mRNA 
from whole blood. 
 
3.3 Materials and methods  
3.3.1 Ethics clearance and study design 
!
Donors had been recruited using the healthy donor protocol (HREC 126/2006) and 
the TB disease protocol (HREC 288/2008). These protocols were reviewed and 
approved by the Human Research Ethics committee of the Faculty of Health 
Sciences at the University of Cape Town. All study participants gave written informed 
consent to participate in this pilot study. 
 
Donors were recruited at the SATVI Clinical Site in the Worcester municipality of the 
Western Cape province of South Africa. Written informed consent was obtained from 
all study participants. Healthy Mtb-infected individuals and newly diagnosed active 
pulmonary TB diseased adults with or without HIV infection were invited to 
participate in the study. Mtb infection was determined using the QuantiFERON-TB 
Gold In-Tube assay (Qiagen, IFNγ levels >0.35 IU/mL). Active TB disease cases 
were diagnosed by Xpert® MTB-RIF (Cepheid), performed in community clinics.  
Participant enrolment !
Adults who satisfied the inclusion criteria below were enrolled into the study. 
Inclusion criteria: 
Mtb-infected persons  
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• Healthy adults at least 18 years old 
• QuantiFERON-TB Gold In-Tube (QFT) positive (>0.35 IU/mL) 
Active TB persons!
• Adults at least 18 years old  
• Xpert® MTB-RIF-positive 
 Exclusion criteria: 
We used the following clinical criteria to exclude adults from enrolment into this 
study: 
• Anaemia with haemoglobin less than 8.0 g/dl 
• BMI equal to or less than 17  
• Signs of other chronic or systemic illnesses not consistent with TB 
 
A basic questionnaire was administered to all participants for capturing demographic 
data including anthropometric data. HIV status was confirmed at screening using a 
rapid serological test by the SATVI clinical team. All HIV-infected persons were 
referred to ART clinics for ART and, if appropriate, INH prophylaxis. 
 
To allow for the potential re-parameterisation of the gene expression signature to 
PBMC, in case our results would show poor signature performance in the cohorts, 
we predefined a random division of the cases and controls in the HIV-uninfected 
study arm into a training and a test set at a 1:1 ratio. Experiments and analysis were 
performed sequentially in a blinded manner, first for the training set, and then for the 
test set based on either satisfactory performance of the signature in the training set, 
or after re-parameterisation on the training set in the case of poor signature 
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performance. Finally, the HIV-infected samples were also analysed. In this analysis 




Ex-vivo whole blood in PAXgene™ tubes and PBMC were collected in parallel from 
each person. PBMC were harvested from blood collected in Cell Preparation Tubes 
(BD) at the SATVI clinical immunology laboratory, in Worcester. 
 
3.3.3 RNA extraction and quantification !
RNA from PAXgene tubes was extracted using the PAXgene blood RNA kit, as per 
manufacturer’s instructions (described in section 2.2.1). RNA from PBMC was 
extracted immediately after thawing and washing using the Qiagen RNeasy Plus 
Mini Extraction Kit as per manufacturer’s instructions (described in section 2.2.2). 
RNA was extracted immediately to avoid deviations from in-vivo gene expression as 
much as possible. Thus we did not try stimulating or resting PBMC after thawing 
because cryopreservation and resting might result in upregulation or downregulation 
of some of the gene of interest transcripts.  
 
3.3.4 Gene expression measurement!
cDNA was synthesised from extracted RNA using SuperScript II reverse 
transcriptase (described in section 2.3.1). Gene expression levels of transcripts in 
the ACS 11-gene signature were measured by qRT-PCR using the Fluidigm Biomark 
HD (described in section 2.3.2).  
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3.3.5 Data analysis !
Fisher’s exact test and Mann Whitney U test were used to analyse baseline 
participant characteristics. Gene expression data was quality controlled using scripts 
generated in R (described in section 2.3.2) and signature scores were calculated. 
Signature scores were determined by mathematically associating a coefficient with 
the relative abundance of primer-probe pairs in the signature (as described in 
chapter 2.5) and ROC AUCs were generated using the pROC (Robin et al. 2011) 
and verification (Pocernich 2015) packages in R. Median and 95% CI of the relative 
difference of primer-probes of interest between Mtb-infected and active TB disease 
was calculated using the rank inversion method and bootstrapping 2000 times using 
the quantreg R package (Koenker 1994).  
 
3.3.6 Re-parameterisation of the signature to PBMC and HIV infection !
In an attempt to potentially improve the performance of the ACS 11-gene signature 
for PBMC samples in an HIV-infected population, we re-parameterised the signature 
by determining more optimal coefficients for each transcript-pair in the signature. To 
do this, transcript Ct values from the ACS 11-gene signature generated from PBMC 
of HIV-infected participants were standardised using the mean Ct values of all the 
reference primer-probes. This was done because the ACS 11-gene signature scores 
are calculated using the relative abundance of transcripts of interest to the reference 
primer-probes. All the transcripts were then ranked by standard deviation (SD) of 
their dCt values of PBMC relative to whole blood; SD was used because PCR data is 
already log transformed. As data was standardised to reference primer-probes, they 
were expected to have lower SDs than transcripts of interest. Consequently, 
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reference primer-probes with large SDs ranked lower than transcripts of interest. 
These reference primer-probes were removed to pave way for the generation of a 
new signature. Transcripts of interest were standardised to the new set of reference 
primer-probes and the ability of the transcripts to diagnose active TB disease was 
determined. Transcripts of interest that did not significantly discriminate between 
active TB disease and Mtb infection were removed from the signature (p>0.05). The 
remaining transcript-pairs were retrained using linear support vector machines, 
changing the weighting and pairing in the signature. To test the performance of the 
new signature termed “rPSVM.1”, the model was applied to the HIV-uninfected 
participants in this cohort, and to progressor and control participants from the ACS 
and GC6-74 cohorts.  
 
3.4 Results  
3.4.1 Cohort characteristics!
One hundred and fifty-three adults were approached to participate in this pilot study. 
Newly diagnosed Xpert® MTB-RIF-positive TB patients (n=50) and healthy Mtb-
infected (QFT-positive) individuals (n=50) were enrolled (Figure 5). In each of these 
groups, 30 participants were HIV-uninfected and 20 were HIV-infected. In the HIV-
uninfected cohort, more active TB cases were younger, males, and had lower body 
mass index (BMI) than the Mtb-infected control participants in the cohort (Table 4). 
Most (80%) of the healthy Mtb-infected participants were of Cape Mixed Ancestry 
(Coloured) whilst only about half (53.3%) of the active TB disease participants were 
of Cape Mixed Ancestry. HIV-uninfected participants were randomly split into equally 
sized training and test sets at a 1:1 ratio of active TB cases and Mtb-infected 
controls (Figure 5). There was no difference in baseline characteristics between the 
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training and test sets (Table 5).  Similar demographics were collected in the HIV-
infected persons and there were no differences between the active TB cases and 
Mtb-infected controls (Table 6). Plasma viral loads and CD4 T cell counts were not 




Figure 5: The pilot cohort. Participant screening and enrolment in the pilot cohort and assignment of 












Mtb infected (n=30)  ActiveTB (n=30)  
HIV-uninfected
   153 individuals screened  
Active TB (n=20) 
Training set (n=30)
Mtb infected (n=15)
Active TB (n=15) 
Excluded (n = 53)
• QuantiFERON GIT negative (n=40) 
• Low BMI: <17.5 (n=4) 
• Anaemic (n=2)
• Misbleed (n=1)
• Indeterminate QuantiFeron GIT (n=2)
• Previous TB (n=1)
• TB negative (n=1)





Mtb infected (n=20) 
Mtb infected (n=15)
Active TB (n=15) 
Test set (n=30)
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Table 4: Participant characteristics of the HIV-uninfected cohort. P <0.05 was considered 










Sex, n (%) Male 22 (73) 8 (27) 0.0007 
Median age, years 
(range) 
 34 (18-62) 40.5 (22-65) 0.01 
Race, n (%) Black African 14 (46.7) 5 (16.7) 0.03 
Caucasian 0 (0) 1 (3.3) 
Cape Mixed 
Ancestry 
16 (53.3) 24 (80) 
Median BMI, kg/m2 
(range) 
 20.5 (17.6-26.5) 30.4 (18.5-47.2) <0.0001 
Median QFT, 
IU/mL (range) 
 - 6.7 (0.5-13.8) N/A 
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Table 5: Participant characteristics of the training and test set splits of the HIV-uninfected 









Sex, n (%) Male 19 (63.3) 11 (36.7) 0.07 
Median age, 
years (range) 
 37.5 (18-65) 38 (19-54) 0.80 
Race, n (%) Black African 9 (30) 10 (33.3) 0.60 
Caucasian 1 (3.3) 0 (0) 
Cape Mixed 
Ancestry 
20 (66.7) 20 (66.7) 
Median BMI, 
kg/m2 (range) 
 21.5 (17.6-44) 25.1 (18.1-47.2) 0.05 
Median QFT, 
IU/mL (range) 
 5.7 (0.5-11) 8.4 (0.7-13.8) 0.40 
 
Table 6: Participant characteristics in the HIV-infected cohort. P <0.05 was considered 










Sex, n (%) Male 10 (50) 10 (50) 1.00 
Median age, years 
(range) 
 36 (23-62) 31.5 (24-55) 0.10 
Race, n (%) Black African 14 (70) 16 (80) 0.70 
Cape Mixed 
Ancestry 
6 (30) 4 (20) 
Median BMI, kg/m2 
(range) 
 22.5 (18.4-39.9) 22.1 (18.3-54.2) 0.8 
Median QFT, 
IU/mL (range) 
 - 2.8 (0.35-13.1) N/A 
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3.4.2: Indistinguishable diagnostic performance of the ACS 11-gene signature 
in whole blood and PBMC from HIV-uninfected participants!
We first sought to determine if the signature could classify TB disease from healthy 
Mtb infection in PBMC in the training set. The 11-gene signature classified Mtb 
infection from active TB disease in whole blood and PBMC with comparable 
accuracy. The AUCs for whole blood and PBMC were equivalent at 0.93 (95% CI 
0.80 to 1.00) and 0.96 (95% CI 0.89 to 1.00), respectively, p=0.71 (Figure 6A). Due 
to the excellent performance of the signature in PBMC, we proceeded to perform 
blind predictions of the unmodified 11-gene signature on the test set. An 
indistinguishable diagnostic performance was observed between whole blood and 
PBMC in the test set (Figure 6B). Performance in whole blood and PBMC was 
equivalent at 1.00 (95% CI 1.00 to 1.00) and 0.99 (0.98 to 1.00) respectively, 
confirming the results observed in the training set.  
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Figure 6: Performance of the ACS-11 gene signature in discriminating between active TB 
disease and Mtb infection in PBMC and whole blood from the HIV-uninfected cohort. A-C: Area 
under the Receiver Operating Characteristic curves illustrating the diagnostic performance of the 11-
gene signature when measured in RNA from whole blood or PBMC samples from (A) the training set 
(n=30), (B) the test set (n=30), (C) the combined training and test sets (n=60). (D) Signature scores 
measured in whole blood or PBMC from active TB cases or healthy Mtb-infected persons. Horizontal 
lines represent medians, the box represents the interquartile range (IQR) and the whiskers represent 
the range. (E) Differences in transcript expression between TB cases and healthy controls when 
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measured in whole blood or PBMC samples. Negative differences indicate higher expression in TB 
than QFT+ controls. Dots represent medians and the bars 95% CI for each transcript identified by its 
TaqMan primer-probe set, computed with the rank inversion method and bootstrapping 2,000 times. 
Dashed lines represent the cut-off at which no difference was observed between cases and controls. 
 
3.4.3: Expression differences of individual signature transcripts and signature 
scores in PBMC and whole blood !
In light of the excellent performance results, we combined the training and test set 
data for subsequent analyses of the signature scores and to understand single 
transcript expression in PBMC and whole blood. The diagnostic performance of the 
signature in the combined datasets remained indistinguishable between whole blood, 
AUC 0.97 (95% CI 0.91 to 1.00) and PBMC, AUC 0.98 (95% CI 0.95 to 1.00) (Figure 
6C). However, signature scores were lower in RNA from PBMC compared with RNA 
from whole blood (Figure 6D). As the lower signature scores from PBMC suggest 
lower gene expression in PBMC, we proceeded to determine the differences in 
single transcript expression between active TB cases and healthy Mtb-infected 
controls in whole blood and PBMC. Single transcript expression was higher in cases 
than in controls regardless of sample type (reflected by a negative difference in 
Figure 6E). Median relative differences in transcript expression between whole blood 
and PBMC were equivalent for most of the genes. However, for transcripts 
representing SCARF1, GBP1, GBP5, BATF2 and TRAFD1 the differences between 





3.4.4: Performance of the signature in diagnosing active TB disease in the HIV-
infected cohort 
As observed in the HIV-uninfected cohort, the 11-gene signature could also 
successfully stratify Mtb infection from active TB disease in RNA samples from 
whole blood and PBMC from HIV-infected persons (Figure 7A). Again, AUCs were 
not significantly different (p=0.55) between whole blood, AUC 0.83 (95% CI 0.71 to 
0.96) and PBMC AUC 0.88 (95% CI 0.76 to 0.99). Signature scores were lower in 
PBMC in comparison to whole blood (Figure 7B), although with a considerable 
overlap between Mtb-infected persons and TB cases. Single transcript expression 
was greater in TB cases in comparison to Mtb-infected controls in whole blood 
samples except for a few transcripts representing the STAT1 gene and TRAFD1 
(Figure 7C). Single transcript expression was also greater in TB cases than controls 
in PBMC, except for a few transcripts representing the SCARF1 gene and again 






Figure 7: Performance of the ACS 11-gene signature in discriminating active TB disease and 
Mtb infection in PBMC and whole blood in HIV-infected participants (n=40). (A) ROC curves 
illustrating the diagnostic performance of the signature when measured in RNA from whole blood or 
PBMC. (B) Signature scores measured in whole blood or PBMC from HIV-infected active TB cases or 
Mtb-infected persons. Horizontal lines represent medians, the box represents the IQR, and the 
whiskers represent the range.(C) Differences in transcript expression between cases and controls 
when measured in whole blood or PBMC samples. Negative differences indicate higher expression in 
TB than QFT+ controls. Dots represent medians and the bars represent the 95% CI for each 
transcript, computed with the rank inversion method and bootstrapping 2,000 times. Dashed lines 
represent the cut-off at which no difference was observed between cases and controls. 


















































































































































































































































































































































































































































































































3.4.5: HIV infection upregulates Type I IFN gene expression in whole blood and 
PBMC 
The higher signature scores (representing higher IFN responses) in the QFT+ 
participants suggest lower specificity in HIV infection due to the higher number of 
false positives. The lower specificity resulted in a poorer diagnostic performance of 
the signature in both whole blood and PBMC samples in comparison to the HIV-
uninfected cohort. We investigated if the difference significantly decreased the 
diagnostic utility of the signature by comparing the ROC AUCs using the pROC 
package. In addition, we investigated the difference in transcript expression between 
HIV-infected and uninfected active TB cases and Mtb-infected controls to determine 
the effect of HIV infection on gene expression. A decrease in ROC AUCs of at least 
10% was observed in HIV-infected persons in comparison to HIV-uninfected persons 
in whole blood and PBMC (Figure 8A & B). The difference was not significant for 
PBMC (p=0.10) and approached significance in whole blood (p=0.06). Signature 
scores observed between HIV-infected and uninfected TB cases in both whole blood 
and PBMC were not significantly different (p= 0.05 and p = 0.15, respectively; Figure 
8C & D). In both whole blood and PBMC samples, markedly increased signature 
scores were observed in Mtb-infected HIV-infected persons compared to their HIV-
uninfected counterparts. We also observed generally higher single transcript 
expression in HIV-infected relative to HIV-uninfected participants (indicated by a 
negative difference in dCt between HIV-infected and uninfected persons in Figure 8E 
& F), irrespective of sample type (whole blood or PBMC). However, some STAT-1 
transcripts in whole blood and PBMC as well as SCARF-1 transcripts in PBMC were 
expressed at lower levels in HIV-infected than in HIV-uninfected persons. These 
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patterns in signature scores and single transcript expression suggest that HIV 
infection drives type I IFN gene expression leading to lower specificity of the 
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Figure 8: Comparison of the performance of the ACS 11-gene signature in HIV-infected and 
uninfected persons in RNA samples collected from whole blood and PBMC. A-B: ROC curves 
illustrating the diagnostic performance of the signature in classifying active TB from healthy Mtb 
infection when measured in HIV-infected and uninfected persons from (A) whole blood and (B) PBMC 
samples. C-D: Signature scores measured in HIV-infected or uninfected active TB cases or healthy 
Mtb infected persons in (C) whole blood and (D) PBMC. Horizontal lines represent medians, the box 
represents the IQR, and the whiskers represent the range. E-F: Differences in transcript expression 
between HIV-infected and uninfected persons when measured in active TB or Mtb-infected samples 
in (E) whole blood or (F) PBMC. Negative differences indicate higher expression in HIV-infected than 
HIV-uninfected persons. Dots represent medians and the bars 95% CI for each transcript, identified 




3.4.6: Development and validation of a modified signature with enhanced 
diagnostic performance in HIV infection 
It is well described that viral infections, and TB disease, increase type I IFN gene 
expression in blood leukocytes (Berry et al. 2010; Singhania et al. 2017; Scriba et al. 
2017), as we also observed here. This elevation in type I IFN gene expression 
results in a reduction in specificity of the signature and is the most likely reason for 
the decrease in diagnostic performance in HIV-infected persons, relative to 
uninfected persons.  
 
In an attempt to improve diagnostic performance of the 11-gene signature, we set 
out to adapt the signature for HIV infection to increase the accuracy of the signature 
in differentiating active TB disease from Mtb infection. We removed transcripts that 
resulted in diminished signature performance in HIV infection and re-parameterised 
the gene-pair weightings or coefficients that comprise the signature algorithm. First, 
the 10 reference (housekeeper) primers were ranked by their computed SD of the Ct 
values to determine variability in expression. The five reference primers with the 
largest SDs were removed (Figure 9). Ct values of GOI transcripts of PBMC samples 
from the HIV-infected cohort were then standardised to the mean of the five 
remaining reference primers, yielding dCt values. Ability of each individual GOI 
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transcript to discriminate active TB disease from Mtb infection in HIV-infected 
persons was assessed and eight primer-probes that could not classify active TB 
disease at a p-value cut-off of at least 0.05 were removed from the signature. Four 
SCARF1 primers, three STAT1 primers, and the TRAFD1 primer that yielded poor 
differentiation in PBMC from HIV-infected participants (Figure 8F) were removed. 
The remaining transcripts were re-trained (finding the best model by identifying 
transcript pairs and their optimal coefficients) to differentiate between active TB and 
Mtb-infected samples using linear SVM. The new signature, referred to as rPSVM.1 
(re-parameterised pair-wise SVM), consisted of 30 transcripts or primer-probes 
(Table 7), representative of 115 transcript-pairs. However, when applied to both HIV-
infected and uninfected groups of this cohort, rPSVM.1 did not yield significantly 
improved diagnostic performance than the original 11-gene signature (Table 8). We 
also tested if rPSVM.1 could differentiate between the HIV-uninfected TB 
progressors and controls from the ACS and GC6-74 cohorts to determine prognostic 
performance. Although rPSVM.1 yielded an AUC of 0.83 (95% CI, 0.77 to 0.88) in 
the ACS training set, which appeared higher than the 0.76 (95% CI, 0.71 to 0.82) 
obtained with the 11-gene signature, this difference was not significant (Table 8). 
Prognostic performance of rPSVM.1 in the ACS test set and the GC6-74 cohort were 











   
Figure 9: Development and validation of a re-parameterised signature (rPSVM.1) derived from 
the ACS 11-gene signature for HIV-infection. SD = standard deviation, SVM= support vector 








ACS 11-gene signature 
       38 primer probes
10 reference primer probes
Remaining primer probes (n=30) re-trained on linear 
SVMs using PBMC from HIV+ cohort
              Data standardisation
Data:PBMC from HIV-infected cohort (n=40) 
Data standardised using all reference primers
Data re-standardised on remaining reference primers
Ability of primer probes in differentiating TB disease and Mtb infection measured
Primer probes with p >0.05 removed (n=8)
Removal of primer probes of interest
Diagnostic and Prognostic ability of new signature
                    New signature applied to:
        Pilot (HIV-infected and uninfected participants)
        ACS (HIV-uninfected)
        GC6-74 (HIV-uninfected)
Reference and primer probes of interest ranked by SDs
Reference primers with large SDs removed (n=5)
Removal of reference primers
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Table 7: Genes and primer-probe IDs of transcripts in the rPSVM.1 signature. 
Gene  Assay ID Role in signature 
ADRBRK1 Hs01056345_g1 Reference primer 
CDC42 Hs03044122_g1 Reference primer 
CSDE1 Hs00918650_m1 Reference primer 
TMBIM6 Hs00162661_m1 Reference primer 
USF2 Hs01100994_g1 Reference primer 
GBP1 Hs00977005_m1 GOI primer 
GBP2 Hs00894837_m1 GOI primer 
GBP2 Hs00894846_g1 GOI primer 
SERPING1 Hs00934330_m1 GOI primer 
STAT1 Hs01013995_g1 GOI primer 
SERPING1 Hs00934329_m1 GOI primer 
GBP1 Hs00266717_m1 GOI primer 
GBP1 j1 GOI primer 
GBP2 Hs00894842_g1 GOI primer 
GBP5 j4 GOI primer 
STAT1 Hs01014002_m1 GOI primer 
SERPING1 Hs00935959_m1 GOI primer 
GBP2 j1 GOI primer 
ETV7 j2 GOI primer 
ETV7 Hs00903230_g1 GOI primer 
TAP1 Hs00897093_g1 GOI primer 
STAT1 Hs01013993_m1 GOI primer 
SERPING1 Hs00934328_g1 GOI primer 
SERPING1 Hs00163781_m1 GOI primer 
BATF2 Hs00912736_m1 GOI primer 
STAT1 Hs01013997_m1 GOI primer 
STAT1 Hs01013996_m1 GOI primer 
STAT1 Hs01013994_m1 GOI primer 
STAT1 Hs01013991_m1 GOI primer 
STAT1 Hs01013989_m1 GOI primer 
FCGR1C Hs00417598_m1 GOI primer 
GBP2 Hs00894840_mH GOI primer 
ETV7 Hs00903228_m1 GOI primer 
GBP5 Hs00369472_m1 GOI primer 

















Table 8: Diagnostic and prognostic performance of the re-parameterised ACS 11-gene 
(rPSVM.1) signature in the pilot, ACS, and GC6-74 cohorts 
















5.3 x 10-10 0.97 
(0.91-1.00) 
0.93 
Pilot Uninfected PBMC 0.99  
(0.97-1.00) 
5.2 x 10-11 0.98  
(0.95-1.00) 
0.56 
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0.93 
Pilot Infected PBMC 0.93  
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TB biomarkers are important tools that can help to identify individuals at the highest 
risk of developing active TB disease, or those who have subclinical or active TB 
disease, before and/or at TB diagnosis. Most published TB transcriptomic biomarker 
studies have focused on classifying active TB disease from healthy Mtb-uninfected 
or Mtb-infected controls, while some have demonstrated performance in 
differentiating between TB disease and other respiratory diseases such as 
pneumonia (Anderson et al., 2014; Berry et al., 2010; Bloom et al., 2013; Kaforou et 
al., 2013; Maertzdorf et al., 2012; Walter et al., 2016). These signatures typically 
return to levels observed in controls during TB therapy, suggesting that the selected 
transcripts reflect TB disease pathogenesis and the underlying immune responses 
(Berry et al. 2010; Bloom et al. 2012). Indeed, we have shown that the transcripts in 
our prognostic 16-gene and 11-gene signatures are highly upregulated at time points 
closest to TB diagnosis (Zak et al. 2016; Darboe et al. 2018). This chapter 
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demonstrates that these signatures performed well as diagnostic PCR-based 
biomarkers when differentiating between active TB disease and healthy, Mtb-
infected controls. Similar diagnostic performance was also observed when the 16-
gene signature was re-parameterised to published microarray datasets and applied 
to distinguish between active TB disease and healthy Mtb-infected persons (Zak et 
al. 2016). In addition, the 16-gene signature could differentiate active TB disease 
from diseases such as lung cancer, pneumonia, and sarcoidosis when applied to the 
published datasets of Bloom (2013), Kaforou (2014) and Anderson (2014) (Zak et al. 
2016). A limitation in our analysis is the exclusion of other diseases that have similar 
clinical presentation as active TB disease, which would be encountered in a health-
care setting. An advantage of PCR-based blood diagnostic tests in clinical settings is 
the ability to differentiate active TB disease from other diseases. The 11-gene 
signature has the potential to be used as such a diagnostic test, but this could not be 
confirmed in our cohorts. 
 
The risk of progression to active TB disease is significantly increased by HIV 
infection (Parida and Kaufmann 2010). TB diagnosis in HIV-infected persons is 
complicated by the paucibacillary nature of sputum produced by HIV-infected and 
especially highly immunocompromised TB patients. This makes it difficult to 
diagnose active TB in HIV-infected persons, especially when using sputum smear 
microscopy, which has a poor sensitivity. Sputum cultures are more sensitive than 
sputum smears in diagnosing active TB (Cain et al. 2010; Stephen D Lawn et al. 
2006), but diagnosis using sputum cultures can take up to 42 days. Blood-based 
RNA signatures could serve as important new tools for TB diagnosis in HIV-infected 
persons. We demonstrate here that the 11-gene signature can diagnose active TB in 
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HIV-infected persons using whole blood samples, could potentially be used as a 
triage test for TB disease in clinical settings.  
 
Large clinical trials with long follow-up periods are needed to test the utility of 
prognostic signatures for identifying HIV-infected persons at risk of active TB 
disease. Biobanked PBMC samples from a longitudinal cohort of HIV-infected 
persons are available for such an evaluation, using the ACS 11-gene risk signature. 
In this chapter, we sought to prepare for these analyses by testing the performance 
of the whole-blood derived signature in PBMC samples. We reasoned that reliable 
performance of the signature using PBMC would allow testing of the signature in the 
biobanked samples from the TRuTH study. We show here that the signature yielded 
excellent diagnostic performance for active TB using PBMC from both HIV-infected 
and uninfected persons and that this performance was equivalent to that obtained 
with whole blood samples. 
 
Despite the excellent performance of the signature in diagnosing active TB in PBMC, 
signature scores were lower in PBMCs than whole blood. These lower signature 
scores could be attributed to the lower mRNA expression in PBMCs for multiple 
transcripts, most likely due to the absence of certain cell types, such as neutrophils, 
in PBMCs, which are removed by gradient centrifugation. Neutrophils from active TB 
patients and healthy controls displayed very pronounced differences in expression of 
type I/II IFN response transcripts and appeared to contribute the strongest 
expression differences when compared to other blood cell subsets (Singhania et al. 
2017; Berry et al. 2010; Scriba et al. 2017). We did not carry out any flow cytometry 
analyses on the samples to measure gene expression in different cell subsets. We 
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therefore do not know how the gene expression signatures performed in different cell 
subsets.  
 
The signature performance in HIV-infected persons was at least 10% lower than in 
HIV-uninfected persons, as has been previously observed (Zak et al. 2016). 
However, the ROC AUCs were not statistically different, suggesting either an 
equivalent accuracy in the two populations or highlighting that the sample sizes in 
our study were not large enough. Some of the Mtb-infected HIV-infected persons 
could have been on INH prophylaxis, this could decrease gene expression in these 
participants. In addition, modulation of gene expression could occur due to its effects 
independent of Mtb. We, however, did not have enough statistical power to study the 
effect of INH on signature modulation.  
 
We show that the reduction in signature performance in the HIV-infected cohort is 
likely attributable to the higher signature scores observed in Mtb-infected controls in 
this population. HIV infection was previously shown to increase immune activation 
and serum type I IFN response (Psomas et al. 2016; Bosinger and Utay 2015). 
Higher signature scores in the controls decreased the diagnostic performance and 
specificity of the signature. In addition, the degree of immune activation is associated 
with HIV viral load (Psomas et al. 2016; Klatt et al. 2013), thus the increase in 
signature scores in the Mtb-infected cohort are also likely to be affected by the viral 
load levels. This is investigated further in Chapter 6 of this thesis.  
 
Despite the limited sample size of this cohort, the results generated are consistent 
with those of other studies of diagnostic TB biomarkers (Lee et al. 2016; Lu et al. 
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2011). Previous studies have also shown a reduction in the performance of TB 
diagnostic RNA signatures in HIV-infected persons (3 to12%) relative to HIV-
uninfected persons (Sweeney et al. 2016; Walter et al. 2016; Dawany et al. 2014; 
Kaforou et al. 2013). Hence, a reduction in signature performance in HIV-infected 
persons is generally observed, further strengthening our observations.  
 
We set out to generate an HIV-adapted signature that may perform better on PBMC 
samples by removing transcripts that decreased the specificity of the ACS 11-gene 
signature.  We also adjusted the model parameters for PBMC samples by re-training 
transcript pairs on linear SVMs whilst maintaining the pair-wise ensemble in the 
signature. It was somewhat surprising that the diagnostic and prognostic 
performances of the rPSVM.1 signature were equivalent to the performances of the 
ACS 16 and 11-gene signatures. However, the result suggests that signatures of 
active TB of whole blood adjusted for PBMC samples and HIV-infected persons can 
accurately diagnose and predict active TB in whole blood samples and HIV-
uninfected populations.  
 
In conclusion, we show here that the ACS 11-gene signature can differentiate active 
TB disease from healthy Mtb infection in both whole blood and PBMC. The weaker 
IFN response signature in PBMC indicates the need for a different sample-type 
specific threshold for diagnosis of active TB disease due to the absence of signal 
from certain cell types, such as neutrophils. Regardless, the comparable 
performance between whole blood and PBMC demonstrates feasibility of applying 
the signature to biobanked cryopreserved PBMC for assessment of TB risk. This 
increased our confidence in testing the prognostic performance of the signature in 
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HIV-infected persons, and as a result we applied these signatures to the TRuTH 
(discussed in Chapter 4) and IMPRESS (discussed in Chapter 5) cohorts. 
 
3.6: Contributions 
Ms F. Darboe designed and conducted the experiments and wrote this chapter under 
the supervision of Dr A. Penn-Nicholson and A. Prof T.J. Scriba. The new signature 
was developed and tested by Dr E.G. Thompson. R scripts to calculate signature 



































Chapter 4: Predicting recurrent TB disease in HIV-infected persons on ART 
 
The aim of this chapter is to determine if the TB risk signatures can predict recurrent 
TB disease in HIV-infected persons on ART. 
 
4.1: Introduction!
Two critical issues related to the management and care of active TB disease in HIV-
infected populations is how to effectively reduce mortality and prevent TB recurrence 
after treatment. The World Health Organisation (WHO) policy on collaborative 
TB/HIV activities aims to “reduce the burden of TB in people living with HIV, by 
ensuring the delivery of the three “I”s (intensified case finding, infection control and 
IPT), for HIV/TB” (WHO, 2012). In order to achieve this, it is recommended that 
adults and adolescents living with HIV should be regularly screened for TB and 
should receive at least six months of IPT irrespective of degree of immune 
suppression (WHO, 2012). A systematic review of 12 randomized controlled trials of 
HIV-infected individuals showed that a six to12 month course of daily INH therapy 
reduced TB incidence by up to 60% (Akolo et al., 2010). 
 
This approach is however undermined by poor adherence and incomplete Mtb 
sterilisation by IPT (Samandari et al. 2011). A study in more than 70,000 South 
African gold miners showed no significant effect of prophylaxis on both TB incidence 
and prevalence after the treatment period, likely in part due to poor adherence to the 
treatment regimen (Churchyard et al. 2014). Poor adherence may be attributable to 
the duration of the prophylaxis. In addition, mathematical modelling of the data from 
the study suggested that a small proportion of Mtb infection were cured, resulting in 
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the lack of detectable impact of the prophlaxis in the gold mining community 
(Vynnycky et al. 2015). More targeted provision of directly observed TB treatment, 
and novel regimens, such as provision of short-course, high-dose rifapentine and 
INH (Sterling et al. 2011), may be significantly more effective in improving adherence 
to prophylaxis, thus reducing progression to active TB disease. Mtb-infected persons 
appear to transition through a subclinical phase of disease when progressing to 
active TB disease (Esmail et al., 2014; Salgame et al., 2015; Young et al., 2009). In 
this phase patients are asymptomatic but may have evidence of replicating bacteria 
and may be identified by occasional sputum culture positivity (Pai et al. 2016; 
Salgame et al. 2015). In autopsy studies from the 1920s, replicating bacteria were 
identified in persons dying of other causes, suggesting on-going active infection or 
disease (Opie and Aronson 1927). Mass screening and surveys regularly identify 
asymptomatic persons with microbiologically positive subclinical TB (Corbett and 
MacPherson 2013; Onozaki et al. 2015) which would have otherwise been 
undetected, increasing the pool of infectious individuals and risk of TB transmission. 
Identification of HIV-infected persons at high risk of primary and recurrent TB 
disease, or with subclinical disease, would allow targeted provision of active TB 
treatment and could significantly contribute to decreasing transmission within 
communities.  
 
To our knowledge, only one study has attempted to identify transcript signatures of 
recurrent TB in HIV-uninfected adults (Mistry et al. 2007). In this study, HIV-
uninfected participants with recurrent TB disease were matched to active TB cases 
(with no previous history of TB), Mtb-infected persons, and participants who had 
been clinically cured of active TB disease after one TB episode. Three hundred and 
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thirty-seven genes were identified to be differentially expressed between the four 
groups from 27,566 cDNA probes analysed by microarray. Nine genes were derived 
from the 337 most differentially expressed genes by step-wise linear discriminant 
analysis, and were shown to accurately distinguish between the different groups.  
This study illustrates that TB treatment can be monitored using a blood-based 
transcriptomic signature, a tool that would circumvent the reliance on sputum-based 
diagnostic tests. More studies are necessary to determine if such signatures are 
applicable to other populations, epidemiological and environmental settings. The 
Mistry et al study was limited by the small sample size (n=10 for each group), while 
recurrent TB cases had two or three previous TB episodes. Importantly, the 
biomarker signatures they discovered were not validated in an external or 
independent cohort, a critical criterion for any promising biomarker. 
 
We showed that active TB disease can be predicted and diagnosed by the ACS 11-
gene signature (Chapter 3) and developed an adapted signature, termed rPSVM.1, 
with the aim of increasing its accuracy for diagnosing active TB disease in HIV-
infected populations. We showed that these signatures could predict active TB 
disease a year before clinical symptoms manifested in HIV-uninfected persons (Zak 
et al. 2016), suggesting the detection of underlying incipient or subclinical TB 
disease. However, it is not known if these signatures can predict recurrent TB 
disease in HIV-infected persons. Thus, we set out to determine the prognostic 
potential of ACS 11-gene and rPSVM.1 signatures for TB recurrence in HIV-infected 
persons who are on ART.  
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We collaborated with investigators from the Centre for the AIDS Programme of 
Research in South Africa (CAPRISA), who completed a prospective observational 
cohort study, which aimed to determine the rate at which recurrent TB disease 
occurs in patients who completed TB therapy. The TB Recurrence upon Treatment 
with Highly Active Antiretroviral therapy (TRuTH) study was carried out at the 
CAPRISA eThekwini clinic, Durban. This study followed up newly diagnosed active 
TB cases who had completed the SAPiT (Starting AIDS treatment at three Points in 
TB treatment) (Abdool Karim et al., 2011; Abdool Karim et al., 2010) and START 
(Starting TB and ART) (Gengiah et al. 2012) trials, wherein they started ART. 
Participants who had completed participation in these trials were screened for 
participation in the TRuTH study after obtaining informed consent. The study was 
conducted between 2009 and 2013 and 92 episodes of recurrent TB was recorded 
from 82 patients during a median of three years of follow-up.  
 
4.2: Aim and hypothesis  
Aim!
To determine the prognostic value of the ACS 11-gene and rPSVM.1 transcriptomic 
risk signatures for recurrent TB disease in HIV-infected persons on ART.  
Hypothesis!
The risk signatures will significantly predict recurrent TB disease in HIV-infected 






4.3.1: Study design 
Participant enrolment into TRuTH!
Participants from the START and SAPiT trials who satisfied the following criteria 
were enrolled into the TRuTH study.  
Inclusion criteria 
• Adults at least 18 years old  
• Previously enrolled in the SAPiT and START trials  
• Previous history of active TB disease with HIV co-infection 
• Consent to participate and contribute specimens to the KwaZulu-Natal 
Research Institute for TB and HIV (K-RITH) repository for future investigations  
Exclusion criteria 
• Refusal to consent  
• Diagnosed with XDR TB  
This study was reviewed and approved by the University of Kwazulu-Natal 
biomedical research ethics committee (BF051/09). All participants gave informed 
consent and consented to have samples stored for future studies.  
 
Participants who met the above criteria were enrolled and longitudinally followed up 
for up to three years. Recurrent TB disease was detected by chest x-rays, sputum 
smear and culture using induced sputa, at study entry (baseline), at monthly intervals 
for the first three months and at three-monthly intervals thereafter. Additional cultures 
were performed when participants presented with TB symptoms and/or abnormal 
chest x-rays outside of the follow-up time points. Only cases with microbiologically 
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confirmed TB were included in our biomarker sub-study. In addition to TB 
investigations, serum and PBMC were collected at every visit. 
 
Of the 82 microbiologically confirmed progressors, 43 had PBMC samples available 
and were all included in our sub-study to determine the prognostic value of the ACS 
11-gene and rPSVM.1 signatures. Each progressor was assigned to two non-
progressors, who did not develop recurrent TB during follow up. Non-progressors 
were matched to progressors based on time on ART and gender at TRuTH baseline. 
Due to the confounding effects of CD4  counts on risk of TB disease and viral loads 
on IFN responses, we compared these variables between the 43 progressors and 86 
non-progressors at first TB episode diagnosis, end of TB treatment, and at TRuTH 
baseline and confirmed that they were not different. At least three PBMC samples 
were selected for analysis at three to six monthly intervals from baseline to recurrent 
TB diagnosis, where possible. Samples collected around the same study day (visit) 
were selected for progressors and matched non-progressor controls. 
 
Because we could not predict how well the two signatures would perform, we 
prepared an analysis plan to allow the possible re-parameterisation of the signatures 
should they perform poorly. Thus, progressors and non-progressors were split into a 
training and test set. Ten different iterations, randomly selecting 29/14 progressors 
per split were done and a split with suitable distributions of two-thirds of samples in 
the training set and a third of samples in the test set was nominated. 
 
We also sought to determine the ability of the signatures to differentiate subclinical 
TB from active TB disease or Mtb infection in HIV-infected persons in a cross-
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sectional cohort of ART naïve HIV-infected individuals (Esmail cohort). We 
hypothesized that the signatures would differentiate subclinical TB from Mtb infection 
but not from active TB disease. HIV-infected persons with no previous history of 
active TB disease were screened from an outpatient clinic just outside Cape Town 
(Esmail et al., 2016, 2018). This study was reviewed and approved by the research 
ethics committees of the Universities of Cape Town (013/2011) and Stellenbosch 
(N12/11/079). Informed consent was obtained from all participants before screening 
and study entry. Mtb-infected (QFT-positive) persons, with no evidence of active TB 
on chest x-ray and CD4 counts greater than 350/mm3 were recruited to undergo a 2-
deoxy-2 [18F] fluoro-D-glucose positron emission and computed tomography (PET-
CT) scan. Included in this analysis were participants with no features of disease 
activity on PET-CT, classified as latently (Mtb)-infected persons. Those with features 
of disease activity on PET-CT, but who were asymptomatic with initial negative 
sputum culture, were classified as subclinical TB. In addition, culture or Xpert MTB-
RIF positive symptomatic active TB disease cases were included (Esmail et al., 
2016, 2018).  
 
4.3.2: RNA extraction and quantification !
RNA from the TRuTH cohort was extracted from cryopreserved PBMC as per 
manufacturer’s instructions, as described in section 2.2.2. Extracted RNA was 
quantified using the Nanodrop ND 2000 spectrophotometer as described in section 
2.2.3. Already extracted RNA samples from whole blood from participants enrolled 




4.3.3: Gene expression measurements !
cDNA was synthesized, reverse transcribed and pre-amplified using TaqMan primer-
probes (described in section 2.3.1). Gene expression levels of the signature genes 
were measured by microfluidic qRT-PCR on the Biomark HD instrument (described 
in section 2.3.2).  
 
4.3.4: Data analysis 
!
Data generated were quality controlled and analysed as described in sections 2.4 
and 2.5. Blind predictions were applied to both the training and test sets 
simultaneously before unblinding of participants’ progressor/non-progressor status in 
the training set. Analyses on the test set were only carried out after analyses of the 
training set were complete. Time to diagnosis of recurrent TB (days) was calculated 
for all progressors by subtracting the sample collection date from the date of 
recurrent TB diagnosis. For non-progressors, a “time to recurrent TB” was calculated 
by subtracting sample collection date from the recurrent TB diagnosis date of 




4.4.1: Participant selection and characteristics!
Five hundred and twenty participants who completed follow-up in the SAPiT (n=642) 
and START (n=58) clinical trials were enrolled into the TRuTH study (Figure 10). 
Ninety-two episodes of recurrent TB in 82 participants were recorded during the 
three-year follow-up period. Of these, 43 participants with pulmonary TB had PBMC 
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samples stored, which were available for this sub-study (Figure 10). TB recurrence 
occurred at a median time of 470 days (IQR: 250 to 672 days) after enrolment into 
the TRuTH cohort. Of the 438 participants who remained healthy during follow-up, 
86 non-progressors were selected. Samples between enrolment and recurrent TB 
disease diagnosis were selected at approximately six monthly intervals. Where 
possible, at least three samples were selected prior to recurrent TB diagnosis. When 
realigned to time to recurrent TB diagnosis, most of the samples were collected up to 
a year before recurrent TB diagnosis (Figure 11A). A total of 103 and 196 samples 
were available from progressors and non-progressors, respectively. CD4 T cell 
counts, pVL and BMI at the start of first TB episode treatment were not different 
between the progressors and assigned non-progressors (Figure 11B-D).  CD4 T cell 
counts and pVL were also not different at the end of primary TB treatment (Figure 
11E-F). Time on ART was also not different between the two groups at TRuTH 
enrolment (Figure 11G). Participant characteristics such as sex, race, BMI and pVL 
were also similar between the two groups at TRuTH baseline with the exception of 
CD4 counts, which were higher in the non-progressors (Table 9). The training/test 
split with 66 progressors and 130 non-progressors samples  in training set, and 37 











Figure 10: Selection of participants for the TRuTH cohort, in which prediction of recurrent TB 
disease in people living with HIV was tested. Progressors with PBMC samples stored before 
recurrent TB episodes were matched to eligible non-progressors (1:2).  
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Figure 11: Selection of recurrent TB progressors and controls and their samples for 
transcriptomic signature testing. (A) Distribution of progressor samples depicted by time since 
TRuTH enrolment (left) and time to recurrent TB diagnosis (right). Each line depicts a progressor and 
the dots represent the time points of selected PBMC samples. (B-F) Differences in demographics and 
risk factors of TB between progressors and non-progressors at (B-D) the start of treatment of TB 




Table 9: Basic demographics of participants who were included in this sub-study at TRuTH 
baseline. For each progressor, two non-progressors were selected from a set of available non-
progressors with the same range of CD4 counts and plasma viral loads (pVL) as the progressors. pVL 








Sex, n (%) Male 21 (49) 42 (49) 1.00 
Median age, 
years (range) 
 35 (25-53) 37.5 (23-62) 0.38 
Race, n (%) Black African 43 (100) 85 (99) 1.00 
Other 0 (0) 1 (1) 
Median BMI, 
kg/m2 (range) 
 24 (16.5-41.9) 24.3 (16.4-40.8) 0.58 
Previous TB, n 
(%) 
1 27 (62.8) 58 (67.4) 0.69 
2 16 (36.4) 28 (32.6) 
 Median time since 
previous TB, days 
(range) 





35 (81.4) 79 (92.9) 0.07 
 Median of log 
detectable pVL 
(range) 





 336 (14-884) 406 (66-1211) 0.03 
Median time on 
ART, days 
(range) 



















Figure 12: Distribution of samples in the training and test sets in the chosen iteration. (A&B) 
The number of participant samples at each 90-day time window in the training (A) and test (B) sets. 













































































































































4.4.2: QC of qRT-PCR data!
Seven 96.96 GE chips were required to run qRT-PCR on all 299 samples in 
duplicate. Before blind predictions, Ct values of all assays for the duplicate IPC 
samples from the seven chips were analysed using Spearman’s correlation test to 
determine consistency between the runs. The correlation coefficients between all the 
chips exceeded 0.95 (Figure 13A). We also compared the distributions of the 
average dCt of GOI primer-probes between the chip runs, to ensure that the 
distribution of primer of interest expression was similar between the chip runs. No 
marked differences in these distributions between the chip runs were observed as 
shown by overlapping histogram plots (Figure 13B). In addition, signature scores 
were compared between the seven chips and found to differ by less than 10% for 
both the ACS 11-gene (score range: 87 to 94) and the rPSVM.1 (score range: 90 to 
94) signatures. To assess consistency of the QC, the signature score script, and its 
application to the Fluidigm qRT-PCR data, both SATVI and collaborators in CIDR 
performed blind predictions on the raw qRT-PCR data. The signature scores 
between the two institutes were compared before unblinding of progressor/non-
progressor class, and were found to be identical (data not shown). The training set 




Figure 13: Correlation of duplicate internal positive controls (IPC) in the seven qRT-PCR chips. 
(A) Correlation of duplicate Ct values of all 96 assays of the IPC in the seven chips. Each square 
represents a correlation coefficient between two replicates from different chips. Numbers denote the 
chip IDs and the letters denote the replicates. Correlations were calculated by Spearman correlation. 
(B) Distribution plots depicting the distribution of delta average Ct values in the IPC of the seven 
chips. (C) Consistency in ACS 11-gene and rPSVM.1 signature scores obtained for the IPC sample 





















































a- IPC replicate 1
b- IPC replicate 2


















































4.4.3: Signatures can only predict recurrent TB in the three months preceding 
diagnosis in the training set!
To determine if the ACS 11-gene or rPSVM.1 can differentiate between recurrent TB 
progressors and non-progressors we stratified samples into six-monthly time 
windows relative to recurrent TB diagnosis. Samples within six months of recurrent 
TB diagnosis were further stratified into two three-monthly time windows. We first 
compared signature scores of all progressor and non-progressor samples, 
irrespective of time to recurrence, to determine if the signatures had any prognostic 
potential during the entire follow-up period. The signatures could significantly 
differentiate between progressors and non-progressors but only weakly (ACS 11-
gene, AUC 0.65 (95% CI 0.57 to 0.73), p=0.0005; rPSVM.1, AUC 0.66 (95% CI 0.57 
to 0.75), p=0.0002 (Figure 14A &B, Table 10). No difference in AUC was observed 
between the two signatures (p=0.55). When stratified into six-monthly time-to-TB 
diagnosis windows only the ACS 11-gene signature predicted recurrent TB disease 
in the six months preceding diagnosis (Figure 14A & B, Table 10). To understand the 
effect of time further we stratified samples within this six-month time window into two 
three-monthly time windows. Both signatures significantly differentiated between 
recurrent TB progressors and non-progressors only three months preceding 
diagnosis (Figure 14C & D, Table 10). Performance of the ACS 11-gene signature 
during this period was highly significant (p=0.003) whilst that of rPSVM.1 was barely 
significant (p=0.01) despite equivalent ROC AUCs of 0.77 (95% CI: 0.61 to 0.93) and 
0.74 (0.57 to 0.91), respectively (Table 10). These AUCs were not different by pROC 
analysis, p=0.82. These results suggest that the differentiation observed for ACS 11-
gene signature within six months of recurrence diagnosis was driven by signal 







Figure 14: Performance of signatures in the TRuTH training set. ROC curves depict predictive 
potential of recurrent TB during HIV infection for discriminating progressors and non-progressors 
before diagnosis. (A&B): ROC curves correspond to 180-day intervals relative to TB recurrence and 
all time points combined for the ACS 11-gene (A) and rPSVM.1 (B) signatures. (C&D) Each ROC 
curve corresponds to a 90-day time interval relative to TB recurrence for the ACS 11-gene (C) and 
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Table 10: ROC AUC depicting the performance of the ACS 11-gene and rPSVM.1 signatures in 
the TRuTH training set 
Days to 
recurrent TB  
ACS 11-gene rPSVM.1 
ROC AUC (95% CI)  p-value ROC AUC (95% CI) p-value 
 
All time points 0.65 (0.57-0.73) 0.0005 0.66 (0.57-0.75) 0.0002 
By 3-month period 
0-90 0.77 (0.61-0.93) 0.003 0.74 (0.57-0.91) 0.01 
91-180 0.64 (0.41-0.87) 0.13 0.47 (0.22-0.73) 0.60 
By 6-month period 
0-180 0.72 (0.58-0.85) 0.0043 0.63 (0.49-0.78) 0.08 
181-360 0.54 (0.36-0.71) 0.67 0.68 (0.52-0.84) 0.03 
361-540 0.64 (0.45-0.83) 0.24 0.68 (0.46-0.89) 0.12 
>540 0.68 (0.48-0.87) 0.12 0.63 (0.41-0.86) 0.24 
 
 
4.4.4: Performance of transcriptomic signatures in the combined TRuTH 
training and test set !
We expected the rPSVM.1 signature to perform better than the ACS 11-gene 
signature in predicting recurrent TB disease in the training set because the rPSVM.1 
signature was specifically adapted and parameterised for PBMC and HIV infection. 
However, we observed equivalent performance between  the rPSVM.1 and  ACS 11-
gene signatures showing that adaptation of such signatures does not necessarily 
improve performance. We also decided against generating yet another signature 
based on the premise that application of an existing signature to a new cohort 
provides a more valuable assessment of predictive performance than fitting a revised 
or adapted signature to a new dataset. We therefore decided that further re-
parameterisation of signatures would not be warranted, unblinded the 
progressor/non-progressor status of the TRuTH test set, and combined this with the 
training set for analysis of the entire cohort providing a larger sample size and more 
statistical power. Stratified into six-monthly windows, the ACS 11-gene and rPSVM.1 
signatures significantly predicted recurrent TB within six months of TB diagnosis 
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(Table 11). The signatures also predicted recurrent TB disease within three months 
of recurrent TB diagnosis; the ACS 11-gene signature with an AUC of 0.72 (95% CI: 
0.58 to 0.85, p=0.004, Table 11) and the rPSVM.1 signature with an AUC of 0.73 
(95% CI: 0.59 to 0.87, p=0.002; Table 11). These AUCs were equivalent by pROC 
analysis (p=0.49), confirming what was observed in the training set.  
 
Table 11: Performance of the ACS 11-gene and rPSVM.1 signatures in the combined training 
and test sets of the TRuTH cohort. 
Days to 
recurrent TB  
ACS 11-gene rPSVM.1 
ROC AUC (95% CI) p-value ROC AUC (95% CI) p-value 
 
By 3-month period 
0-90 0.72 (0.58-0.85) 0.004 0.73 (0.59-0.87) 0.002 
91-180 0.63 (0.43-0.82) 0.11 0.53 (0.33-0.74) 0.36 
By 6-month period 
0-180 0.68 (0.57-0.79) 0.005 0.65 (0.53-0.76) 0.02 
181-360 0.58 (0.45-0.71) 0.23 0.68 (0.56-0.80) 0.006 
361-540 0.57 (0.39-0.75) 0.46 0.65 (0.46-0.83) 0.14 
>540 0.59 (0.44-0.75) 0.26 0.63 (0.48-0.78) 0.13 
 
4.4.5: Lower signature scores in non-progressors than in progressors in the 
three months preceding TB recurrence, despite heterogeneity of scores!
Next, the longitudinal kinetics of the signature scores were investigated to determine 
any temporal changes in relation to time to recurrent TB diagnosis. Longitudinal 
median scores of either signature were not different over time between the 
progressors and non-progressors, except during the three months preceding 
recurrent TB diagnosis when scores were significantly higher in progressors than 
non-progressors (Figure 15A & B), mirroring what was observed in the ROC AUCs. 
Kinetics of longitudinal signature scores were highly variable in individual 
progressors and non-progressors (Figure 15C & D), highlighting the high degree of 
heterogeneity of IFN responses in HIV-infected persons with previous TB disease. 
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4.4.8: Signature scores were not associated with time to sputum culture 
positivity at recurrent TB diagnosis!
In a recent study of TB disease progression in non-human primates, magnitudes of 
Type I IFN signatures in macaques was highly correlated with the extent of disease 
and FDG uptake as measured by PET-CT (Gideon et al., 2016). Similarly, in a 
human study of TB treatment, FDG uptake and Type I IFN were associated with the 
presence of mycobacteria in the sputum of HIV-uninfected persons during TB 
treatment (Malherbe et al. 2016; Thompson et al. 2017). These studies suggest that 
Type I IFN gene expression signatures and mycobacterial load are associated with 
disease severity at the site of infection. Hence, we set out to determine the 
relationship between signature scores of progressor samples collected within three 
months of diagnosis and mycobacterial load in sputum, using time to culture 
positivity as a measure of disease severity. There was no association between 
signature scores and time to culture positivity in a subset of cases (n=18) who had 
data available on time to culture positivity (Figure 15E &F).  
 
4.4.9: Time since previous TB diagnosis, time on ART and number of previous 
TB episodes were not associated with signature scores !
In the Malherbe et al study of TB treatment, inflammation detected in the form of 
PET-hot lesions measured by PET-CT was observed in HIV-uninfected persons up 
to a year after end of successful TB therapy (Malherbe et al., 2016). We investigated 
the effect of time since previous TB diagnosis and number of previous TB episodes 
on on-going inflammation measured by signature scores. Since effective ART results 
in lower risk of active TB, decreased immune activation and inflammation in HIV 
infection (Klatt et al., 2013), the effect of time on ART on signature scores was 
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measured to determine the effect of ART on on-going inflammation. Time since 
previous TB and time on ART were calculated by subtracting the dates of ART start 
and TB treatment start (within seven days of diagnosis) from the sampling date. 
Some participants had previous TB episodes at the start of primary TB study (i.e. 
START/SAPiT) but the number of previous TB episodes was not recorded. Thus, we 
stratified the number of previous TB episodes into one or more than one in our 
analyses of the TRuTH study. The median time from previous TB to sampling time 
was 1,325 days (IQR: 1,042 to 1,605 days). No association was observed between 
time since previous TB and ACS-11 gene or rPSVM.1 signature scores. Time on 
ART (median = 1,089 days, IQR: 791 to 1,436 days) was also not associated with 
signature scores at the corresponding sampling time points. Signature scores were 
not different between persons with one previous TB episode and those with more 
than one previous TB episode, p=0.49 and p=0.43 for the ACS 11-gene and 
rPSVM.1 signatures,respectively. This disproves our hypothesis that signature 
scores will be higher in persons with more than one episode of previous TB. 
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Figure 15: Longitudinal kinetics of signature scores in the TRuTH cohort.  (A&B) Longitudinal 
kinetics of the ACS 11-gene (A) and rPSVM.1 (B) signature scores in progressors and non-
progressors. Median and interquartile ranges are shown. (C&D) Longitudinal kinetics of the ACS 11-
gene (C) and rPSVM.1 (D) signature scores in individual progressors and non-progressors. Dots 
represent time points and connecting lines represent individuals. (E&F) Association between the ACS 
11-gene (E) and rPSVM.1 (F) signature scores and bacterial burden measured by days to culture 
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4.4.11: The ACS 11-gene and rPSVM.1 signatures could not differentiate Mtb 
infection from subclinical TB in ART naïve HIV-infected persons!
The TRuTH study was designed to detect recurrent TB disease using very intensive 
case finding methods, including performing induced sputum collection at every study 
visit. It is important to note that most study participants who were diagnosed with 
recurrent TB were asymptomatic at the time of TB diagnosis (n=25), suggesting that 
many of the progressors had subclinical TB, rather than active TB disease. Our 
previous work with the ACS 16-gene signature showed that subclinical TB could be 
detected in asymptomatic HIV-uninfected progressors up to a year before active TB 
diagnosis (Zak et al. 2016). These data support our interpretation that the ACS 11-
gene and rPSVM.1 signatures are detecting subclinical disease in the TRuTH cohort, 
within three months of recurrent TB disease diagnosis.  
 
To address this further, we aimed to determine if the signatures can differentiate 
between subclinical TB and Mtb-infected controls and active TB cases in HIV-
infected persons. We hypothesized that the signatures can differentiate subclinical 
TB from Mtb infection in HIV-infected persons.  
 
In order to address this, the ACS 11-gene and rPSVM.1 signatures were applied to a 
small cross-sectional cohort of HIV-infected individuals established by Esmail and 
Wilkinson, wherein subclinical TB was diagnosed by PET-CT in 10 asymptomatic 
individuals with Mtb infection who were identified to have active pulmonary lesions 
(Esmail et al., 2016, 2018). A group of 21 asymptomatic HIV-infected individuals with 
Mtb infection and no active pulmonary lesions were included as controls while 15 
patients with microbiologically-confirmed active TB were included as cases. As 
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observed in the pilot cohort in Chapter 3, the signatures could readily differentiate 
active TB from Mtb-infected controls (Figure 16, Table 12). The ACS 11-gene 
signature could also differentiate subclinical TB from active TB, whilst the rPSVM.1 
signature did not significantly differentiate between these two groups (Figure 16A & 
B, Table 12). Neither signature could differentiate subclinical TB from Mtb infection. It 
was very notable that signature scores were generally very high in all three groups, 
including the Mtb-infected controls, perhaps suggesting very high HIV loads. 
Regardless, median ACS 11-gene signature scores were higher in active TB cases 
than in subclinical TB and Mtb-infected controls (Figure 16C). The rPSVM.1 
signature scores from the active TB cohort were only higher than that of the Mtb-
infected control group (Figure 16D). 
 
 
Table 12: Performance of the signatures in distinguishing subclinical TB from Mtb infection 
and active TB disease in ART naïve HIV-infected persons from the Esmail cohort (Esmail et al., 
2016, 2018) 
 ACS 11-gene rPSVM.1 
ROC AUC (95% CI) p-value ROC AUC (95% CI) p-value 
Subclinical vs 
Mtb infection 
0.55 (0.33-0.76) 0.69 0.64 (0.42-0.86) 0.20 
Subclinical vs 
Active TB 
0.77 (0.56-0.98) 0.03 0.71 (0.49-0.92) 0.09 
Active TB vs 
Mtb infection 













Figure 16: Ability of the signatures to distinguish subclinical TB from Mtb infection and active 
TB disease in the Esmail cohort. (A and B) ROC curves depict classification potential of the ACS 
11-gene (A) and rPSVM.1 (B) signatures in distinguishing subclinical TB from Mtb infection and active 
TB disease in HIV-infected persons. (C and D) Distribution and differences in ACS 11- gene (C) and 
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HIV infection, as well as a history of previous TB disease, increases risk of 
progression to recurrent TB disease. According to current policy, Mtb-infected 
persons who are HIV-infected should receive INH prophylaxis (World Health 
Organization 2011). However, poor adherence and incomplete sterilisation of the 
bacilli undermines the effectiveness of the prophylaxis and in practice many HIV-
infected persons do not receive or adhere to IPT. Recurrent TB disease adds to the 
infectious pool of TB cases. It is therefore imperative to identify those most at risk of 
developing recurrent TB disease irrespective of HIV status. In this project, we aimed 
to identify HIV-infected persons already on ART who are at risk of progressing to 
recurrent TB disease.  
 
Both the ACS 11-gene and rPSVM.1 signatures could differentiate between 
recurrent TB cases and controls, but only within three months of diagnosis in this 
cohort. Intensive active case finding was performed in the TRuTH study by induced 
sputum at every visit and most participants (25 out of 43, 58%) were asymptomatic 
at time of diagnosis. This suggests that the signatures detected subclinical TB 
disease. This is consistent with our finding in the ACS study (Zak et al. 2016) where 
the ACS 16-gene signature significantly predicted incident TB at least a year before 
diagnosis suggesting detection of subclinical TB many months before symptoms 
manifested in HIV-uninfected persons. A number of the asymptomatic TRuTH 
participants with positive sputum tests who refused to start TB therapy developed 
clinical symptoms after diagnosis (Dr Kogie Naidoo, personal communication). This 
further strengthens the hypothesis that many participants had subclinical TB at 
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diagnosis and may explain the short prognostic window of the transcriptomic 
signatures relative to those reported in the ACS study. Epidemiological field studies 
have also shown that subclinical culture positive TB disease can be diagnosed when 
intensified case finding for active TB is carried out in household contacts or at HIV 
care clinics in high TB transmission settings (Corbett and MacPherson 2013). 
Furthermore, a review of surveys conducted in Asia observed that up to 40% to 60% 
of bacteriologically positive TB cases were asymptomatic (Onozaki et al. 2015). This 
study confirms that active TB case-finding in asymptomatic persons can result in 
detection of subclinical TB that might have remained undetected, and are likely 
sources of on-going transmissions in their communities. HIV infection is known to 
rapidly increase progression to active TB disease and IPT should be  given to HIV-
infected persons to decrease the risk of progression to active TB disease. However, 
several studies have observed an increase in TB incidence shortly after the end of 
IPT (J. E. Golub et al. 2015; Samandari et al. 2015) suggesting rapid progression to 
active TB immediately after stopping IPT in HIV-infected persons. This may be due 
to incomplete cure or immediate reinfection. In the TRuTH cohort, study participants 
eligible for IPT (n=212) were initiated on six months of daily IPT (Maharaj et al. 2017) 
and most developed recurrent TB within three months of stopping IPT as observed 
previously. It is tempting to speculate that cessation of IPT in these individuals could 
also have increased the risk of progression to recurrent TB disease in these 
individuals, which may have contributed to the short prognostic window of the 
signature for recurrent TB. 
 
To further determine if the transcriptomic signatures can distinguish between 
subclinical TB and active TB, and between subclinical TB and asymptomatic Mtb-
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infected persons, we applied the signatures to the the well-characterised Esmail 
cohort of subclinical TB (Esmail et al., 2016, 2018). The finding that the signatures 
could not differentiate subclinical TB from Mtb infection in HIV-infected persons is to 
some degree consistent with the finding that recurrent TB cases in the TRuTH study 
could not be differentiated from controls until three months before diagnosis. This is 
very likely also due to the small range in signature scores, which were also 
universally high in the different groups in the Esmail cohort. The elevated scores 
were likely due to high HIV loads (further discussions in Chapter 6).    
 
In the ACS cohort, signature scores in progressors increased closer to TB diagnosis 
indicating increasing IFN responses, with low and more stable signature scores in 
non-progressors (Thompson et al. 2017; Zak et al. 2016). However, this trend was 
not clear in progressors and controls in the TRuTH cohort. Kinetics of signature 
scores in individuals showed very high degrees of heterogeneity over time in both 
progressors and non-progressors. Samples analysed in this study were collected as 
early as 706 days and up to 2,295 days after diagnosis of the first TB episode. We 
propose that ongoing inflammation from this previous disease process could have 
been detected in our analyses. This is supported by the study by Malherbe et al, 
which shows that pulmonary inflammation, measured by PET-CT, was present in 
many HIV-uninfected persons up to one year after end of TB treatment, even in 
patients with microbiological cure (Malherbe et al. 2016). To delve deeper into this, 
we analysed if time since previous TB episode was associated with the magnitude of 
Type I IFN gene expression at the early study time points in the TRuTH cohort. No 
association between time since previous TB and signature scores was observed. 
Although not significant, signature scores appeared to be higher at time points closer 
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to previous TB disease, again suggesting an effect of the previous TB episode on 
signature scores. ART decreases viral replication and associated immune activation 
and inflammation in HIV-infected persons. Duration of time on ART is therefore 
another important consideration. However, we did not observe an association 
between signature scores and time on ART. This is consistent with another study 
that showed ART duration was also not associated with risk of TB in a South African 
community cohort with a recurrent TB burden of 75% (Gupta et al., 2012). Since 
ART decreases plasma viral load levels and undetectable plasma viral load levels 
are associated with a decrease in the risk of TB, the effect of plasma viral loads on 
the signature scores is also a critical consideration. This is discussed in detail in 
Chapter 6. 
 
A previous study in NHPs suggest that type I/II IFN expression signatures are 
associated with the amount of Mtb bacilli in the lungs (Gideon et al., 2016).  The 
degree of pulmonary inflammation as detected by FDG uptake on PET-CT scans 
was associated with type I/II IFN signatures in NHPs and humans (Gideon et al. 
2016; Thompson et al. 2017). We observed no association between signature scores 
and days to culture positivity measured by MGIT culture positivity as a proxy for 
bacterial burden in the lungs. A major limitation of this analysis was the small 
number of available samples with time to culture positivity data (n=18). 
 
The poor prognostic performance of the signatures in predicting recurrent TB at time 
points earlier than three months before diagnosis in this population could be due to 
the rapid progression to recurrent TB disease in HIV-infected persons. 
Epidemiological studies in high-risk populations have observed a higher recurrent TB 
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disease progression rate in HIV-infected persons in comparison to uninfected 
persons (Charalambous et al., 2008; Fitzgerald et al., 2000; Mallory et al., 2000). 
Recurrent TB disease occurred within two years after end of TB treatment in HIV-
infected persons from these cohorts. ART was not readily available when these 
studies were carried out, thus ART status of participants is unknown. In our cohort, 
recurrent TB disease occurred at a median of 3.5 years after end of previous TB 
episode. This longer time to recurrent TB diagnosis was very likely due to provision 
of ART while IPT was also given to a number of participants. 
 
We show here that the prognostic value of the ACS 11-gene and rPSVM.1 
signatures for predicting recurrent TB disease in HIV-infected persons was low. 
Prognostic ability of these signatures may be better in HIV-infected persons who 
have not previously had TB. We are currently testing the diagnostic and prognostic 
value of the ACS 11-gene signature in a study of 860 South African HIV-infected 
adults, namely the Correlates of Risk Targetted Intervention Study-High Risk 
(CORTIS-HR) study. Results from this study will address important questions about 
the prognostic ability of the signature in asymptomatic HIV-infected persons and the 
effect of ART and viral load in a much larger sample size. 
 
4.6: Contributions 
Sample selection and matching were done by Mrs N. Yendeh-Zuma and Dr S.M. 
Kimbung. R scripts to calculate signature scores were written by Drs S.M Kimbung 
and E.G Thompson. Ms F. Darboe designed,conducted the experiments, performed 
data analyses, and wrote this chapter under the supervision of Dr A. Penn-Nicholson 
and A. Prof T.J. Scriba. 
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Chapter 5: Treatment response monitoring in HIV-infected persons on ART: 
results from the IMPRESS cohort 
 
The aim of this chapter is to determine if the transcriptomic signatures can 




The current standard chemotherapy for pulmonary TB entails at least six months of 
drugs heavily reliant on isoniazid and rifampicin. For the majority of TB patients, 
treatment results in disease cure, however some do not achieve sterilisation or 
clearance of Mtb and are at risk of relapse (Wallis et al. 2000). Poor treatment 
adherence is one of the factors contributing to insufficient treatment, leading to a 
high risk of treatment failure and relapse. Shortening the six-month regimen is one of 
the goals of the global strategy to combat the TB pandemic and is an active area of 
research. Mathematical modelling predicts that shortening of treatment regimens 
would increase adherence and successful treatment rates (Abu-Raddad et al. 2009). 
Several studies have evaluated new treatment regimens aimed at shortening TB 
treatment, for example using fluoroquinolones (Gillespie et al. 2014; Burman et al. 
2006; Rustomjee et al. 2008; Merle et al. 2014; Jindani et al. 2014). Sterilising 
activity of the new TB treatment regimens is typically measured by their ability to 
prevent treatment failure and relapse after treatment completion (Burman et al. 
2006). However, large clinical trials with long follow-up times are needed to study 
relapse and treatment failure rates. Human studies to test treatment regimen 
shortening with an endpoint to measure relapse rates require at least two years 
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follow-up after the end of chemotherapy of at least 1,000 individuals (Mitchison 1993; 
Burman et al. 2006). 
 
Currently, sputum conversion from positive to negative (either by sputum smear 
microscopy or culture) is used as the marker of cure and potential relapse. The rate 
of relapse is strongly correlated with sputum conversion after two months of therapy 
(Mitchison, 1993). Despite high proportions of culture conversion in the trials 
evaluating new shortened treatment regimens, relapse rates were higher than the 
standard of care regimen,  two months of HRZE and four months of HR (Gillespie et 
al. 2014; Burman et al. 2006; Rustomjee et al. 2008). A systematic review of 28 
published studies observed a low sensitivity (40%) and modest specificity (85%) of 
sputum culture conversion in predicting treatment failure and relapse (Horne et al. 
2010). These studies suggest that culture conversion at two months has a poor 
positive predictive value (18%) in predicting relapse. Recently, the Xpert MTB/RIF 
assay has been tested as a treatment response marker in South African and 
Tanzanian adults with smear positive TB (Friedrich et al. 2013). Mtb  DNA was 
associated with both sputum smear positivity (or grade) and the time to culture 
positivity. Despite the high sensitivity of Xpert, it had a low specificity (48.6%), 
possibly due to detection of dead bacillli, impeding its’ usage as a biomarker for 
treatment response monitoring. Thus, better markers are therefore needed to 
determine treatment response.  
 
As mentioned in previous chapters, uptake of 18F-labelled fluorodeoxyglucose ([18F] 
FDG) viewed on PET-CT scans is indicative of glucose metabolism. [18F] FDG 
uptake is thus a useful marker of inflammation and has been successfully used to 
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track pulmonary inflammation during TB treatment (Malherbe et al. 2016). Observed 
inflammation patterns in lungs were associated with clinical outcomes in this study, 
suggesting PET-CT scans can be used to determine treatment outcomes in HIV-
uninfected persons. However, measurement of [18F] FDG uptake by PET-CT 
requires expensive CT and PET imaging scanners, which are not readily available in 
resource-poor settings with the highest disease burden. In addition, PET-CTs are not 
feasible due to large number of patients would require scans requiring trained 
radiologists, who are scarce in resource-poor settings, to interprete scans.  
 
As discussed in previous chapters, blood transcriptomic gene signatures based on 
IFN response genes are able to distinguish TB disease Mtb infection and other 
diseases. These signatures could also be useful to monitor inflammatory resolution 
during treatment. Several studies have shown that gene expression of these 
signatures decrease upon TB treatment as early as two weeks post-treatment start 
(Berry et al., 2010; Bloom et al., 2013; Cliff et al., 2013; Sweeney et al., 2016), 
suggesting that the signatures may be used to monitor treatment response. The 
recently published ACS-16 gene signature was applied to the Catalysis Foundation 
for Heath Treatment Response Cohort (CTRC) described by Malherbe and 
colleagues (Malherbe et al. 2016) to determine if the signature can predict treatment 
outcome (Thompson et al. 2017). One hundred and thirty-one HIV-uninfected adults 
with newly diagnosed pulmonary TB were enrolled in the CTRC study and followed-
up during TB treatment. Ninety-nine of these participants completed study follow-up 
and TB treatment was stratified based on sputum culture results at the end of six 
months of treatment. Eighty-four were defined as cured, eight were treatment failures 
(sputum culture positive at the end of the treatment) and the remaining seven with 
! 133!
unevaluable culture results were not included in the analyses. Eighteen of the 84 
cured participants attained mycobacterial conversion within four weeks of start of 
treatment and were referred to as rapid converters. Treatment failure and cure could 
be differentiated as early as four weeks after commencement of TB therapy with the 
ACS-16 gene signature (AUC = 0.72, p = 0.02). At the end of 24 weeks of treatment 
the signature could strongly discriminate between treatment cures and failures 
(AUC=0.92, p=0.00005), confirming that the ACS 16-gene signature can predict 
treatment response in HIV-uninfected active TB cases undergoing therapy. To the 
best of our knowledge, no study has investigated blood transcriptomic signatures as 
treatment response monitoring tools in HIV-infected persons. Furthermore, it is not 
clear whether blood transcriptomic signatures can differentiate between HIV-infected 
persons who have achieved microbiological clearance after undergoing TB therapy 
for two months and those who have not. A blood-based biomarker that can make this 
differentiation at two months, when the intensive phase of TB treatment is typically 
completed, would be useful to guide the length of the continuation phase. 
 
Diagnosis of active TB disease in HIV-infected persons is dependent on sputum 
smears or cultures, similar to HIV-uninfected individuals. However, sputum collection 
from unwell and immunocompromised individuals is often difficult and sometimes not 
possible. Furthermore, HIV-infected persons often have paucibacillary TB disease 
and as a result may have smear and culture negative sputum test results. Because 
TB treatment response is currently monitored by sputum smear or culture 
conversion, HIV co-infected persons could be incorrectly classifies as “cured” could 
be a source of ongoing Mtb transmission in their communities. Blood-based 
transcriptomic signatures thus have the potential to be more accurate and more 
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universal TB treatment monitoring tools in HIV-infected persons and could allow 
customisation of the length of TB treatment.  
 
The Improving Retreatment Success (IMPRESS) study was an open label, 
randomized controlled clinical trial in HIV-infected TB retreatment patients conducted 
by CAPRISA at the CAPRISA eThekwini clinical research site in Durban, South 
Africa. The aim of the study was to determine if a moxifloxacin-containing regimen, 
wherein moxifloxacin was substituted for ethambutol, was superior to the standard of 
care in improving treatment outcomes in patients with recurrent TB. Study 
participants were randomized to receive either the moxifloxacin-containing regimen 
or RIFAFOUR (HRZE), at TB diagnosis. The moxifloxacin-containing regimen 
consisted of a two-month intensive phase of daily isoniazid, rifampicin, pyrazinamide 
and moxifloxacin (2HRZM) and four months of the continuation phase of isoniazid, 
rifampicin and moxifloxacin (4HRM). Participants randomized into the control arm 
(standard of care) had a two-month intensive phase of isoniazid, rifampicin, 
pyrazinamide and ethambuthol (2HRZE) followed by a four-month continuation 
phase of daily isoniazid and rifampicin (4HR). All study participants also received a 
daily dose of the vitamin B6 supplement, pyridoxine, regardless of randomization 
arm.The two arms will henceforth be referred to as HRZM and HRZE arms, 
respectively. Participants were followed up for a total of 24 months, including six 
months of treatment and 18-months post treatment. HIV testing was mandatory to 
confirm HIV status. HIV-infected participants already on ART were only allowed into 
the study if their treatment regimen was not contraindicated with the study drugs. 
Participants were enrolled irrespective of CD4 T cell counts and whether they were 
on ART or not. Those not yet initiated on ART were provided ART. The study 
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protocol was amended after the study started enrolment to allow PAXgene sample 
collection so that the TB risk signatures could be measured. As a result, whole blood 
RNA was not available for all enrolled participants.   
 
5.2: Aims and hypotheses 
5.2.1: Aims 
!
1. Determine if the ACS 11-gene and rPSVM.1 signatures could differentiate 
HIV-infected early sputum culture converters from late sputum culture 
converters at the start of therapy, two months into therapy, at the end of TB 
treatment, and six months after treatment in TB retreatment patients. 
2. Determine if signature scores resolve in HIV-infected TB retreatment patients 
after successful TB treatment. 
3. Determine if there is an association between signature scores and time to 
sputum culture conversion at baseline, two months after the start of therapy, 




1. The ACS 11-gene and rPSVM.1 signatures will differentiate early from late 
converters at the start of TB treatment, two months after treatment start, and at 
the end of TB treatment. 
2. Signature scores will significantly decrease in HIV-infected TB retreatment 
patients from TB diagnosis to the end of TB treatment. 
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3. Sputum culture conversion at TB diagnosis will be associated with signature 
scores from baseline, two months, end of treatment and post treatment samples.  
5.3: Methods  
5.3.1: Study design 
Participant enrolment into IMPRESS 
Participants who satisfied the following criteria were enrolled into the study  
Inclusion criteria: 
• At least 18 years of age  
• History of previous TB treatment  
• Smear positive and rifampicin susceptible TB determined by Xpert MTB-RIF 
• Karnofsky score (measurement of functional impairment) of at least 70 
• A negative pregnancy test  
•  Female participants were required to agree to use one form of contraception  
Exclusion criteria: 
• Patients on a Nevirapine containing ART regimen at screening  
• Pregnant or lactating women 
• Received an antibiotic active against TB in the 14 days prior to screening  
• Mtb resistant to any of the study drugs  
• Allergies or intolerance to study drugs  
 
Sputum samples for cultures were collected every two weeks in the first two months 
of treatment and monthly thereafter until completion of TB chemotherapy. PAXgene 
samples collected at baseline, two, six, eight and fourteen months after start of 
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therapy were available for this project. End of treatment time points were calculated 
according to when TB therapy was stopped. In addition to these time points, 
PAXgene samples were collected at further follow-up visits. These additional 
samples were not investigated in this chapter. Signature performance was evaluated 
in HIV-infected participants with a baseline sample and at least two other visit time 
points mentioned above. 
 
Patient clinical outcomes in our analyses were defined based on time from study 
baseline (i.e. start of TB treatment) for sputum cultures to convert to negative. Time 
to culture conversion was calculated by subtracting the date of the first positive 
culture at diagnosis from the date of the first persistent negative culture result. 
Participants were stratified into “early converters” where sputum culture conversion 
occurred within two months (56 days) and “late converters” where culture converted 
after two months of treatment start. This data was unavailable until after all 
experiments and analyses were completed to ensure that wet-lab experiments and 
analyses were done in a blinded manner. Some participants stopped TB treatment at 
six months, whilst others completed treatment later based on clinical reasons. As 
such, the time at which they stopped TB treatment was used as the end of treatment 
time point.  
 
5.3.2: RNA extraction  
RNA from the PAXgene samples was extracted using the Tecan Freedom EVO 150 
automated system as described in Chapter 2. RNA was not quantified after 
extraction because this extraction protocol is highly optimised and a very consistent 
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RNA yield is typically obtained, based on extensive experience from the Correlate of 
Risk Targeted Intervention Study (CORTIS) trial.  
5.3.3: Gene expression measurement 
cDNA was synthesized by reverse transcription using Taqman primer-probes as 
described in section 2.3.1. Gene expression levels of the signature transcripts were 
measured by Biomark HD multiplex microfluidic qRT-PCR as described in section 
2.3.2.  
 
5.3.4: Data analysis 
Quality control of the data was performed as described in sections 2.4 and 2.5. Blind 
predictions were applied to the entire cohort before calculation of time to culture 
conversions. Culture conversion dates were made available by the clinical team only 
at the time of unblinding, once all signature scores had been generated for all 
samples and other blinded analyses had been completed. Differences in basic 
demographics were calculated using Mann-Whitney U test for continuous data and 
Fishers’ exact test for categorical data in GraphPad Prism (v7.0a). ROC analyses 
was done in Prism, AUCs were compared using pROC and verification packages in 
R. Non-parametric tests, Mann-Whitney U and Kruskal-Wallis tests were used to 
analyse differences between two and three groups, respectively. 
 
5.4: Results  
5.4.1: Participant characteristics and sample stratification 
Newly diagnosed HIV-infected and uninfected persons with a history of previous TB 
disease were screened and enrolled into the IMPRESS study (n=197), the majority 
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of whom were HIV-infected (n=139, 71%) (Figure 17). Of the 197 participants 
enrolled, only 154 had PAXgene samples collected at any time point and 115 of 
these participants were HIV co-infected. Due to the few HIV-uninfected participants 
with PAXgene samples available, these were excluded from analysis and we only 
focused on treatment response in HIV-infected patients. Furthermore, only 
participants with samples collected at three time points or more, including study 
baseline, were included in analysis in order that TB treatment response could be 
monitored. Of the 70 participants that were selected, seven were excluded from 
analyses. The reasons for these exclusions were prolonged TB treatment (n=2), 
treatment interruption (n=1), treatment failure (n=1), and no culture results at 
baseline/diagnosis (n=3) (Figure 17). Hence, 63 participants were included in the 
analysis, 33 of these were from the treatment arm (HRZM) and 30 were from the 
control arm (HRZE). Forty-four participants culture converted (became culture 
negative) within two months of diagnosis and 19 participants culture converted after 
56 days (Figure 17).  
 
Most of the participants in this substudy were male (n=44) (Table 13). When 
comparing early and late converters the proportion of males was not different 
between the two groups. In addition, race and age were also not different between 
the groups (Table 13).  Median BMI of 20.0 Kg/m2 was observed in the substudy; 
late converters had lower median BMI than early converters (p=0.05). Most of the 
early converters were from the HRZM arm, whilst late converters were mainly in the 
HRZE arm. No differences were observed in median detectable plasma viral load nor 
in the proportion of persons with undetectable plasma viral loads early and late 
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converters. Median CD4 T cell counts were lower in late converters in comparison to 






Figure 17: The IMPRESS cohort for the prediction of recurrent TB disease in people living with 
HIV. HIV-infected participants starting retreatment for TB disease were included in our biomarker 
study. Participants were allocated to early converters (culture conversion within two months) and late 


















Participants with samples (n=115)
Excluded from experiments
(not enough sample time points)
HIV-infected (n=45)
Excluded from analysis
Prolonged TB treatment (n=2)
Treatment interruption (n=1)
Treatment failure (n=1)




























Sex, n (%) Male 44 (69.8) 28 (63.6) 16 (84.2) 0.1 
Median age, 
years (range) 
 37 (19-51) 37 (21-51) 35 (19-51) 0.3 
Race, n (%) Black African 62 (98.4) 43 (97.7) 19 (100) >0.9 
Cape Mixed 
Ancestry 










Study arm, n 
(%) 
HRZM 33 (52.4) 28 (63.6) 5 (26.3) 0.01 




















4.7 (3.3-6.1) 4.3 (2.8-5.6) 0.6 
* Only 62 participants have data available, early converters (n=44), late converters (n=18). 
** Only 61 participants had CD4 T cell count information, early converters (n=43), late converters 
(n=18). 
*** Only 60 participants had plasma viral load data, early converters (n=42), late converters (n=18). 




















5.4.2: QC of qRT-PCR data 
Samples were run in duplicate across a total of seven Fluidigm 96.96 GE chips. Ct 
values of the data from duplicate IPC reactions were analysed between the different 
chip runs using Spearman correlation test to determine consistency between the 
runs. The correlation coefficients between the between the chip runs exceeded 0.90 
(Figure 18A). Distributions of normalised Ct (delta Ct) values of genes of interest 
were compared between the chip runs using histograms and were found not to be 
markedly different between the chip runs (Figure 18B). Finally, signature scores of 
the IPC were very consistent between the chips for both the ACS 11-gene (range: 
92% to 96%) and rPSVM.1 (range: 86% to 93%) signatures (Figure 18C). These 
results confirm that the qRT-PCR data generated from different GE chips is 
consistent, inter-assay variability is low between the different chips and no obvious 
batch effects were observed.  
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Figure 18: Variability of duplicate internal positive controls (IPC) in the seven qRT-PCR chips. 
(A) Correlation of duplicate Ct values of all 96 assays of the IPC in the seven chips. Each square 
represents the Spearman correlation coefficient computed between different chips. Numbers denote 
the chip IDs and the letters denote the replicates. (B) Distribution plots depicting the average delta Ct 
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b- IPC replicate 2































































5.4.3: Signature scores decrease over treatment duration but do not resolve at 
the end of TB treatment 
We set out to determine if retreatment of HIV-infected TB patients leads to resolution 
of inflammation, which we proposed would be reflected by decreases in ACS 11-
gene and rPSVM.1 signature scores. Median signature scores decreased gradually 
from TB diagnosis to the end of treatment, but a considerable proportion of patients 
still had very high signature scores at the end of treatment, indicating ongoing type 
I/II IFN inflammation (Figure 19A & B). To determine if this inflammation would 
resolve further after the end of treatment, we also measured ACS 11-gene and 
rPSVM.1 signature scores six to eight months after treatment cessation. Surprisingly, 
ACS 11-gene signature scores six to eight months after TB treatment completion 
were not significantly different to scores observed at the end of TB treatment (Figure 
19A). The rPSVM.1 scores increased significantly after TB therapy was stopped 
(Figure 19B). ROC analyses showed that both signatures could differentiate between 
the pre-treatment time points (i.e. at TB diagnosis) and the month-two treatment time 
point, the end of treatment time point and samples collected six to eight months after 
TB treatment (Figure 19C & D).  
 
5.4.4: Signature scores were not different between early and late converters 
during TB treatment.  
Next we sought to determine if patients could be classified into early and late 
converters based on their culture conversion status at two months, typically the end 
of the intensive phase of TB therapy. No striking differences in the kinetics of 
signature scores were observed between early and late converters (Figure 20A & B). 
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Median signature scores were not different at baseline, two months, and at the end 
of treatment in early and late converters for both the ACS 11-gene and rPSVM.1 
signatures (statistical analyses are shown in Figure 22A & B). A very high degree of 
inter-individual heterogeneity in signature scores was observed in early and late 
converters (Figure 20C & D). To further unpack the kinetic changes longitudinal 
signature scores of participants with at least three time points were classified into; 1) 
no change (<10% difference between two treatment time points), 2) decrease (>10% 
change), 3) increase (>10% difference between consecutive time points), or 4) 
mixed. The 10% cut-off was derived from analysis of variability observed in signature 
scores of the internal positive control sample run across different chips, which was 
below 10%.  
 
Forty-three participants in the early conversion group had at least two time points 
with ACS 11-gene signature scores available. Amongst these, signature scores 
decreased in 24 (56%), increased in one, did not change in five, and were mixed in 
13 (30%) participants. Amongst 17 late converters with at least two available ACS 
11-gene signature scores, scores decreased in 10 (59%), did not change in one, and 
were mixed in six participants. A similar pattern was observed for the rPSVM.1 
signature. All 44 early converters had at least two time points with available 
signature scores for rPSVM.1. Signature scores decreased in 22 (50%), increased in 
one, did not change in two, and were mixed in 19 (43%) participants. Only 18 late 
converters had rPSVM.1 scores for at least two time points and the score decreased 
in seven (39%), increased in two, did not change in one participant, and were mixed 






Figure 19: ACS 11-gene and rPSVM.1 signature score kinetics in the IMPRESS cohort over 
treatment duration. A and B) Signature scores decrease during TB therapy in the ACS 11-gene (A) 
and rPSVM.1 (B) signatures. C and D) ROC curves depict differentiation of baseline samples 
(collected before start of TB therapy) and samples collected during TB treatment (Month two), at the 
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AUC (95% CI)      p-value
0.63 (0.52-0.74)   0.01
0.80 (0.71-0.88)   4.13 X 10-08
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0.89 (0.83-0.94)   1.10 X 10-13





Figure 20: Kinetics of ACS 11-gene and rPSVM.1 signature scores in early and late TB 
treatment converters. A and B) Longitudinal kinetics of signature scores during and post TB 
treatment in early and late converters in the ACS 11-gene (A) and rPSVM.1 (B) signatures. Medians 
and interquartile ranges (IQR) are shown. C and D) Longitudinal kinetics of individual signature 
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5.4.5: The ACS 11-gene signature can monitor treatment response in HIV-
infected persons 
At TB diagnosis (TB treatment initiation), neither the ACS 11-gene nor rPSVM.1 
signature could predict early sputum conversion (Figure 21A & B). However, at two 
months the ACS 11-gene signature could differentiate early from late converters, 
AUC, 0.73 (95% CI 0.58 to 0.89), p=0.006. Ability of the signature to differentiate 
these groups was lost by the end of TB treatment and six to eight months after end 
of treatment (Figure 21A). The rPSVM.1 signature on the other hand could not 
classify late from early converters at any of the time points measured, whether 



















Figure 21: Differentiation between early and late converters by signatures in the IMPRESS 
cohort. Each ROC curve depicts signature differentiation between early and later converters. Each 
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5.4.6: Early sputum culture conversion is not associated with signature scores 
and time to culture positivity at diagnosis  
ACS 11-gene signature scores were only significantly different between early and 
late conversion at two months after treatment start (Figure 22A), while rPSVM.1 
signature scores were not different at any of the time points (Figure 22B). In HIV-
uninfected TB patients, Xpert MTB-RIF Ct values measured as early as seven days 
post diagnosis have been shown to be predictive of time to culture conversion and 
treatment failure (Shenai et al. 2016). This suggests that sputum bacterial load 
measured early during treatment by Xpert MTB-RIF may be an important variable in 
understanding the behaviour of transcriptomic signatures. Unfortunately, Xpert MTB-
RIF Ct values were not recorded in the IMPRESS study. However, in a paediatric 
study Xpert MTB-RIF detected 75% of mycobacterial growth indicator tube (MGIT) 
culture positive cases in HIV-infected and uninfected children with a high specificity 
(Nicol et al. 2011), suggesting that MGIT time to culture positivity data may reveal 
similar clues about sputum bacterial load and host inflammation. We therefore 
analysed time to culture positivity of MGIT cultures at IMPRESS baseline as a 
measure of bacterial load. However, time to culture positivity on MGIT cultures was 
not different between early and late converters (Figure 22C). We also sought to 
determine whether time to culture positivity would be associated with signature 
scores at TB diagnosis and if the combination of these two variables may be used to 
predict early and late converters.  
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However, signature scores were not associated with mycobacterial load in sputum 
and combining these two variables did not improve the prediction of early and late 









Figure 22: Association between signature scores and culture conversion in early and late 
treatment converters. A and B) ACS 11-gene (A) and rPSVM.1 (B) signature scores in early and late 
converters. C) Time to MGIT culture positivity at TB diagnosis in early and late converters. D) & E) 
Association between baseline ACS 11-gene (D) and rPSVM.1 (E) signature scores and time to culture 
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Poor adherence to TB therapy is a risk factor for treatment failure and relapse. 
Shortening of treatment regimens could increase adherence and consequently 
successful treatment rates (Abu-Raddad et al. 2009). High treatment success rates 
would result in a decrease in relapse cases, which are mostly due to treatment 
failure. Thus, predicting treatment response could play an important role in 
personalising therapy and testing the efficacy of drug regimens for active TB 
(Burman et al. 2006). Culture conversion after two months of intensive TB treatment 
is typically used as a proxy for treatment cure and microbiological sterilisation (Wallis 
et al. 2009). Furthermore, culture conversion after two months of therapy can predict 
relapse after completion of TB therapy (Mitchison 1993). Despite this, high relapse 
rates have been observed in clinical trials in participants who achieved mycobacterial 
clearance in their sputa after two months of therapy (Gillespie et al. 2014; Rustomjee 
et al. 2008; Merle et al. 2014). Data from these trials suggest that culture conversion 
after two months of TB treatment is insufficient for predicting relapse and monitoring 
treatment response, hence better markers are needed. Gene expression signatures 
of active TB disease could be useful markers in monitoring treatment response.  
 
Gene expression signatures of active TB have been used to monitor treatment 
response in HIV-uninfected persons (Bloom et al. 2013; Sweeney et al. 2016; Berry 
et al. 2010), and the ACS 16-gene signature is no exception (Thompson et al. 2017). 
We show here that gene expression of both the ACS 11-gene and rPSVM.1 
signatures can monitor treatment response in HIV-infected TB retreatment patients. 
Expression of the signatures in the participants was highly heterogeneous in the 
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IMPRESS participants, with some participants having persistently high signature 
scores at the end of treatment, as was observed in HIV-uninfected persons 
(Sweeney et al. 2016; Thompson et al. 2017). This suggests underlying inflammation 
and high type I/II IFN responses in these participants despite clinical and 
microbiological cure. Indeed, a heterogeneous pattern of pulmonary inflammation, 
measured by FDG-uptake, was also observed in the CTRC study, with some 
participants developing new lesions whilst a mixed response was observed in some 
participants (Malherbe et al. 2016). FDG uptake improved in 60% and resolved in 
14% of the CTRC participants. Signature scores decreased in approximately 56% of 
the IMPRESS cohort at the end of treatment. However, because we did not have a 
matched control group to define signature scores in HIV-infected persons without TB 
with a history of previous TB disease, we could not define what a resolved response 
would be. This precluded distinguishing between resolved and improved response in 
this cohort. Underlying pulmonary inflammation was observed up to a year after 
successful cure in the CTRC study, suggestive of residual mycobacterial disease or 
bacterial activity despite control of disease after successful cure. This was also 
suggested by the detection of mycobacterial RNA in bronchoalveolar lavage samples 
(Malherbe et al. 2016). Consistent with this observation in HIV-uninfected patients, 
we observed underlying type I/II IFN response up to eight months after end of TB 
treatment in the IMPRESS cohort. The rPSVM.1 signature suggested that type I/II 
IFN activity increased up to eight months after successful cure, however the reason 
for this in not clear to us. Residual bacterial products may continue to trigger 
inflammation after recent TB disease, while circulating HIV loads may also trigger 
gene expression patterns in the periphery (the effect of HIV plasma viral loads on 
gene expression is discussed in the next chapter). Finally, this study was performed 
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in a high Mtb-transmission setting and reinfection may also contribute to elevation of 
signature scores. We conclude that our TB risk signatures can monitor TB 
retreatment response in HIV-infected persons, but with a reduced accuracy to that 
observed in HIV-uninfected persons. 
 
When we applied the ACS 11-gene signature to identify rapid converters at baseline 
the signature could not correctly identify rapid converters at this time point. Our 
cohort consisted of HIV co-infected persons, most of who were not on ART (n=34) 
and had unsuppressed pVL (n=36) (see Chapter 6) at diagnosis. The ACS 16-gene 
signature could distinguish rapid from late converters at baseline in the CTRC and 
most importantly, treatment failures were identified at 24 weeks after the start of 
therapy (Thompson et al. 2017). This suggests that the ACS 16-gene signature 
could be a useful tool for customising duration of therapy, especially in individuals 
with treatment failure. The ACS 11-gene and rPSVM.1 signatures measure 
expression of ISGs. Expression of the transcripts in our signatures were higher 
around the TB diagnosis time points. However, both HIV infection and active TB 
disease induce expression of ISGs. Thus, the effect of active TB and HIV co-
infection on type I/II IFN signature gene expression resulted in the inaccurate 
differentiation between early and late converters at TB diagnosis. After two months 
of treatment, signature expression remained elevated in some persons likely due to 
the presence of actively replicating bacteria. Thus late converters could be 
distinguished from early converters by the ACS 11-gene signature at month two. The 
gene signatures does not improve upon the diagnostic performance of culture 
conversion, but can be performed in individuals who cannot produce sputum and can 
be done in a much shorter time than culture, offereing some advantages.  
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Xpert MTB-RIF Ct values have been used as a measure of bacterial load and have 
been shown to predict treatment response and treatment failure in HIV-uninfected 
persons at diagnosis (Shenai et al. 2016). Time to culture positivity at diagnosis has 
been associated with sputum culture conversion at two months of TB treatment 
(Hesseling et al. 2010). In addition, sputum smear grading at diagnosis in the same 
study could predict treatment response. Thus, mycobacterial loads measured at 
baseline can be used to monitor treatment response in HIV-uninfected persons. In 
the IMPRESS study, culture conversion at month two was not associated with time 
to positivity at diagnosis. This raises the question whether mycobacterial load may 
be poorly predictive of treatment response in HIV-infected persons. In addition to HIV 
infection, the methodologies used to determine the time to positivity is different 
between the two studies. Hesseling and colleagues used the BACTEC 12B liquid 
radiometric culture method to determine time to positivity whilst we used the more 
sensitive MGIT automated system, thus we might be identifying participants as early 
converters who could have been identified as late converters using the radiometric 
system. Time to culture positivity used in conjunction with a biomarker may increase 
its’ accuracy in monitoring treatment response (Hesseling et al. 2010). The ACS 11-
gene and rPSVM.1 signature scores were not associated with time to culture 
positivity in our cohort, contrary to what was observed in the CTRC study (Thompson 
et al. 2017). In addition, Thompson and colleagues observed an increase treatment 
response monitoring when mycobacterial load was combined with signature score 
into a new model. In our cohort, assessing signature scores and time to culture 
positivity at baseline did not improve clustering accuracy at baseline, month two, or 
at the end of treatment in monitoring treatment response. Based on this result, we 
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believed that it was not warranted to develop a model that combined time to culture 
positivity with signature scores into a classifier. We observed that HIV infection 
increased ACS 11-gene signature scores (Chapter 3) leading to a decreased 
specificity and diagnostic accuracy for active TB disease. We propose that high 
signature scores in all participants in the IMPRESS cohort resulting from HIV load is 
the most likely explanation for the poor classification of early and late converters 
(more discussion in Chapter 6).  
 
The small sample size, particularly in the late converters study arm, was a limitation 
of our study. In addition, we could not determine the utility of signature scores in 
identifying treatment failures because no participants were identified with clinically 
defined treatment failure.  
 
To conclude, the ACS 11-gene and rPSVM.1 signatures could not predict early 
conversion at TB diagnosis but showed promise as treatment monitoring tools in 
HIV-infected TB retreatment patients. 
5.6: Contributions 
Ms F. Darboe designed, conducted the experiments, performed the analyses, and 








Chapter 6: The effect of HIV viraemia on transcriptomic signature performance 
in predicting TB recurrence and monitoring treatment response.  
 
The aim of this chapter is to determine the effect of HIV plasma viral load (pVL) on 
transcriptomic signature scores and performance of the signatures.  
 
6.1: Introduction 
HIV pVL is a key factor in the determination of HIV-related morbidity and mortality 
(Suthar et al. 2015). The pVL remains relatively stable during untreated 
asymptomatic chronic HIV infection (Fraser et al. 2014). Immune activation and 
inflammation are directly associated with pVL levels (Deeks et al., 2013; Joshi et al., 
2016). HIV replication is thought to be responsible for increased immune activation 
and inflammation (Deeks, Tracy, and Douek 2013). Viraemic individuals express 
higher levels of soluble inflammation and activation markers, such as soluble CD14 
and Ki-67, than aviraemic individuals (pVL < 40 copies/mL, or lower than the 
detectable limit) and HIV-uninfected controls (Somsouk et al. 2015).  
 
ART suppresses the replication of HIV and reduces pVL resulting in an 
asymptomatic aviraemic state in most HIV-infected persons. Immune activation and 
persistent inflammation due to HIV infection remain elevated in HIV-infected persons 
who have suppressed viral replication due to ART, when compared to uninfected 
persons (Klatt et al. 2013). Despite ART, up to a quarter of HIV-infected persons 
remain immunosuppressed in the asymptomatic phase, as CD4 cells are not 
restored to their full capacities (Corbeau and Reynes 2011). The relative risk of TB 
disease in HIV-infected individuals with pVL >1000 copies /mL is 1.74 (95% CI: 1.39-
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2.17) higher than the risk in persons with pVL<1000 copies/mL (Gupta et al., 2012). 
HIV-infected persons with suppressed pVL of <50 copies per mL had higher 
activation of the immune, endothelial and coagulation systems in comparison to HIV-
uninfected persons (Psomas et al. 2016). Despite a partially restored immune 
system, an inflammatory milieu is still observed in HIV-infected persons on ART.  
 
In addition to contributing to inflammation and gut leakage, activated pDCs also 
produce Type I IFNs, such as IFN-α and β, which interfere with stages of viral 
replication thereby mediating antiviral immunity (F. McNab et al. 2015). The pro-
inflammatory antiviral activities of type I IFN may paradoxically hasten HIV disease 
progression (Stifter and Feng 2015). Progression of HIV disease has been 
associated with an increase in IFNα production from pDCs (Lehmann et al. 2008). 
Early studies of Type I IFN in untreated acute HIV infection observed a widespread 
induction of ISGs in peripheral blood cells regardless of viral load (Bosinger and Utay 
2015).  
 
Type I IFN signalling is associated with TB disease severity as measured by 
bacterial load in mice ( Manca et al., 2001; Manca et al., 2005; Stanley et al., 2007). 
Expression of ISGs by blood immune cells is highly elevated at TB diagnosis relative 
to controls without disease (Berry et al., 2010; Bloom et al., 2013; Cliff et al., 2013; 
Maertzdorf et al., 2011, 2015). Elevated ISG expression was also the basis for 
detecting Mtb-infected individuals who progresed to TB disease which was used to 
develop the 16-gene transcriptomic signature of risk of TB (Zak et al. 2016). These 
studies confirm the observation in mice that the presence of type I IFN is indicative of 
TB disease and is a useful measure of disease severity. In addition, type I IFN 
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production is correlated with mycobacterial virulence and host susceptibility (Stifter 
and Feng 2015).  
 
Collectively these results suggest that high expression of ISGs due to HIV infection 
can lead to a decrease in accuracy of transcriptomic signatures of TB due to an 
increase in false positives. Most published transcriptomic signatures of TB disease 
were developed in HIV-uninfected cohorts and some have been applied to HIV-
infected cohorts to determine diagnostic signature performance. Few studies have 
developed RNA transcriptomic signatures to specifically distinguish TB disease from 
other infectious diseases in HIV-infected persons (Dawany et al., 2014; Kaforou et 
al., 2013; Sweeney et al., 2016). Kaforou and colleagues developed a 27-transcript 
signature that could distinguish TB disease from Mtb infection in HIV-infected (AUC 
97, 95% CI 95-100) and uninfected cohorts, (AUC, 100 (95% CI, 100-100)) (Kaforou 
et al. 2013). Another study of HIV-infected persons developed a 251-transcript 
signature, which could differentiate HIV-TB co-infection from HIV mono-infection with 
an accuracy of 81.4% (Dawany et al. 2014). Sweeney and colleagues observed an 
8% reduction in performance of a 3-gene signature in discriminating of TB from Mtb 
infection in HIV-infected persons, relative to HIV-uninfected persons (Sweeney et al., 
2016). When the ACS 16-gene signature, re-parameterised to microarray data, was 
applied to the published datasets from Kaforou and colleagues, a similar 10% 
reduction in signature performance in HIV-infected relative to HIV-uninfected cohorts 
was also observed (Zak et al. 2016). These findings suggest that IFN response 
signatures yield lower accuracy in HIV-infected cohorts, likely due to the effects of 
viral replication. When the diagnostic performance of the ACS 11-gene signature 
was assessed (described in Chapter 3, Figure 7), a 10% decrease in diagnostic 
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performance was observed in HIV-infected persons compared with uninfected 
persons. The rPSVM.1 signature was developed with the explicit aim of increasing 
the accuracy of the ACS 11-gene signature for HIV-infected cohorts. However, we 
did not observe a significantly improved performance in the TRuTH and IMPRESS 
cohorts (Chapters 4 and 5). To address the question of HIV load in the context of 
these IFN response signatures, we set out to determine the effect of HIV viraemia 
(plasma viral loads) on the performance of the signatures in detecting recurrent TB 
and in monitoring treatment response.  
Aim 
To determine the effect of HIV pVL on the performance of the signatures in 
predicting recurrent TB disease and monitoring of treatment response. 
Hypothesis 
IFN response signature scores will be higher when pVL is detectable than when pVL 
is undetectable and signature scores will correlate with pVL. 
 
6.2: Methods  
6.2.1: Study design  
Samples collected in the TRuTH and IMPRESS cohorts were stratified into two 
groups based on whether pVL was detectable or undetectable. Different pVL assays 
were used during the conduct of the TRuTH and IMPRESS studies and we sought to 
avoid performing analyses with different lower limits of viral detection. Hence, the 
detection limit for pVL was 400 copies/mL. The performance of the ACS 11-gene 
and rPSVM.1 signatures was measured by area under the ROC curve. Viral load 
data was available for all sampling time points in the TRuTH study. However, viral 
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load data in the IMPRESS cohort was only available at baseline and end of 
treatment.  
 
The Mann Whitney U test was used to compare signature scores between 
undetectable and detectable pVL samples.  
 
6.3: Results  
6.3.1: Stratification of samples in the TRuTH and IMPRESS cohorts for pVL 
analysis. 
Out of 299 samples in the TRuTH study, 272 samples were collected when pVL was 
undetectable and 27 when pvL was detectable. For some samples (n=37), pVL data 
was not available at the sample time point. In these circumstances we assigned the 
pVL values collected within two weeks of sampling. Fifteen of the 27 (56%) samples 
with detectable pVL were from progressors, as compared to only 88 of the 272 
(32%) samples from those with undetectable pVL (Figure 23A).  
 
In the IMPRESS cohort only 86 samples had associated pVL data. Fifty of these had 
undetectable pVL whilst 36 had detectable plasma viral loads (Figure 23B). Of the 
samples with pVL data, 60 were baseline samples, 25 were end of treatment 
samples and one was at the 2-month time point. Of the baseline samples 27 had 
undetectable pVL, and 22 of the end of treatment samples had undetectable pVL 
(Figure 23B).  The single two-month sample with undetectable pVL data was not 









Figure 23: Sample selection for analysis of effect of plasma viral loads (pVL) on signature 
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6.3.2: HIV viraemia levels are associated with signature scores  
In the TRuTH cohort, ACS 11-gene and rPSVM.1 signature scores were higher 
when HIV pVL was detectable (median score 51%, IQR, 25% to 78%) than when 
pVL was undetectable (median score 14%, IQR, 10% to 22.3%), irrespective of 
whether the samples were from progressors or controls (Figure 24A). A weak 
positive association was observed between pVL and signature scores when only 
data from detectable pVL samples were analysed (Figure 24C and D). pVL and CD4 
T cell counts were not predictive of recurrent TB disease at any time point before 
diagnosis (data not shown).  
 
Similarly, signature scores in the IMPRESS cohort were higher in samples with 
detectable pVL than those with undetectable pVL (Figure 24B). However, contrary to 
what was observed in the TRuTH cohort, signature scores were not correlated with 
detectable pVL for either the ACS 11-gene or rPSVM.1 signatures in the small 
IMPRESS cohort. Most of the samples in the TRuTH and IMPRESS studies were 
collected when study participants had undetectable pVL. Sample numbers were too 




Figure 24: Association between ACS 11-gene and rPSVM.1 signature scores and pVL. (A) Effect 
of pVL on signature scores in the TRuTH cohort. Progressors and controls were combined. (B) Effect 
of pVL on signature scores in the IMPRESS cohort with all time points combined. (C-F) Association 
between signature scores and detectable pVL from the TRuTH (C and D) and the IMPRESS (E and 
F) cohorts. Spearman correlation coefficients are shown. P-values are not adjusted for multiple 
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6.3.3: Differentiating between recurrent TB progressors and controls and 
monitoring treatment response when HIV pVL is undetectable  
Signature scores from TRuTH cohort samples with undetectable HIV pVL were 
stratified into six-month (180-day) time to TB windows. The period within six months 
of recurrent TB diagnosis was further subdivided into two three-month (90-day) 
windows as done in Chapter 4. In the three months preceding TB recurrence 
signature performance was equivalent when all samples (samples with both 
detectable and undetectable pVL) or only those with undetectable pVL were included 
in the same ROC (Figure 25).  
 
In the IMPRESS cohort performance of the signatures in differentiating early from 
late converters was also not different when the entire cohort was analysed or when 
only undetectable pVL samples were analysed (Figure 26A & B). In addition, the 
performance of the signatures in differentiating samples taken at diagnosis from 
samples taken at treatment completion  was also equivalent when the entire cohort 





Figure 25: Classification of progressor and control samples from only those with undetectable 
pVL in the TRuTH cohort. Each ROC curve depicts the AUC for progressor vs. control at the 
indicated time point by the ACS 11-gene (A) and rPSVM.1 (B) signatures. 
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Figure 26: Effect of pVL on performance of signatures in treatment response monitoring in the 
IMPRESS cohort. (A &B) Each ROC curve depicts the ability of the ACS 11-gene (A) and rPSVM.1 
(B) signatures in differentiating early from late converters at study time points. (C&D) Each ROC 
curve depicted the ability of the ACS 11-gene (C) and rPSVM.1 (B) signatures in differentiating 
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In this chapter, we investigated the effect of HIV viraemia on the performance of the 
ACS 11-gene and rPSVM.1 signatures in the TRuTH and IMPRESS studies. We 
show that signature scores were significantly higher when participants had 
detectable HIV virus in the plasma and a weak association was observed between 
pVL and signature scores for both ACS 11-gene and rPSVM.1 signatures in the 
TRuTH cohort. These data corroborate our findings in the previous chapters that 
underlying HIV infection increases IFN response signature scores and that the 
diagnostic performance in HIV-infection, and especially in viraemic individuals, is 
reduced by virus-induced inflammation.  
 
A limitation of the work in this chapter is that the clinical studies were not sufficiently 
powered to investigate the performance of the signatures in samples with detectable 
or high pVLs. This will be possible in a study currently underway at SATVI, the 
CORTIS-HR study, in which we are assessing the performance of the ACS 11-gene 
signature in 860 HIV-infected persons.  
 
Despite this limitation and small sample sizes, to our knowledge this is the first time 
that the effect of HIV pVL on transcriptomic gene signatures of TB has been 
described. Our work suggests that underlying HIV infection has a marked effect on 
performance of IFN response signatures, which requires further examination. Of 
note, a recent transcriptomic study by Esmail, Wilkinson and colleagues 
demonstrated that a transcriptomic TB signature based on complement pathway 
genes may have greater utility in ART naïve HIV-infected persons (Esmail et al., 
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2018). In this study, pVL did not affect circulating immune complexes, which were 
associated with transcripts involved in the complement pathway. 
 
We conclude that the decrease in the performance of type I IFN signatures of TB in 
HIV-infected persons is due to the stimulatory effect of circulating virus on type I 
IFNs production. We hypothesise that TB signatures developed in HIV-infected 
cohorts may perform better in HIV-uninfected persons.  
 
6.6: Contributions 
Ms F. Darboe designed, conducted the experiments, performed the analyses, and 
















Chapter 7: Signature reduction to pave the way for a point-of-care diagnostic 
test: the ACS 6-gene signature 
!
7.1 Introduction 
Most recently published gene signatures for diagnosing active TB have been 
developed on microarray and RNA sequencing platforms, which are expensive and 
measure expression of the entire transcriptome. Although these platforms are ideal 
for the discovery of transcriptomic signatures, the size of most signatures that have 
been discovered, including the 11-gene, 48-transcript ACS signature, makes them 
impractical for clinical use at a point-of-care level. There is an urgent need to 
develop these signatures into cheap and easy-to-use diagnostic tools especially for 
use in resource-poor settings. Cheaper and highly targeted gene expression 
quantification methods such as qRT-PCR assays can make the signatures more 
accessible for the development of point-of-care diagnostics. This underlies the 
motivation for translating the ACS correlate of risk signatures from RNA-seq into 
qRT-PCR, before they were validated on independent clinical cohorts (Zak et al. 
2016).   
 
For translational purposes it is believed that fewer transcripts in a signature will have 
a higher probability of success when implementing such an assay into a hand-held 
diagnostic device, due to lower costs, and simplicity. Several recent studies have 
discovered small signatures in a bid to develop cheaper and simpler diagnostic tests 
for TB disease (Maertzdorf et al., 2016; Roe et al., 2016; Sweeney et al., 2016). 
Sweeney and colleagues discovered and validated a three-gene signature that 
distinguished active TB disease from Mtb infection in published datasets of both HIV-
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infected and uninfected individuals with excellent accuracy (Sweeney et al., 2016). 
This 3-gene signature also distinguished active TB disease from other diseases, 
including sarcoidosis and pneumonia. Maertzdorf and colleagues developed and 
validated a 4-gene signature that can classify TB disease from healthy persons 
(Maertzdorf et al., 2016). This signature was compared to a 15-gene signature 
developed in the same cohort; both signatures were applied to publicly available 
datasets and could distinguish active TB disease from Mtb infection, also with 
excellent accuracy. In another study, transcript levels of a single gene, BATF2, 
allows differentiation between active TB disease and healthy HIV-uninfected persons 
in individuals with diverse ethnic backgrounds (Roe et al. 2016). The performance of 
these signatures in diagnosing TB disease suggest that signatures based on a few 
transcripts may provide equivalent diagnostic performance to signatures with large 
number of transcripts. 
 
We developed a qRT-PCR signature consisting of six transcripts representing six 
genes that could predict active TB in adolescents before onset of symptoms and 
diagnosis in the ACS cohort. The signature was independently validated on the GC6-
74 cohort. Referred to as the “ACS 6-gene signature”, it can be measured using six 
Taqman primer-probe assays (Penn-Nicholson, unpublished data). The 6-gene 
signature consists of three transcripts, GBP2, FCGR1B, and SERPING1, that are 
upregulated in progressors or TB patients (Taqman primer-probe assays: 
GBP2.Hs00894846_g1, FCGR1B.Hs0234185_m1, and 
SERPING1.Hs00934329_m1, respectively) and three transcripts, TUBGCP6, 
TRMT2A, and SDR39U1, that are downregulated in progressors or TB patients 
(Taqman primer-probe assays: TUBGCP6.Hs00363509_g1, 
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TRMT2A.Hs01000041_g1 and SDR39U1.Hs01016970_g1, respectively), resulting in 
nine-transcript pairs (Figure 27). The score for the ACS 6-gene signature is derived 
from computing the ratio between the nine transcript pairs, where each pair contains 
one transcript that is upregulated in active TB with one that is downregulated in 
active TB, relative to healthy controls. This pair-ratio format presents two advantages 
over other signatures. Firstly, the up-down pairing provides a “self-standardisation” 
function that eliminates the need for housekeeper transcript-based standardisation to 
account for variability in input RNA. Secondly, the pair-ratio format allows a signature 
score to be calculated even if a Ct value for one primer probe is not derived, due to a 
failed PCR reaction for example. As observed for the pair-wise ACS 16-gene 
signature, this provides important robustness to the signature (Zak et al. 2016). The 
sum of the ratio of the transcript pairs and a coefficient “d” (weighting between the 
pairs, which was originally derived from model parameterisation on the ACS study) 
results in a binary score (Table 14). Samples are classified as “progressors or TB 
cases” or “non-progressors or controls” by each pair based on whether this 
calculation is greater (progressor/case) or less (non-progressor/control) than zero. A 
final score is given as the summation of the progressor voting pairs divided by the 
total number of voting pairs. For example, if six out of the nine pairs vote “progressor 
or TB case” and all nine pairs voted (a Ct value was obtained for all six transcripts), 













Figure 27 Pair structure of the ACS 6-gene signature. The signature comprises nine transcript 
pairs that each links a transcript that is upregulated in active TB with one that is downregulated in 
active TB relative to healthy controls. Lines indicate the pairing of the transcripts. Transcripts that are 

















Table 14: Taqman primer-probe pairs in the ACS 6-gene signature and coefficients for 
calculating signature scores. 
Primer #1 Primer #2 Coefficient d 
GBP2.Hs00894846_g1 TUBGCP6.Hs00363509_g1 -2,3 
GBP2.Hs00894846_g1 TRMT2A.Hs01000041_g1 -5,7 
GBP2.Hs00894846_g1 SDR39U1.Hs01016970_g1 -4,7 
FCGR1B.Hs02341825_m1 TUBGCP6.Hs00363509_g1 2,4 
FCGR1B.Hs02341825_m1 TRMT2A.Hs01000041_g1 -1,2 
FCGR1B.Hs02341825_m1 SDR39U1.Hs01016970_g1 -0,2 
SERPING1.Hs00934329_m1 TUBGCP6.Hs00363509_g1 0,7 
SERPING1.Hs00934329_m1 TRMT2A.Hs01000041_g1 -2,5 
SERPING1.Hs00934329_m1 SDR39U1.Hs01016970_g1 -1,5 
 
In this chapter, we sought to assess the diagnostic, prognostic and treatment 
response monitoring performance of the ACS 6-gene signature in HIV-infected 
persons. 
  
7.2: Aims and Hypotheses 
7.2.1 Aims 
7.2.1.1 To determine if the ACS 6-gene signature can differentiate active TB from 
Mtb-infected persons in PBMC from HIV-uninfected persons. 
7.2.1.2 To determine the diagnostic performance of the ACS 6-gene signature in 
HIV-infected participants.  
7.2.1.3 To determine if the ACS 6-gene signature can predict TB recurrence in HIV-
infected persons on ART. 
7.2.1.4 To determine the performance of the ACS 6-gene signature as a treatment 





7.2.2.1 The ACS 6-gene signature will diagnose active TB disease in PBMC from 
HIV-uninfected persons and its diagnostic performance will be equivalent to the 
diagnostic performance of the ACS 11-gene signature. 
7.2.2.2 The ACS 6-gene signature will diagnose active TB in whole blood and PBMC 
from HIV-infected persons with an equivalent performance to the ACS 11-gene 
signature.  
7.2.2.3 The ability of the ACS 6-gene signature in predicting recurrent TB disease in 
HIV-infected persons on ART will be equivalent to the prognostic ability of the ACS 
11-gene signature in the same cohort. 
7.2.2.4 The ACS 6-gene sigature will be able to differentiate rapid treatment 
responders from late treatment responders in HIV-infected TB retreatment patients.  
 
7.3 Methods 
7.3.1 Study design  
Samples from the cross-sectional study of TB cases and Mtb-infected controls 
(described in Chapter 3) were used to analyse the diagnostic performance of the 
ACS 6-gene signature in classifying active TB disease from Mtb infection. In the 
TRuTH (described in Chapter 4) and IMPRESS (described in Chapter 5) cohorts, we 
aimed to determine if the ACS 6-gene signature could predict recurrent TB disease 
and predict treatment response respectively, as was described for the 11-gene and 
rPSVM.1 signatures in Chapters 4 and 5. The study designs described in the 
respective chapters were maintained in this chapter.  
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7.3.2 Experimental set up and data analyses  
Primer-probes for the ACS 6-gene signature were included in each 96.96-gene 
expression chip along with the other signatures that were run. The chip quality 
control results shown in Figures 13 and 18 in Chapters 4 and 5 therefore apply to the 
assays performed here. However, one of the primer-probe assays, 
TRMT2A.Hs01000041_g1, was not included in the gene expression chips that were 
used for comparing PBMC and whole blood gene expression from TB cases and 
controls (Chapter 3). This TRMT2A primer-probe assay was not included in the pilot 
study because the ACS 6-gene signature was developed after completion of the 
experiments for this cohort. However, since five of the six primer-probes for this 
signature were co-incidentally already assayed in the gene expression chips, we 
proceeded to calculate scores for the ACS 6-gene signature from this cohort. This 
therefore provided a test of the robustness of the pairwise formulation, because it 
allowed the assessment of the effect of the missing transcript on signature 
performance. Signature scores were calculated using in-house scripts in R 
developed with our collaborators at CIDR (Seattle, USA). ROC AUCs were 
calculated in R using the pROC and verification packages. Statistical analyses were 
done using Mann Whitney U for differences between two groups, Wilcoxon ranked 




7.3 Results  
7.3.1 Diagnostic performance of the ACS 6-gene signature in HIV-infected and 
uninfected persons 
To measure the diagnostic performance of the ACS 6-gene signature in PBMC, it 
was applied to whole blood and PBMC samples collected in parallel from participants 
enrolled in the pilot cohort (Chapter 3). Results of this experiment would also allow 
us to make go/no-go decisions about the suitability of the ACS 6-gene signature for 
assessing the prognostic potential of the ACS 6-gene signature in the TRuTH cohort.  
 
The diagnostic performance of the ACS 6-gene signature in HIV-uninfected persons 
was excellent, whether RNA from whole blood or PBMC was tested. The AUCs for 
the ACS 6-gene signature of 0.96 (95% CI 0.89 to1.00) and 0.99 (95% CI 0.99-1.00) 
in whole blood and PBMC respectively (Figure 28A) were equivalent to the ACS 11-
gene signature with AUCs of 0.97 (95% CI 0.91-1.00) and 0.98 (95% CI 0.95-1.00) in 
whole blood and PBMC respectively (Figure 6C). As also observed for the ACS 11-
gene signature, differentiation between active TB disease and Mtb infection using 
whole blood or PBMC samples was equivalent (Figure 28A), p=0.25. Again, ACS 6-
gene signature scores were lower in PBMC samples than RNA from whole blood 
samples (Figure 28B).  
 
We proceeded to determine the difference in single transcript expression between 
TB cases and controls in whole blood and PBMC, to assess the contribution of each 
transcript to the signature scores. Expression of two gene transcripts (FCGR1B and 
SERPING1) was significantly higher in TB cases than in Mtb-infected controls in 
whole blood (Figure 28C). Expression was not different between the two groups for 
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GBP2, SDRR39U1, and TUBGCP6 in whole blood, as indicated by 95% CIs that 
crossed zero. In PBMC, expression of SDR39U1 and TUBGCP6 transcripts was 
significantly lower in TB cases than Mtb-infected controls whilst there was no 
difference in expression between the two groups for the remaining three genes 
measured (Figure 28C). These data suggest an interesting picture where different 
transcripts within the ACS 6-gene signature appear to drive the signal that underlies 
diagnostic potential, when PBMC and whole blood are tested.    
 
We next determined the ability of the signature to diagnose active TB in HIV-infected 
persons. The ACS 6-gene signature (whole blood AUC 0.92, 95% CI 0.85-1.00 and 
PBMC AUC 0.89, 95% CI 0.77-1.00, Figure 29A) yielded similar diagnostic 
performance to the ACS 11-gene signature (whole blood AUC 0.83, 95% CI 0.71-
0.96 and PBMC AUC 0.88, 95% CI 0.76-0.99, Figure 7A) in HIV-infected persons. 
Although there was an indication of superior performance of the smaller signature in 
whole blood, this was not significantly different, p=0.24. As observed with the HIV-
uninfected cohort, AUCs of the ACS 6-gene signature were not different between 
whole blood and PBMC in HIV-infected individuals, p = 0.60 (Figure 29A). Similarly, 
signature scores were lower in PBMC than in whole blood samples as observed in 
the HIV-infected cohort (Figure 29B).  
 
As observed in the HIV-uninfected cohort, significant differences in transcript 
expression between TB cases and Mtb-infected controls were observed for FCGR1B 
and SERPING1 transcripts in whole blood (Figure 29C). In PBMC samples, 
significant differences in gene expression between active TB cases and Mtb-infected 
controls were observed only in the TUBGCP6 gene. No differences in GBP2 
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expression were observed between active TB cases and Mtb-infected controls 











Figure 28: Diagnostic performance of the ACS 6-gene signature in whole blood and PBMC 
from HIV-uninfected persons from the pilot cohort. A) ROC curves for classification of active TB 
disease (n=30) from Mtb infection (n=30) in whole blood and PBMC. B) Signature scores measured in 
whole blood and PBMC from HIV-uninfected persons. Horizontal lines represent medians, the box 
represents the IQR and the whiskers the range. Dots represent individuals. C) Differences in 
transcript expression between TB cases and healthy Mtb-infected persons when measured in whole 
blood or PBMC samples. Negative differences indicate higher expression in active TB cases than 
Mtb-infected controls. Dots represent the medians and the bars the 95% CI for each transcript 
identified by its Taqman primer-probe set, computed with the rank inversion method and 
bootstrapping 2,000 times. Dashed lined represent the cut-off of which no difference was observed 
between cases and controls. 
 
 















PBMC               0.99 (0.99-1.00)    2.84 x 10-11 
Whole blood   0.96 (0.89-1.00)   1.34 x10-09 




















































































































Figure 29: Diagnostic performance of the ACS 6-gene signature in whole blood and PBMC 
from the HIV-infected group from the pilot cohort. A) ROC curves for classification of active TB 
cases (n=20) from Mtb infection (n=20) in whole blood and PBMC. B) Signature scores measured in 
whole blood from PBMC from HIV-infected active TB cases or Mtb-infected persons. Horizontal lines 
represent medians, the box represents the IQR, and the whiskers the range. Dots represent 
individuals C) Differences in transcript expression between TB cases and Mtb-infected persons when 
measured in whole blood or PBMC samples. Negative differences indicate higher expression in active 
TB cases than Mtb-infectd controls. Dots represent medians and the bars 95% CI for each transcript 
identifies by its TaqMan primer-probe set, computed with the rank inversion method and bootsrapping 
2,000 times. Dashed lines represent the cut-off at which no difference was observed between cases 
and controls.  
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The ACS 6-gene signature performance in HIV-infected persons was 4% and 10% 
lower than in HIV-uninfected persons in whole blood and PBMC, respectively (Figure 
30A & B). However, the lower ROC AUCs observed in HIV-infected persons were 
not statistically different from the ROC AUCs observed in HIV-uninfected persons, 
either for whole blood (p=0.55) or PBMC (p=0.07) samples. Signature scores in TB 
cases and Mtb-infected controls were higher in HIV-infected individuals than in their 
HIV-uninfected counterparts (p<0.0001) for each of the comparisons (Figure 30C & 
D), as observed for the ACS 11-gene and rPSVM.1 signatures. To unpack this 
further, we compared the differences in individual transcript expression between 
HIV-infected and uninfected persons. Expression of GBP2, FCGR1B, SDR39U1 and 
SERPING1 in whole blood was significantly higher in HIV-infected than uninfected 
individuals from the Mtb-infected control group (Figure 31A). In TB cases, only GBP2 
was expressed at significantly higher levels in HIV-infected than uninfected persons 
(Figure 31A). In PBMC, transcript expression of FCGR1B and SERPING1 were 
significantly higher in HIV-infected than HIV-uninfected Mtb-infected and TB cases 
(Figure 31B). The relative difference in gene expression by HIV-status was not 
different between Mtb-infected controls and active TB cases as indicated by 




Figure 30: Comparative diagnostic performance of the ACS 6-gene signature between HIV-
infected and HIV-uninfected individuals. ROC curves for classification between active TB cases 
and Mtb-infected controls in whole blood (A) and PBMC (B). Signature scores measured in whole 
blood (C) and PBMC (D) from HIV-infected and uninfected active TB cases or healthy Mtb-infected 
persons. Horizontal lines represent medians; the box and whiskers represent the IQR and range, 
respectively. Dots represent individuals. 
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Figure 31: Differences in transcript expression between HIV-infected and uninfected persons 
when measured in whole blood (A) or PBMC (B) samples from TB cases or Mtb-infected 
controls. Negative differences indicate higher expression in TB than QFT+ controls. Dots represent 
medians and the bars 95% CI for each transcript identified by its Taqman primer-probe set, computed 
with the rank inversion method and bootstrapping 2,000 times. Dashed lines represent the cut-off at 

















































































































































7.3.2 Predicting recurrent TB disease in HIV infected persons on highly active 
antiretroviral therapy from the TRuTH cohort 
To determine the prognostic performance of the ACS 6-gene signature for recurrent 
TB disease in HIV-infected persons, samples from participants in the TRuTH cohort 
were stratified as previously described (Chapter 4). Briefly, participants who 
developed recurrent TB during the three-year follow-up (n=43) were assigned to two 
controls each by gender and time on ART. Samples from study participants were 
split into six-month time windows relative to diagnosis of recurrent TB disease. The 
six-month window preceding TB diagnosis was further divided into two three-month 
time periods. The ACS 6-gene signature could not differentiate those who developed 
recurrent TB from those who remained disease free in any of the six-month time 
windows (Figure 32A). However, within the three-month window preceding TB 
diagnosis the signature differentiated those who developed recurrent TB from those 
who did not with an AUC of 0.68 (95% CI 0.53 to 0.83, Figure 32B). Signature scores 
were highly heterogeneous in both progressors and non-progressors over the follow-
up period, as was observed for the ACS 11-gene signature (Figure 32C). ACS 6-
gene signature scores of samples collected from progressors in the three months 
preceding recurrent TB diagnosis correlated weakly (Spearman r = -0.46, p = 0.06) 
with MGIT time to sputum culture positivity at diagnosis suggesting a possible 




Figure 32: The ACS 6-gene signature can differentiate between progressors and non-
progressors within three months of diagnosis in the TRuTH cohort. A and B) ROC curve 
illustrating the prognostic performance of the signature in diagnosing recurrent TB disease in HIV-
infected persons. Each ROC curve depicts time to recurrent TB diagnosis: times to TB diagnosis are 
stratified into six-monthly time windows (A) and three-monthly time windows (B). p-values have not 
been corrected for multiple comparisons. C) Longitudinal signature scores of samples stratified by 
time to recurrent TB diagnosis and recurrent TB status at the end of follow-up. D) Association 
between signature scores within three months of diagnosis and time to culture positivity at recurrent 
TB diagnosis as an indicator of bacterial load in the TB cases. 
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Figure 33: Treatment monitoring using the ACS 6-gene signature in the IMPRESS cohort. A) 
Signature scores during TB treatment. Horizontal lines depict medians and error bars depict the IQR. 
Dots represent individual scores. B) ROC curves depicting signature performance in differentiating 
samples collected at diagnosis and samples collected during TB treatment (two months, at the end of 
treatment, and post treatment). C) Kinetics of signature scores in early and late converters, median 
and IQR shown.  
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7.3.3 Treatment response monitoring using the ACS 6-gene signature  
We applied the ACS 6-gene signature to the IMPRESS cohort (Chapter 5) to 
determine its ability to monitor treatment response. Participants were stratified 
according to their time on TB treatment and further stratified into early and late 
converters based on time to culture conversion by month two. During the first two 
months of TB treatment, a significant decrease of approximately 10% was observed 
in median signature scores (Figure 33A). A further decrease was observed during 
the continuation phase of TB treatment from month three to the end of treatment 
(Figure 33A). As opposed to the results obtained with the ACS 11-gene and 
rPSVM.1 signatures (Figures 19A & B), the ACS 6-gene signature scores continued 
to decrease up to eight months after the end of TB treatment. The ACS 6-gene 
signature differentiated between pre-treatment baseline (TB disease diagnosis), two-
month treatment (end of intensive phase), end of treatment, and eight-month post-
treatment samples with good accuracy (Figure 33B), confirming that the signature 
can monitor treatment response. The decrease in signature scores was observed in 
both early and late converters, but scores were not different between the two arms at 
any of the time points (Figure 33C).  
 
ROC analysis of differentiation between early and late converters using the ACS 6-
gene signature showed that treatment response could not be predicted at baseline or 
the other time points (Figure 34A). Signature scores were also not associated with 
time to culture conversion at the measured study time points (Figure 34B) and time 
to MGIT culture positivity at baseline was not associated with signature scores 
measured at treatment baseline (Figure 34C). A combination of the two variables to 
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determine clustering of the late and early converters did not correctly stratify early 




Figure 34: Application of the ACS 6-gene signature to predict treatment response in the 
IMPRESS cohort. A) ROC curves show differentiation between early and late converters at the 
indicated time points during TB treatment. B) Signature scores in early and late converters. Dots and 
squares represent individuals. Horizontal lines and error bars depict median and IQR, respectively. C) 
Association between signature scores at treatment baseline and time to culture positivity at diagnosis. 
Red dots represent late converters and teal dots represent early converters.  
A
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r (95% CI) = 0.13 (-0.13 - 0.38)
p = 0.32
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7.3.4 Effect of plasma viral load levels on ACS 6-gene signature scores in the 
TRuTH and IMPRESS cohorts 
Samples from the TRuTH and IMPRESS cohorts were stratified into detectable and 
undetectable pVL samples, as described in Chapter 6. ACS 6-gene signature scores 
from samples collected when participants had undetectable pVL were significantly 
lower than when pVL was detectable in both the IMPRESS and TRuTH cohorts 
(Figure 35A). In the TRuTH cohort, equivalent ROC AUCs from the three-month time 
window prior to recurrent TB diagnosis were observed in samples with undetectable 
pVL and all samples (i.e. irrespective of pVL (Figure 35B). In the IMPRESS cohort 
similar ROC AUCs were obtained from samples with undetectable pVL to those from 
all samples, in differentiating early converters from late converters at baseline and 
end of treatment (Figure 35C). In addition, an equivalent performance was observed 
between samples with undetectable pVL and all samples in differentiating baseline 





Figure 35: Effect of HIV viraemia on ACS 6-gene signature scores and performance. A) 
Signature scores stratified by samples with detectable or undetectable pVL in the TRuTH (PBMC 
samples) and IMPRESS (whole blood samples) cohorts. Dots represent individual samples collected 
when viral loads were detectable (open dots) or undetectable (closed dots). Median and IQR are 
shown. (B-D) ROC curves depicting ability of the ACS 6-gene signature to detect recurrent TB 
disease (B) or monitor treatment response (C and D). Solid ROC curves represent samples collected 
when viral loads were undetectable and dashed curves depict signature performance in the whole 
cohort (including both detectable and undetectable pVL samples). C) ROC curves depict ability of the 
signature in differentiating early converters from late converters. D) ROC curves ability of the 
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AUC (95% CI)     p-value
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In this chapter we sought to develop a reduced transcriptomic signature of TB that is 
more parsimonious than the ACS 11-gene signature for possible future application 
as a point-of-care test. We reduced signature to six transcripts by training a new 
pair-wise signature from qRT-PCR data from ACS progressor and non-progressor 
samples. We demonstrated that this ACS 6-gene signature could diagnose active TB 
disease in HIV-infected and uninfected persons, predict recurrent TB disease, and 
monitor treatment response in HIV-infected persons.  
 
Diagnostic performance of the 6-gene signature was equivalent between whole 
blood and PBMC in both HIV-infected and uninfected persons. Importantly, the 6-
gene signature performed at least as well as the ACS 11-gene signature, which 
comprised 48 primer-probe assays, even though measurements for one primer-
probe were missing. These data demonstrate that the pair-wise formulation of the 
signature makes it robust to missing primer-probes, a very important feature for such 
a biomarker.  
 
Three of the six genes are ISGs, which are predominantly expressed by neutrophils 
during TB disease (Berry et al. 2010; Singhania et al. 2017; Scriba et al. 2017). It is 
thus not surprising that signature scores were lower in PBMC, which is deficient in 
neutrophils. Our results that HIV infection increases signature scores and thereby 
decreases the diagnostic accuracy of the signature in HIV-infected persons is 
consistent with the reduced performance of other published signatures (Sweeney et 
al. 2016; Zak et al. 2016).  
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The ACS 6-gene signature shows promise as a point-of-care triage test that could be 
deployed in resource-poor settings in both HIV-infected and uninfected persons to 
identify individuals who require further investigation for TB disease. Such a triage 
test ideally needs to be as sensitive as the confirmatory (likely microbiological) test in 
diagnosing TB, or else participants would be missed by the test (Denkinger et al. 
2015). The diagnostic ROC AUC of the ACS 6-gene signature appeared equivalent 
to previous studies of small gene signatures (Laux Da Costa et al., 2015; Maertzdorf 

































Table 15: Performance of small gene signatures in diagnosing active TB disease using whole 

















Three Negative Model fit 123 RT-PCR  0.96  
(0.89-1.00) 
(Laux Da 
Costa et al. 
2015) 













Negative Validation  75 0.89  
(0.81-0.96) 
Negative Validation 62 0.82  
(0.71-0.93) 
Fifteen Negative Model fit 
and 
validation 
189 0.98  
(0.96-1.00) 








et al. 2016) 
Negative  Validation  296 0.93 
(0.84-0.97) 
Positive Validation N/A 0.89 
(0.87-0.91) 
One Negative Model fit  46 Microarray 0.95 (Roe et al. 
2016) 
38 plus 10 
(ACS 11-
gene) 
Negative Validation 60 RT-PCR 0.97 
(0.91-1.00) 
Chapter 3 
Positive Validation 40 RT-PCR 0.83 
(0.71-0.96) 
30 plus 5 
rPSVM.1 
(10 genes) 








Negative Validation 60 RT-PCR 0.96 
(0.89-1.00) 
Chapter 7 




As discussed previously (Chapter 4), most participants in the TRuTH cohort had 
subclinical TB with more than half of the recurrent TB patients (25 out of 43) being 
asymptomatic identified through intensified case finding using induced sputa. The 
finding that the ACS 6-gene signature could predict recurrent TB disease within three 
months of microbiological confirmation suggests that this signature can detect the 
inflammatory signal of subclinical disease, as has been reported in HIV-negative 
persons in the ACS study (Zak et al. 2016; Scriba et al. 2017). This is further 
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supported by the observation that most asymptomatic participants who elected not to 
receive TB treatment manifested with TB symptoms some months later. These 
results suggest that the ACS 6-gene signature performs in a similar manner to the 
larger ACS 11-gene signature. We propose that the ACS 6-gene signature should 
perform with equivalent accuracy to the ACS 11-gene signature in other studies with 
larger sample sizes, such as the CORTIS and CORTIS HR trials.  
 
We also show that the ACS 6-gene signature score tracked the progress of TB 
treatment in the IMPRESS cohort and could differentiate with good accuracy 
between pre-treatment samples and samples collected at the end of treatment. 
Despite the promising diagnostic performance of the signature for active TB disease 
in HIV-infected persons, the signature could not differentiate early from late 
converters. It is unclear to what degree the signature performance was poor because 
participants in this cohort were TB retreatment patients, most of whom had a TB 
episode within five years before the IMPRESS study.  
 
As discussed in previous chapters, there is evidence that patients with recent TB 
disease have ongoing inflammation that can be detected by IFN response 
signatures. This inflammation was also detected by FDG uptake on PET-CT in HIV-
uninfected persons up to a year after mycobacterial cure (Malherbe et al. 2016). 
Furthermore, we showed that HIV-infection and pVL increased signature scores, 
while Type I IFNs are known to be upregulated in HIV-infected persons with high 
levels of immune activation (Herbeuval and Shearer 2007). We hypothesise that the 
poor distinction by the ACS 6-gene signature between patients who have achieved 
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and not achieved mycobacterial clearance as measured by sputum culture at two 
months is due to underlying HIV and the ongoing effects of the previous TB episode.   
 
The 6-transcript pairwise configuration of the ACS 6-gene signature has several 
advantages. The most important feature of this signature is its robustness to missing 
primer-probes despite the small numbers of genes. This suggests that the signature 
is as robust to missing primer-probes as the large ACS 11-gene signature, which 
comprises of 48 primer-probes. The lack of reference (or housekeeper) genes 
means that only six primer-probes are needed to measure the gene signature and 
simplifies the data processing steps since no standardisation is necessary. 
Surprisingly, the performance of the signature was equivalent to that of the ACS 11-
gene signature including diagnosis of active TB disease, prediction of recurrent TB 
(or detection of subclinical TB), and monitoring treatment response in HIV-infected 
persons. In light of its small size, we propose that the ACS 6-gene signature is an 
ideal TB biomarker in HIV-uninfected and HIV-infected persons. The test could be 
used a triage test in clinical stteines, however we currently do not have an estimate 
of the required sensitivity and specificity in patient clicare that is missng. The 
signature could be a useful tool for host-direct therapy and work is already underway 
to adapt the signature assay such that it can be measured in a simple, point-of-care 
battery operated device to be used as a triage test in primary healthcare facilities, 
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Chapter 8: General Discussion and Conclusions !
The targets set by the STOP-TB Partnership to eradicate TB by 2050 will not be 
reached unless highly innovative and new approaches are promoted. This includes 
high-quality, non-sputum based diagnostic or triage tests that can be done either in 
community settings or in primary clinics where individuals first present for healthcare. 
Such tests, especially if found to be sensitive in persons with subclinical disease, will 
increase early TB case detection, reduce missed cases at the initial stage of the care 
cascade, and perhaps even reduce transmission of Mtb.  
 
Many novel blood transcriptional signatures, consisting mainly of Type I/II IFN 
stimulated genes (ISGs), have recently been developed as diagnostic (Berry et al., 
2010; Maertzdorf et al., 2011, 2012; Ottenhoff et al., 2012; Sweeney et al., 2016) or 
prognostic (Zak et al. 2016; Darboe et al. 2018) biomarkers of active TB disease. 
The readouts of such signatures also correlate with the extent of disease, suggesting 
that ISG signatures can be used for TB treatment response monitoring (Berry et al. 
2010; Cliff et al. 2013; Thompson et al. 2017). Despite the massive disease burden 
of TB in HIV-infected persons and the high risk of progression to active TB in this 
population, only a few studies have investigated diagnostic gene expression 
biomarkers in HIV-infected persons (Kaforou et al. 2013; Anderson et al. 2014; 
Sweeney et al. 2016). Increasing evidence suggests these signatures may have 
universal utility, with diagnostic, prognostic, and treatment response applications 
(Singhania et al. 2017; Zak et al. 2016; Thompson et al. 2017). However, to the best 
of our knowledge this universal application has not yet been tested in a single study, 
either in HIV-infected or in HIV-uninfected persons. The aim of this thesis was to 
determine the diagnostic, prognostic and treatment response performance of 
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previously discovered ISG-based prognostic gene signatures of TB, applied in 
blinded analyses, in HIV-infected individuals. Our findings represent the first steps in 
the endeavour to develop blood-based gene expression signatures for TB, highlight 
some important challenges with the approach, and present interesting conclusions.  
 
Our first major finding was that signatures developed in HIV-uninfected populations 
for prognostic application, (i) identify HIV-infected persons with active TB disease, (ii) 
predict incident recurrent TB three months before microbiological diagnosis and, (iii) 
monitor treatment response of recurrent TB disease. However, the diagnostic 
performance observed in HIV-infected persons was approximately 10% lower than 
that observed in HIV-uninfected persons. We show that this is most likely due to 
higher false positive rates of signature scores in HIV-infected populations. Our data 
also corroborate previous findings that underlying HIV infection drives Type I IFN 
responses (Fernandez et al. 2011; Kamga et al. 2005), thus undermining the 
specificity of the TB signatures in HIV-infected populations. The data further suggest 
that whole transcriptome analysis (or other omics platforms) would be ideal to 
discover novel biological pathways that are not confounded by HIV. We 
acknowledge that the lack of viral load data in the pilot cohort of TB cases and QFT-
positive controls (Chapter 3) was a major limitation. Future studies should collect 
detailed clinical, immunological and virological data to allow careful and 
comprehensive analyses of these factors in biomarker discovery and performance. 
 
Our analyses of the ACS 11-gene, the rPSVM.1, and the ACS 6-gene signatures in 
the TRuTH cohort showed that prediction of recurrent TB disease was only possible 
very close to (within three months) of microbiological TB diagnosis. We showed that 
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the poor performance was not due to utilizing PBMC samples instead of whole 
blood, since we observed equivalent diagnostic performance in PBMC and whole 
blood in our pilot cohort. The poor predictive performance of the signatures in the 
TRuTH  cohort is likely due to a combination of the following five factors: 1) ongoing 
inflammation from the previous episode of TB disease may have affected signature 
sensitivity and specificity; 2) underlying HIV-infection likely affected signature 
performance (as observed for diagnostic performance); 3) most patients had 
subclinical TB disease at diagnosis, which is more likely to present with lower IFN 
signatures than active clinical disease; 4) intensive active case finding by induced 
sputum was frequently performed, allowing cases to be detected early during 
disease progression; and 5) many individuals received IPT, possibly affecting 
disease progression and affecting the risk of recurrent TB disease. Due to intensified 
case finding, most recurrent cases (25 of 43) detected were asymptomatic at the 
time of diagnosis and therefore had subclinical disease. Subclinical TB disease has 
been identified in other studies of active TB screening and case finding (Corbett and 
MacPherson 2013; Onozaki et al. 2015). More than half (n=212) of participants 
eligible for IPT in this cohort were initiated on six months of daily IPT (Maharaj et al. 
2017). Interestingly, recurrent TB disease was diagnosed shortly (median, 279 days) 
after end of preventive therapy in many of these individuals (Maharaj et al. 2017), as 
has been previously observed in other studies of HIV-infected persons who 
underwent six months of IPT (Samandari et al. 2011, 2015; J. E. Golub et al. 2015). 
This highlights that an important novel application of blood-based RNA signatures, 
which could be used to determine if HIV-infected persons are at risk of developing 
TB or already have subclinical TB when they complete their IPT course. This would 
allow prolongation of IPT treatment in individuals with high signature scores, thus 
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allowing their risk of active TB disease to be reduced. Alternatively, provision of full 
TB treatment may be necessary in cases were IPT does not reduce signature 
scores. In addition, gene signatures could be used to monitor preventive treatment 
response in HIV-infected retreatment cases, as was demonstrated for full TB 
treatment in HIV-uninfected persons (Thompson et al. 2017).  
 
Another major finding of this study is the effect of HIV infection and plasma viral load 
on signature scores, which shows that HIV infection elevates ISG expression as 
previously shown (Bosinger and Utay 2015; Fernandez et al. 2011; Kamga et al. 
2005). Within the HIV-infected population, aviraemic persons had lower expression 
of ISGs in comparison to their viraemic counterparts. The association of high 
signature scores in individuals with detectable viral loads suggests an underlying 
state of on-going immune activation and inflammation, decreasing the specificity of 
ISG-based gene expression signatures. These data highlight the importance of 
accounting for HIV co-infection and plasma viral load levels when developing or 
validating signatures of active TB disease. This is clearly illustrated by the finding 
that the 393-gene signature developed in HIV-uninfected persons by Berry et al 
(2010), had 0% specificity in an HIV-infected cohort due to the high signature 
expression in HIV-infected controls (Dawany et al. 2014). A major limitation of our 
sub-analyses was the small sample size such that the performance of the signatures 
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Perhaps the most insightful outcome from our study is that it allowed us to 
summarise the kinetics of type I/II IFN responses during progression to TB disease, 
during treatment, and recurrence of TB disease (Figure 36). Expression of ISGs 
increased as individuals transitioned to subclinical and then active clinical TB 
disease, likely due to the effect of bacterial replication and/or host cell mitochondrial 
damage during cell death (Wiens and Ernst 2016). A rapid decrease in ISG 
expression was observed during TB treatment, more so in HIV-uninfected 
(Thompson et al. 2017) than infected persons. This likely reflects lower levels of 
bacteria that are sensed through pathogen recognition receptors and perhaps 
reduced host cell death. However, in both HIV-infected and uninfected persons, 
gene expression of ISGs did not return to the original levels typically seen in healthy 
persons despite clinical and microbiological cure (Malherbe et al. 2016; Thompson et 
al. 2017). As observed in primary TB disease progression, recurrent TB disease 
progression was associated with an elevation in signature scores. The rapid increase 
of signature scores in HIV-infected persons before recurrent TB disease appears to 
reflect the increased risk and more rapid progression to recurrent TB disease relative 
to HIV-uninfected persons (Korenromp et al., 2003; Maher et al., 2005). As observed 
during treatment of a first TB episode, ISG expression rapidly decreased in HIV-
uninfected persons during TB treatment in comparison to HIV-infected persons 
(Figure 36). These upward and downward waves of type I/II IFN response kinetics 
appear to neatly tie together the transitions between quiescent, subclinical, and 
active disease as well as antibiotic treatment of TB, and even recurrence. However, 
more research on independent cohorts is required to determine if this proposed 
model can be reproduced.  
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The blood transcriptomic signatures could be useful as triage, diagnostic, or 
prognostic tests for active TB disease in resource-poor settings if measurement of 
gene expression can be translated into a cost-effective and near-patient device. A 
triage test ideally should be more sensitive than the confirmatory test in diagnosing 
TB, otherwise participants would be missed by the test (Denkinger et al. 2015). The 
ACS 11-gene, rPSVM.1, and ACS 6-gene signatures could diagnose Xpert MTB-
RIF-positive TB with a high sensitivity and specificity in both HIV-infected and 
uninfected persons. However, we show that the utility of the signatures as triage 
tests may be limited in HIV-infected persons due to viraemia, especially in persons 
not on ART and not virologically suppressed (Table 16). Despite this, due to effective 
roll out of ART in most TB endemic countries (World Health Organization 2017), 
most HIV-infected persons are expected to be aviraemic, which may make IFN 
response signatures particularly useful in XpertMTB-RIF or sputum smear negative 
individuals, before culture results become available. Furthermore, these signatures 
would be particularly useful as a diagnostic tool in HIV-infected persons with 
paucibacillary disease (Cain et al. 2010), and could serve as an important diagnostic 
tool in children, who also cannot provide sputum samples. To detect one case of TB 
using the signatures as triage tests (using the WHO target product profile (TPP) 
specificities), using the 6-gene signature would require lower numbers to screen and 
yield less false-positive tests regardless of HIV-status than the 11-gene signature 
(Table 16). This suggests that the 6-gene signature may perform better than the 11-
gene signature as a triage test in HIV-infected persons. However, a major limitation 
in HIV-infected persons is the interpretation of results, as underlying immune 
activation and inflammation can still lead to false positive results, especially in 
persons with previous TB disease. Regardless, the sensitivity and specificity of the 
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transcriptomic signatures (Table 16) still suggest better diagnostic performance than 
symptom screening alone or symptom screening in parallel with chest radiography in 
HIV-infected persons (Table 16) (Getahun et al. 2011). 
 
Table 16: Performance of the 11-gene and 6-gene signatures as triage tests in HIV-infected and 
uninfected persons based on results from the pilot cohort. 







Triage test (WHO TPP) >95% >80% <55 <11 1 
11-gene Uninfected 100% 80% 50 10 0 
11-gene Infected 65% 80% 77 16 1 
6-gene Uninfected 100% 80% 50 10 0 
6-gene Infected 85% 80% 59 12 1 
Performance of current screening tools in HIV-infected persons  
Symptom screening only 79% 50% 64 32 1 
Symptom screening and 
chest radiography 
91% 39% 55 33 1 
Number needed to screen to detect one case of TB is shown. For these calculations prevalent TB 
was set at 2%. False positives and negatives were calculated per number screened to detect one 
cases of TB. Calculations for symptom screening and chest radiography are based on results from 
Getahun et al 2011. TPP-Target product profile (WHO, 2012). 
 
 
HIV infection represents a highly heterogeneous spectrum of immunosuppression, 
viraemia, lymphoid tissue destruction and co-infections. This study highlighted the 
different effects of viraemic and aviraemic HIV-infection on the sensitivity and 
specificity of ISG signatures in predicting and diagnosing active TB disease. In 
addition, we identified plasma viral load as the main confounder in the application of 
TB signatures based on ISGs in HIV-infected persons. Successful provision of ART 
and good adherence leading to effective suppression of viral replication would 
decrease ISG expression in HIV-infected persons and improve the performance of 
whole blood-based ISG  transcriptomic signatures. Despite ART, it is apparent that a 
certain level of elevated IFN expression persists due to HIV infection. Integrating HIV 
and TB clinical care would allow for the effective monitoring of virological 
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suppression, provision of targeted preventive therapy, or further investigations such 
as sputum induction to determine if the person has TB disease. The utility of gene 
signatures in the control of TB disease would be increased in such an integrated 
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A staggering 23% of the global population is estimated to be infected with Mycobacterium tuberculosis (M.tb) [1], representing an enormous
reservoir of individuals at risk of progressing to active tuberculosis (TB) disease. Identification of those at risk of TB disease would allow targeted
preventive therapy, potentially curtailing transmission [2]. We recently identified and validated a 16-gene whole blood transcriptomic correlate of
risk (CoR) signature that can predict active TB disease in M.tb-infected individuals more than a year before disease manifestations and diagnosis [3].
The transcriptomic signature is measured by microfluidic quantitative reverse transcription polymerase chain reaction (qRT-PCR), comprising a set
of 57 primer-probes (47 primer-probes detecting 47 transcripts representing 16 interferon (IFN) response genes, and 10 primer-probes used as a
reference for standardization). To improve high-throughput processing we sought to trim 9 primer-probes from the signature such that the 48
primer-probes can be conveniently accommodated in duplicate in a typical 96.96 Fluidigm gene expression platform.
We selected the transcripts for removal based on 3 criteria: (1) those that showed the least reproducibility in qRT-PCR assays, (2) those that
yielded redundant signal to the overall signature, and (3) when transcripts were ranked by the number of pairings they form with other transcripts in
the signature only those that form very few pairs were removed (thus contributing little to the signature; data not shown). Based on these criteria, we
removed nine transcripts detected by 9 primer-probes, which represented five IFN response genes.
The reduced 48-primer-probe signature comprised 38 primer-probes representing 11 IFN response genes, and the 10 reference primer-probes.
The removed primer-probes represented the genes, SEPT4, ANKRD22, APOL1, FCGR1A and GBP4. We compared the prognostic performance of the
original, 57 primer-probe signature to the reduced, 48 primer-probe signature (Adolescent Cohort Study (ACS) 11-gene signature), measured by
microfluidic qRT-PCR on samples collected from adolescent progressors and controls that comprised the original training and test sets from the ACS,
in which the signature was discovered [3]. Ribonucleic acid (RNA) was isolated with the PAXgene™ blood RNA kit (QIAGEN); complimentary DNA
(cDNA) was synthesised by reverse transcription and pre-amplified using PCR, as described [3]. Signature transcripts were quantified using TaqMan
primer-probes on 96.96 Gene Expression Chips (Fluidigm) on a Biomark HD multiplex microfluidic qRT-PCR instrument. Signature scores were
calculated as previously described [3]. Risk scores of the original signature and reduced ACS 11-gene signature were essentially identical (Spearman
r = 0.99, p = 0.0 (Fig. 1A)). Predictive performance of TB risk, expressed as receiver operating characteristic (ROC) area under the curve (AUC) also
did not differ (Fig. 1B). Thus, reduction of the CoR signature to 48 primer-probes resulted in equivalent performance.
Next, we sought to determine the performance of the 48 primer-probe whole blood ACS 11-gene signature when measured in peripheral blood
mononuclear cell (PBMC) samples. Reliable measurement of the signature using RNA from PBMC would allow testing and/or further validation using
biobanked samples from historical clinical studies. Because the signature score increases most proximal to the onset of TB disease, we evaluated
diagnostic performance using RNA from PAXgene whole blood and cryopreserved PBMC samples (RNEasy mini kit, QIAGEN) collected in parallel
from 30 HIV-uninfected adults with newly diagnosed active TB disease (sputum Xpert MTB/RIF-positive) and 30 healthy, M.tb-infected
(QuantiFERON Gold In-tube-positive, QIAGEN) adult controls.
We first compared messenger RNA (mRNA) expression differences for each IFN response transcript in the reduced signature between TB cases and
controls in whole blood and PBMC. The difference in median mRNA expression between TB cases and controls (delta cycle threshold (Ct)) was
estimated and 95% confidence intervals (CI) of the median were obtained using the rank inversion method [4], with code from the R package
QUANTREG. All 38 IFN response transcripts were expressed at higher levels in TB cases than in controls, whether measured in whole blood or PBMC
(Fig. 1C). However, for transcripts including SCARF1, GBP2, GBP5, BATF2 and TRAFD1, the relative differences in transcript expression between TB
cases and controls were greater in whole blood than in PBMC. This suggests a substantial contribution of cell subsets present in whole blood but
absent in PBMC, such as granulocytes, to the disease-associated IFN response, as previously described [5].
Nevertheless, the ACS 11-gene signature classified samples from TB cases and healthy controls with equivalent accuracy (Fig. 1D). ROC-AUCs for
whole blood and PBMC were indistinguishable at 0.97 (95% CI 0.91–1.00) and 0.98 (0.95–1.00), respectively. Risk signature scores were markedly
lower in PBMC than in whole blood regardless of disease status, again reflecting the comparatively weaker IFN response transcriptomic signal in
https://doi.org/10.1016/j.tube.2017.11.001
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PBMC (Fig. 1E). This necessitates the use of independent, sample type-specific thresholds for classification of signature-positive or negative samples.
The comparable performance of the CoR signature in discriminating active TB cases from healthy controls in PBMC and whole blood demon-
strates feasibility for applying this signature to ascertain risk of TB in historical studies that have prospectively collected cryopreserved PBMC.
In conclusion, the ACS 11-gene, 48-primer-probe transcriptomic signature has diagnostic utility for TB with identical accuracy as the original 16-
gene, 57- primer-probe signature, and can be measured in cryopreserved PBMC.
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Fig. 1. Performance of the reduced ACS 11-gene signature of TB risk as a classifier of TB disease from M.tb-infection in PBMC. (A) Correlation of the signature scores generated from the
original 57 primer-probe (16 genes) and the reduced, 48 primer-probe (11-genes) qRT-PCR transcriptomic signatures of risk of TB disease in progressors and controls from the Adolescent Cohort Study
(ACS). The Spearman correlation coefficient is shown. (B) Performance of the original and reduced CoR signatures in classifying progressor and control samples from the Adolescent Cohort Study. (C)
Differences in transcript expression between TB cases (Xpert MTB/RIF-positive) and healthy controls (QuantiFERON-positive) when measured in whole blood or PBMC samples. Dots represent
medians and the bars 95% CI for each transcript, identified by its TaqMan primer-probe set. (D) Receiver operating characteristic curves illustrating diagnostic performance of the 48-primer-probe ACS
11-gene signature in distinguishing individuals with active TB disease from healthy QuantiFERON-positive controls when measured in RNA from whole blood or PBMC samples. (E) CoR signature
scores measured in whole blood or PBMC from active TB cases or healthy QuantiFERON-positive persons. Horizontal lines represent medians, the box represents the IQR and whiskers the range.
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